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Rheumatoid arthritis (RA), one of the most common autoimmune diseases, is 
characterized by persistent synovitis, systemic inflammation and expression of 
autoantibodies.1 In industrialized countries approximately 0.5-1.0% of the adult 
population is affected by the disease. There is substantial geographic variation 
in the occurrence of RA with very high prevalences reported in native American 
populations2, 3, and very low prevalences in populations from South-East Asia.4 The 
disease is approximately three times more frequent in women than in men, and 
the prevalence increases with age. As RA is a systemic disease, symptoms as fa-
tique, weight loss and fever as well as disorders of the heart, blood vessels, nerves 
and kidneys are also relatively common. The disease reveals itself by joint swell-
ing and joint tenderness, in which the small joints of the hands and feet are most 
commonly affected.1 The persistency of synovitis can result in the destruction of 
cartilage and subchondral bone, eventually leading to malformations and disabil-
ity. If left unattended or not properly treated, RA can lead to increased disability 
or even invalidity of patients in their normal daily functions, thereby reducing the 
quality of life. For society this can ultimately lead to enormous costs in healthcare 
and loss in workforce.5
The mainstay of treatment in RA, are the Disease Modifying Anti Rheumatic 
Drugs (DMARDs), which are a heterogeneous collection of therapeutic agents of 
which the mechanisms of action are, largely, not well understood. When arthritis 
stays uncontrolled despite these agents, or when toxic effects arise upon admin-
istration of these drugs, biologic agents, such as tumor necrosis factor inhibitors 
can be used and have proven to be highly effective.1 RA is considered as having an 
autoimmune origin because of the presence of self-reactive antibodies, such as an-
ti-citrullinated protein antibodies (ACPA), thereby reflecting the complexity of the 
disease. Although it poses a considerable health problem, relatively little remains 
known about the disease pathogenesis and etiology.
The first description of RA was made in 1800 in Paris. Sixty years later, the 
disease was named ‘rheumatoid arthritis’ for the first time by an English rheu-
matologist, Alfred Baring Garrod.6 As RA seems to be a highly heterogeneous 
disease, several classification criteria have been developed over the years, such 
as the 1956 ARA criteria7, 1961 Rome criteria8 and 1966 New York criteria77, with 
the aim of identifying more homogenous patient groups to facilitate comparison 
of international studies. Since 1987 the disease has been classified based on the 
ACR 1987 criteria9, which were developed using an analytical approach in which 
RA was defined by a regression analysis of disease characteristics of ‘classic cases’. 
As different disease manifestations are included in these criteria, a heterogeneous 
set of patients with conceivably different ‘pathogenic’ backgrounds are identified 
by them. Therefore, the great variation in disease course and treatment response 
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among patients with RA can be explained by the classification criteria describing 
a heterogeneous syndrome. ACPA have an exquisite specificity for RA10, and ACPA 
status was included in the new 2010 ACR–European League Against Rheumatism 
(EULAR) classification criteria for RA11, 12, alongside RF levels (already included in 
the 1987 criteria) (figure 1).9
Figure 1. ACR 1987 criteria and ACR/EULAR 2010 criteria. Classification criteria for 
rheumatoid arthritis. ACR = American College of Rheumatology. EULAR = European League 
Against Rheumatism. RF = rheumatoid factor. ACPA = Anti Citrullinated Peptide Antibodies. 
CRP = C-reactive protein. ESR = erythrocyte sedimentation rate. Adapted from Scott et al.1 
AUTOANTIBODIES IN RA
Various autoantibodies have been described in RA, including antibodies against 
ribosomal proteins (anti-RA33 antibodies)13, 14 and against carbamylated proteins 
(anti-CarP antibodies).15 The first RA-associated antibody, rheumatoid factor (RF), 
was known by 194016, and was later found to be directed to the Fc region of IgG. 
More than 20 years later, Nienhuis et al.17 described antibodies labeling perinu-
clear granules in the superficial cells of the human buccal mucosa epithelium, 
which were named anti-perinuclear factor antibodies (APF). Although it became 
clear that APF were highly specific for RA, testing for these antibodies was rather 
cumbersome; therefore, RF was assessed in daily practice. In 1979, anti-keratin 
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antibodies (AKA) were described, and found to be present in approximately 50% 
of patients with RA.18 Again, although these antibodies were more specific than RF 
for RA, the presence of RF was much more convenient to visualize. It was not until 
1995 that the protein filaggrin was shown to be the common antigen targeted by 
both APF and AKA.19 Since then, research into this unique autoantibody system 
has taken off with unprecedented speed, reaching a climax early in 2011 with the 
inclusion of anti-citrullinated protein antibodies (ACPA) in the new classification 
criteria for RA.11, 12 
Testing for ACPA 
After the discovery of filaggrin as the target of APF and AKA, it took only a year 
to reveal the molecular identity of the antigens that these autoantibodies recog-
nize: the nonclassical amino acid citrulline, embedded on a protein backbone.20, 21 
Citrulline is a non-encoded amino acid, generated by a post-translational modifi-
cation of arginine mediated by protein-arginine deiminase enzymes (figure 2).22 
This modification takes place during a variety of biological processes, including 
inflammation. In 1998, the first ELISA using citrullinated peptides (derived from 
several filaggrin epitopes) was developed21 and was followed, in 2000, by the first 
ELISA based on artificial cyclic citrullinated peptides (CCP).23 The first commercial 
version of this test, the CCP2 assay, became available in 2002 and enabled routine 
testing for antibodies directed against citrullinated epitopes as a biomarker for 
RA.23-27 As well as the CCP2 assay, a few other assays for ACPA, such as CCP3 and 
MCV (Mutated Citrullinated Vimentin), have made their way into the clinic. These 
assays differ slightly in terms of specificity and sensitivity.28 
Figure 2. Citrullination of an amino acid. Posttranslational modification of arginine 
into citrulline, mediated by peptidylarginine deiminase (PAD). 
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ACPA: cause or consequence?  
The association with RA  
ACPA are strongly associated with RA, which suggests they have a 
prominent role in disease pathogenesis. Indeed, it has been suggested that ACPA 
are the ‘spark that lights the RA fire’, and are directly involved in a vicious circle 
that explains the chronicity of RA.29-31 The efficacy of selective B-cell depletion in 
the treatment of RA provides evidence for the involvement of B cells and possibly 
autoantibodies in its pathogenesis.32, 33 Furthermore, most ACPA-positive patients 
with RA seem to be ACPA-positive years before the onset of disease34, although 
the extent of the ACPA armament seems to be limited at this preclinical stage. 
Moreover, ACPA levels show an increase around 2 years before the onset of 
symptoms, after which they seem to stabilize at fairly high levels.  
 
Histological differences in inflamed joints have been found between ACPA-
positive and ACPA-negative patients with RA. For example, synovial tissue 
immune cell infiltrates differ with respect to lymphocyte numbers as well as 
markers of fibrosis; altered synovial inflammatory architecture might indicate a 
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ACPA are strongly associated with RA, which suggests they have a prominent 
role in disease pathogenesis. Indeed, it has been suggested that ACPA are the 
‘spark that lights the RA fire’, and are directly involved in a vicious circle that 
explains the chronicity of RA.29-31 The efficacy of selective B-cell depletion in the 
treatment of RA provides evidence for the involvement of B cells and possibly 
autoantibodies in its pathogenesis.32, 33 Furthermore, most ACPA-positive patients 
with RA seem to be ACPA-positive years before the onset of disease34, although the 
extent of the ACPA armament seems to be limited at this preclinical stage. More-
over, ACPA levels show an increase around 2 years before the onset of symptoms, 
after which they seem to stabilize at fairly high levels. 
Histological differences in inflamed joints have been found between ACPA-pos-
itive and ACPA-negative patients with RA. For example, synovial tissue immune 
cell infiltrates differ with respect to lymphocyte numbers as well as markers of 
fibrosis; altered synovial inflammatory architecture might indicate a role for ACPA 
in synovial inflammation.35 
Interaction of the ACPA and RF responses 
Although the appearance of ACPA in the preclinical phase tends to precede that 
of RF, RF can also be detected years before clinical disease onset.34, 36 RF seems to 
preferentially interact with hypoglycosylated IgG.37 ACPA are hypoglycosylated as 
compared with total IgG38; thus, one might infer that RF can enhance the patho-
logical effects of ACPA through preferential binding to ACPA and potentiation of the 
subsequent immune response. 
Immunological consequences of ACPA deposition 
To be effective, antibodies must, in general, recruit immune effector mecha-
nisms mediated by activation of the complement system39 or Fc receptor-positive 
cells.40 The complement system can be activated via three pathways: the classi-
cal pathway, the lectin pathway and the alternative pathway.41 Each pathway is 
initiated by a specific recognition molecule. The classical pathway is initiated by 
complement C1q, the lectin pathway by mannose-binding lectin or ficolins, and 
the alternative pathway initiated through the spontaneous low level activation of 
C3. Initiation of complement activation via each of these pathways involves the 
formation of C3 convertase complexes (composed of different subunits in each 
pathway), which cleave complement C3 to produce biologically active complement 
fragments. These fragments attract and activate immune cells through their com-
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plement receptors. Intriguingly, ACPA can activate human complement not only 
via the classical pathway, which is known to be activated by antibodies present in 
immunecomplexes, but also via the alternative pathway.42 These observations are 
reminiscent of findings from animal models of arthritis, which show that the alter-
native pathway of complement activation is crucially involved in autoantibody-me-
diated arthritis.43 
Besides activating complement, ACPA are also readily capable of triggering im-
mune cell responses via Fc receptors (FcR). For example, immune complexes con-
taining ACPA and citrullinated fibrinogen have been shown to trigger TNF secretion 
through engagement of FcγR on macrophages.44 Such findings should be inter-
preted in the perspective that many immune complexed model antigens, such as 
ovalbumin, elicit similar effects. Thus these data do not necessarily indicate the 
involvement of ACPA in disease pathogenesis. Nevertheless they are of relevance 
to understanding the pathogenic role of ACPA, as they show that these autoanti-
bodies do have the potency to recruit powerful immune effector mechanisms. 
This notion is further supported by observations made in animal models showing 
that ACPA, reactive with several citrullinated antigens are able to initiate and en-
hance arthritis.45-48 Findings made in these models also indicate that ACPA recog-
nize citrullinated proteins in a hapten-like manner (that is, ACPA binds to citrulline 
as if it were a small molecule. This molecule can be recognized in the context of 
different protein backbones. Such a protein backbone is called a carrier which may 
be one that does not elicit an immune response by itself.).48 Thus, ACPA and an-
ti-CCP2 antibodies crossreact with a variety of citrullinated proteins that bear little 
sequence homology; this crossreactivity, however, is not absolute, as indicated by 
studies using specific citrullinated peptides, some of which did not bind ACPA.49, 50 
Altogether, these data provide fertile soil to fuel the hypothesis that ACPA play 
an important part in disease pathogenesis, although further evidence is required 
to substantiate this putative role in RA. In the following sections, we discuss char-
acteristics of the ACPA response, and summarize emerging evidence for how these 
antibodies are related to clinical course and treatment outcomes in RA. 
ACPA characteristics
The B-cell lineage generates antibody-secreting plasma cells and memory B 
cells, which have enhanced capability to respond to a specific initiating antigen by 
producing antibodies. The most important function of antibodies is protection of 
the host against invading pathogens, primarily through neutralization of molecules 
essential to the lifecycle of the pathogen and/or the recruitment of powerful im-
mune effector mechanisms capable of killing pathogens or pathogen-infected cells. 
To be properly effective, an antibody response needs to develop through avidity 
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maturation and isotype switching stages. T cells are intimately involved in these 
processes as they provide the helper activity essential for the maturation of most 
B cell responses (Figure 3). Similarly, diversification of the antibody response, 
through recognition of more epitopes, is thought to contribute to its efficacy. 
Figure 3. ACPA production by B cells can be stimulated by autoreactive T cells. 
Dendritic cells present peptides to naive T cells in complex with HLA class II molecules, 
activating the T cells and leading to TH cell-mediated stimulation of B cells. In the context 
of APCA production, it has been hypothesized that B cells can recognize citrullinated pep-
tide complexes, for example on apoptotic cells. B cells can internalize these complexes, 
process them and present peptides from them in complex with HLA molecules encoded by 
SE alleles (these peptides may or may not be citrullinated), to T cells. When T cells rec-
ognize those peptides they can provide help to the B cells, resulting in the production of 
ACPA. Antibodies to different epitopes (including citrullinated epitopes) of the internalized 
peptide complex can be produced, leading to the production of ACPA. Therefore, T cell help 
stimulates the production and maturation of ACPA. Abbreviations: ACPA, anti-citrullinated 
protein antibodies; SE, shared epitope; TH cell, T helper cell.
Fine specificity and epitope spreading
ACPA can recognize a variety of citrullinated antigens, including citrullinated 
fibrinogen51,52, citrullinated vimentin (which is also known as the Sa antigen),53 
citrullinated type II collagen54, citrullinated α-enolase55 and many more citrullinat-
ed proteins. An increase or shift in the antigen recognition profile (a phenomenon 
known as epitope spreading) can have important pathophysiological consequenc-
es, as has been described in, for example, systemic lupus erythematosus56 and 
pemphigus. Autoantibodies such as anti-desmoglein antibodies present in patients 
with pemphigus vulgaris have been convincingly shown to mediate a pathogenic 
effect, through transfer into experimental animals.57 Furthermore, in pemphigus 
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(of which there are two major types: pemphigus foliaceus and pemphigus vulgar-
is,) reactivity against different desmoglein epitopes is associated with different 
outcomes. In patients with pemphigus foliaceus, autoantibodies to desmoglein-1 
occur. These autoantibodies mediate blistering of the skin through loss of adhe-
sion in the superficial epidermis, where desmoglein-1, but not desmoglein-3, is 
expressed. By contrast, in mucosal pemphigus vulgaris, the presence of anti-des-
moglein-3 IgG antibodies causes blistering of the mucosae, where desmoglein-3 
is expressed.58 Importantly, the example of pemphigus elegantly demonstrates 
that intramolecular epitope spreading might modulate remissions and relapses, 
as autoantibodies that recognize the EC5 domain of desmoglein-1 seem to be 
nonpathogenic, whereas those directed against the EC1 and EC2 domain of the 
molecule are associated with disease onset and active disease. Passive transfer 
experiments have demonstrated that anti-EC1 and anti-EC2 autoantibodies are 
pathogenic, whereas anti-EC5 autoantibodies are incapable of inducing blisters in 
mice.59 Pemphigus is, therefore, a prototype disease that indicates the relevance 
of epitope spreading in the transition from the preclinical to the clinical stage of 
autoimmune disease. 
The ACPA immune response in RA starts several years prior to diagnosis of the 
disease, even before the onset of symptoms, but in a restricted manner with low 
antibody titers and limited peptide reactivity.60 ACPA titers and peptide-recognition 
profiles increase as the individual approaches disease onset (figure 4a).34 Likewise, 
in patients with arthralgia, the development of arthritis is predicted not only by 
the presence of ACPA, but also by their levels.61, 62 Indeed, patients with arthralgia 
who have an extended ACPA repertoire are at higher risk of developing arthritis.62 
Similarly, ACPA-positive patients with early arthritis that do not fulfill the American 
College of Rheumatology (ACR) classification criteria for RA are more likely to de-
velop RA if their ACPA response is reactive to more citrullinated epitopes.63 These 
findings are consistent with the notion that a ‘broader’ ACPA recognition profile 
is associated with the transition towards (persistent) disease, and resemble the 
observations made in pemphigus with the exception that, thus far, no specific an-
ti-citrullinated epitope or protein reactivity has been identified that would predict 
disease course in RA. Given the hapten-like recognition of citrullinated antigens 
and the high crossreactivity towards multiple citrullinated proteins of the ACPA 
response, this lack of fine specificity is perhaps not surprising. 
Isotype profiles
Isotype switching is another event involved in enhancing the efficacy of (auto)
antibodies, and leads to an increase in the diversity of antibody structure that en-
ables the activation of more immune effector mechanisms. ACPA can be present in 
different forms, including IgG, IgA, IgM and IgE (figure 4b).64, 65 
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Multiple ACPA isotypes are present before the onset of RA.64 Likewise, the ACPA 
isotype distribution does not seem to significantly expand anymore during disease 
progression from undifferentiated arthritis (UA) to RA, indicating that most of the 
expansion of isotype usage by ACPA takes places before the onset of arthritis.
Figure 4. Fine specificity and isotype profiles are important characteristics of an 
ACPA response. A. ACPA can recognize different citrullinated antigens, including for ex-
ample citrullinated vimentin, citrullinated fibrinogen and citrullinated α-enolase. Although 
it is the citrulline moiety that binds to the autoantibody, the context of the amino acids 
surrounding the citrulline are important for recognition by ACPA with differing fine speci-
ficities. The ACPA recognition profile seems to be established in undifferentiated arthritis, 
with a broader profile being associated with subsequent progression to persistent disease. 
The peptides presented by the B cells may or may not be citrullinated. B. Different anti-
body isotypes can activate the immune system via different pathways. For example, IgM, 
IgA and the different IgG subclasses activate the complement system to different extents. 
Although IgG is the most common isotype of ACPA in RA, the other isotypes also occur 
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in some patients. Different isotypes recruit different effector functions, for example, of 
IgE-ACPA it has been hypothesized that it can activate FcεR1-positive cells, such as mast 
cells, adding participation of these cells to a subsequent inflammatory process. Further-
more, the presence of IgM ACPA indicates an ongoing immune response, with recruitment 
of new B cells into the ACPA response. Abbreviations: ACPA, anti-citrullinated protein anti-
bodies; RA, rheumatoid arthritis. 
Maturation of the response 
During a B-cell response against recall antigens, isotype switching and affinity 
maturation typically occur in germinal centers. Following somatic hypermutation, 
different B-cell clones will compete for antigens presented on follicular dendritic 
cells. B cells that express immunoglobulins of sufficiently high avidity will acquire 
the signals necessary for survival and proliferation. As a result, the total avidity 
of the immune response—defined as the overall binding strength of polyclonal 
antibodies to a multivalent antigen—increases, because low avidity B cells will 
not be stimulated and will eventually disappear from the population. The avidity 
maturation of antibody responses against recall antigens, mostly following vacci-
nation, has been studied extensively, but autoantibody responses seem to behave 
differently.66,67,68 For example, the avidity of ACPA is significantly lower than the 
avidity of antibodies to the recall antigens tetanus toxoid and diphtheria toxoid, 
pointing to a different regulation of autoantibody responses as compared with re-
call antigens. In individual patients with RA, ACPA do not show avidity maturation 
during longitudinal follow up and even in patients who displayed extensive isotype 
switching, ACPA avidity was relatively low,69 indicating that these two maturation 
processes are uncoupled in the ACPA response. 
Glycosylation
Although the specificity of antibodies is determined by the variable region, anti-
body-mediated effector functions are crucially dependent on the interactions of its 
constant region (Fc part) with the complement system as well as with the Fc re-
ceptors. These Fc-mediated effects are influenced by Fc-linked carbohydrate struc-
tures known as glycans. By glycosylation, a posttranslational modification process, 
different kind of glycan structures can be attachted to the Fc-parts of the antibod-
ies, resulting in several different glycoforms in human serum. Glycosylataion of 
the Fc-tail of antibodies affects the recruitment of effector function, especially the 
binding to pro-inflammatory respectively anti-inflammatory Fc-receptors.44 Inter-
estingly, early studies have demonstrated a predominance of IgG-G0 (meaning 
without galactose) glycoforms in sera of RA patients, which correlated with dis-
ease activity and reverted to normal levels in patients who achieved remission.70, 
71 Scherer et al investigated whether the glycan chains carried by ACPA differ from 
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the glycans carried by other antibodies in the sera of RA patients.38 A comparison 
of serum ACPA IgG1 to total serum IgG1 revealed that ACPA were associated with 
a characteristic glycan profile lacking sialic acid residues. ACPA from synovial fluid 
of RA patients were highly agalactosylated and due to the attachment of sialic acid 
to galactose, thereby also lacked sialic acid. Since Fc glycosylation directly affects 
the recruitment of Fc-mediated effector mechanisms, these data could contribute 
to the further understanding of the role  of ACPA in disease pathogenesis of RA.
The data described above indicate that ACPA-producing B cells behave different-
ly from ‘conventional’ B cells. In 2010, rituximab was shown in mice to specifically 
deplete B cells that produce autoantibodies, while sparing the ‘conventional’ plas-
ma cells that produce protective antibodies.72 Treatments that target the crucial 
biological mechanisms underlying ‘conventional’ B-cell responses might, therefore, 
prove not to be as effective as anticipated, because ACPA-producing B cells might 
be following other biological routes.73
Figure 5. The maturation of the anti-citrullinated antibody response in the devel-
opment of RA. The maturation of the dragon is depicted as a metaphor for the develop-
ment of the ACPA response. Breaking of tolerance against citrullinated antigens can occur 
in healthy individuals, represented by the hatching of a dragon egg. Although immature 
in terms of isotype profile and breadth of antigen recognition, this early ACPA response 
might still be harmful, and potentially contributes to the progression of preclinical arthritis 
to early RA. We hypothesize that maturation of the ACPA response takes place during the 
preclinical phases, such that by the time early arthritis emerges clinically, the isotype and 
antigen-recognition profiles of the ACPA response are established. Greater breadth of ACPA 
isotype usage and/or recognition profiles predispose an individual to develop the full dis-
ease, but the ACPA response does not mature any further as the disease becomes more se-
vere. Abbreviations: ACPA, anti-citrullinated protein antibodies; RA, rheumatoid arthritis.
Together, the collection of data described above provides credible support for 
the notion that the ACPA response shifts from ‘infancy’ to ‘adulthood’ before tran-
sition to clinical disease (Figure 5). Whether the maturation of the ACPA response 
is a consequence or a cause of disease initiation is not known, but identifying the 
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master switches responsible for the expansion of the ACPA response might be in-
strumental for further elucidation of the disease pathogenesis. 
ACPA and clinical features 
ACPA-positive and ACPA-negative disease have been shown to be associated 
with different genetic and environmental risk factors, fuelling the hypothesis that 
different pathophysiological mechanisms underlie these two separate disease sub-
sets.74-76 For example, ACPA-negative RA associates with HLA-DR377 78, whereas the 
HLA shared epitope (SE) alleles predispose to ACPA-positive disease.74 Likewise, 
the contribution of smoking to disease risk is mainly confined to the ACPA-positive 
HLA-SE-positive patient group.76 Stratifying patients with RA on the basis of ACPA 
status has resulted in the identification of more homogenous patient groups, with 
respect to both disease course and response to treatment. 
ACPA and treatment outcomes 
So what are the therapeutic implications of subgrouping patients with RA ac-
cording to ACPA status? Logically, diseases with distinct pathogenesis might benefit 
from different treatment strategies. Methotrexate is the most prominent DMARD. 
A few years ago, we performed a double-blind placebo controlled randomized trial 
comparing two treatment strategies in patients with UA. Interestingly, the out-
come of this study indicated that ACPA-positive patients with UA treated with 
methotrexate are less likely to progress to RA, and do so at a later time point as 
compared with a placebo control group. Unexpectedly, no effect of methotrexate 
therapy on progression to RA in the ACPA-negative group was observed.79 In-
terestingly, among patients with UA, those with low or intermediate ACPA levels 
respond better to methotrexate than patients with high ACPA levels.80 The data 
from this randomized trial not only indicate that the two ACPA subgroups respond 
differently to methotrexate treatment, but also that in patients with high APCA 
levels methotrexate monotherapy might be insufficient. Indeed, the presence of 
ACPA and IgM RF together with elevated levels of C-reactive protein is predictive 
of more rapid radiographic progression in patients with RA. Patients with ACPA and 
IgM RF are also more likely to respond insufficiently to methotrexate monotherapy 
for recent-onset RA.81 
It is not only in regard to response to DMARDs that ACPA status seems to mat-
ter. In a trial published in 201182, 208 patients with RA refractory to therapy with 
TNF blockers were treated with rituximab. Rituximab is a monoclonal antibody 
directed towards the B-cell marker CD20, and has been shown to be an effective 
treatment in RA. In these patients, the presence of ACPA predicted a better EULAR 
response to rituximab at 24 weeks. Thus, rituximab might have a greater role in 
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ACPA-positive patients with RA than in ACPA-negative individuals.82 The mech-
anisms of rituximab efficacy, and of B-cell involvement in RA, are incompletely 
known; the basis for these differing outcomes remains to be elucidated. 
ACPA, remission and long-term monitoring
The absence of ACPA and IgM RF are independent predictors of drug-free re-
mission.83 As we have outlined, the course of ACPA-positive disease seems to be 
characterized by more persistent inflammation than its ACPA-negative counter-
part. Together, these data indicate that treatment decisions in RA can be guided 
by ACPA status. Seroconversion is uncommon among ACPA-positive and ACPA 
negative patients; therefore, it does not seem to be useful to repeat ACPA mea-
surements in daily practice.84, 85 Thus, these data support the hypothesis that RA 
can be classified into two different disease subsets, and suggest that developing 
different classification criteria for ACPA-positive and ACPA-negative RA might help 
to optimize treatment strategies. 
ACPA and disease outcome
The emerging relevance of ACPA status to treatment decisions is not only based 
on differential treatment efficacies, but is also supported by differences in disease 
outcome. Typically, 50–70% of the patients with RA are ACPA positive.86 Although 
ACPA-positive and ACPA-negative patients with RA show a very similar clinical 
presentation in the early phase of the disease87,88, their subsequent disease course 
is different—extra-articular manifestations are clearly influenced by ACPA status. 
For example, ACPA positivity is associated with an increased risk of developing 
ischemic heart disease89 or lung pathology.90 Likewise, ACPA-positive patients have 
more destructive disease than ACPA negative patients88, 91-93; ACPA-positive patients 
develop erosions earlier and more abundantly than patients without ACPA.94 Owing 
to their more severe disease-course, APCA-positive patients require a more aggres-
sive treatment regimen than ACPA-negative patients.95 Indeed, in the BeSt study 
ACPA-positive patients initially treated with DMARD monotherapy displayed greater 
radiographic joint destruction after 2 years than ACPA-negative patients.95 In patients 
initially treated with combination therapy, by contrast, no difference with respect to 
joint destruction was observed between ACPA-positive and ACPA-negative patients. 
These observations suggest that effective treatment with combination therapy, to-
gether with steering treatment according to disease activity, can prevent radiographic 
progression, even in patients with risk factors for severe damage, such as ACPA-pos-
itive patients. 
The ACPA isotype profile has been associated with a higher risk of radiographic pro-
gression, leading to a 1.4-fold increase in risk per isotype used in the ACPA response, 
illustrating that an extended isotype usage is associated with a worse outcome.96 
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Altogether, evidence is emerging that ACPA-positive and ACPA-negative RA rep-
resent two different disease entities with different outcomes, and, possibly, differ-
ent responses to medication. The latter notion is especially important as it indi-
cates that treatment regimes can be optimized by developing them according to 
ACPA status. 
OUTLINE OF THIS THESIS
The general aim of this thesis was to elucidate the immunological properties 
of ACPA and to investigate the association between ACPA characteristics and the 
disease course of RA. 
ACPA display high association with RA and are implicated in its pathogenesis. 
The presence of ACPAs is known to precede the onset of RA.34, 36 North American 
natives have previously been reported to have a younger age at disease onset and 
an increased prevalence and severity of RA. Genetic studies have also revealed a 
higher prevalence of HLA DRB1 SE alleles in North American natives and increased 
frequency of RF positivity in patients with RA in several North American native 
populations.97 In order to identify the features of ACPA that could confer its patho-
genicity, we extensively characterized this antibody response in a unique North 
American native population of patients with RA and their unaffected relatives in 
chapter 2. 
Furthermore, the synovium is the primary site of pathology in RA, and ACPA are 
readily detectable in the synovial fluid of patients with RA.98 The transition from as-
ymptomatic autoimmunity to clinically detectable synovitis is not well understood. 
Chaper 3 describes the serological and synovial features of a young woman from 
a multi-case RA family from a North American Native population who initially had 
asymptomatic autoimmunity, then subsequently developed clinical features sug-
gestive of early RA.
HLA SE alleles are known to be associated with RA susceptibility99, specifically 
susceptibility to ACPA-positive RA.100 Furthermore, smoking is known to predispose 
to the development of ACPA-positive RA. The combined effect of HLA SE alleles 
and smoking are known to exceed the sum of their single effects: a phenomenon 
known as biological interaction.76, 101, 102 Recent data suggest that a gene–envi-
ronment interaction between smoking and the HLA shared epitope alleles plays a 
role in shaping the autoimmune reaction towards a specific citrullinated antigen.103 
More recently, however, our group has reported a similar interaction for 2 pep-
tides derived from 2 other citrullinated proteins, citrullinated vimentin and ci-
trullinated fibrinogen.104 These latter data indicate that the observed interaction 
might not be confined to an autoimmune response against a specific citrullinated 
antigen. Rather, these findings indicate that these interaction effects extend to 
several citrullinated autoantigens, which might even be explained by a gener-
1
General introduction 21
al predisposition to ACPA development. In chapter 4, we aimed to analyze in 
greater detail the extent of the interaction between HLA shared epitope alleles 
and tobacco exposure on the antigen-recognition profile of ACPA, especially in 
ACPA-positive patients in order to exclude the possibility that the association is 
caused by the presence of ACPA rather than by the presence of an autoimmune 
reaction to specific citrullinated epitopes. 
Another citrullinated protein in inflamed synovial tissue identified previously is 
fibronectin (FN).105 FN, one of the most abundant proteins present in the inflamed 
joint, is a glycoprotein, which can be a component of the extracellular matrix (in-
soluble form) or present in body fluids (soluble form). FN is involved in a variety 
of processes, such as wound healing, haemostasis, thrombosis and embryogen-
esis.106 In chapter 5 we characterized the citrullination of fibronectin in the joints 
of RA patients and studied the prevalence, epitope specificity and HLA association 
of autoantibodies against citrullinated fibronectin in RA.
HLA SE alleles are not only associated with the presence of ACPA74, but also with 
joint destruction107 and the ACPA fine specificity repertoire.108 A large variation in 
joint destruction is seen within the ACPA-positive patient population. It is conceiv-
able that certain citrullinated antigens are more potent than others in activating T 
cells in the context of HLA SE alleles. HLA SE alleles were found to associate with 
antibodies targeting peptides from citrullinated vimentin, but not with the pres-
ence of antibodies recognizing citrullinated fibrinogen.108 This differential modula-
tion of the ACPA response by SE-alleles, and the fact that disease phenotypes vary 
greatly among ACPA-positive patients, has raised the question whether certain 
ACPA fine-specificities might associate with a more severe disease phenotype. If 
so, designing assays that test for these specificities would be of prognostic value 
and could influence treatment decisions in the clinic. Therefore, in chapter 6 we 
investigated whether ACPA fine-specificities, which are formed under the influence 
of SE-alleles, associate with the extent of radiographic joint damage. 
Furthermore, it is conceivable that a certain ACPA recognition profile is associ-
ated with the emergence of certain clinical features and possibly pathogenicity in 
RA, as has been shown in other autoimmune diseases. For example, in pemphigus 
the reactivity against different desmoglein epitopes is associated with different 
outcomes.59 In chapter 7 we determined the association between the ACPA fine 
specificity and phenotypic characteristics within ACPA-positive RA and investigated 
whether specific subsets of RA patients can be distinguished on the basis of their 
epitope recognition profile.
Very early therapy in RA with disease-modifying antirheumatic drugs is associ-
ated with lower levels of joint destruction and a higher chance on achieving remis-
sion.109-113 Having symptoms for >12 weeks at treatment initiation is a strong and 
independent risk factors for a persistent disease course.109, 111-113 These observa-
tions have led to the hypothesis that the ‘window of opportunity’ exist early in dis-
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ease.110 This hypothesis presumes that underlying disease processes are not fully 
matured in the very early stage of arthritis, making modulation more successful. 
As ACPA precede arthritis development and are associated with a severe disease 
course114, we hypothesized that the ACPA response broadens within the very early 
phase of RA and in doing so limits the ‘window of opportunity’. Therefore, it was 
examined in chapter 8 whether patients who were assessed within 12 weeks of 
symptom onset have a less broadened ACPA response than patients with longer 
symptom duration. 
The ACPA response likely represents a T-cell-dependent B-cell response, given 
the protein nature of the antigen recognized and the strong association with the 
HLA SE alleles. The evolution of such a response is typically characterized by a 
first wave of IgM antibodies after the first antigen contact, quickly followed by the 
presence of IgG. After repeated antigen exposure, the IgG responses are further 
boosted while the IgM peak declines. Therefore, it is conceivable that the presence 
of IgM ACPA suggests that activation of recently recruited naïve B cells recognize 
citrullinated antigens because the half-life of circulating IgM is short. In chapter 9 
we determined whether there is a difference in the fine specificity of IgG and IgM 
ACPA.
Previously it has been shown that the levels of anti-CCP2-antibodies are higher 
in synovial-fluid than serum.115-117 However, very limited information on absolute 
levels of ACPA in either synovial-fluid or serum is present as the levels are gener-
ally expressed as arbitrary units. Nonetheless, it is interesting to obtain informa-
tion on the absolute concentration of ACPA as this would allow the comparison of 
the ACPA-response to other antibody responses in quantitative terms. In order to 
quantitate ACPA-levels it is required to isolate ACPA. In chapter 10 we present 
data on the estimation of the minimal ACPA quantities in serum and synovial-fluid.
Recently, a novel family of autoantibodies in RA patients was described: an-
ti-carbamylated protein (Anti-CarP) antibodies, which target carbamylated (ho-
mocitrulline-containing) epitopes.118, 119 Since citrulline and homocitrulline have a 
similar structure, in chapter 11, we wished to determine to what extent human 
autoantibodies can differentiate between them. Unlike human antibodies, the an-
ti-modified citrulline (AMC) antibody developed by Dr Senshu120 is able to recog-
nise citrullinated epitopes irrespective of the neighbouring amino acids. Therefore, 
we also aimed in to verify whether the AMC assay could distinguish between these 
two amino acids.
Finally, chapter 12, provides a summary of the results and a discussion of the 
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Anti–citrullinated protein antibodies (ACPAs) display high association with rheuma-
toid arthritis (RA) and are implicated in its pathogenesis. The presence of ACPAs 
is known to precede the onset of RA. In order to identify the features that could 
confer its pathogenicity, we extensively characterized this antibody response in a 
unique North American native population of patients with RA and their unaffected 
relatives.
Methods 
The levels of IgA, IgM, and IgG ACPAs, as well as IgM and IgA rheumatoid factor 
(RF), were measured in serum samples obtained from 81 patients with RA and 
195 of their unaffected relatives. The isotype distribution, the fine specificity of the 
ACPA response, and its association with RF were compared in health and disease.
Results  
ACPA positivity was observed in 19% of the healthy relatives and ~91% of the 
patients with RA. ACPA isotype usage was strikingly lower in unaffected relatives 
than in patients with RA (1–2 versus 5–6 isotypes). Fine specificity studies showed 
that reactivity to citrullinated fibrinogen and vimentin was present in sera from pa-
tients with RA, while it was virtually absent in their unaffected relatives. Finally, the 
ACPA and RF responses were associated in patients with RA but were discordant 
in their healthy relatives. Extended analyses revealed that the presence of ACPAs 
was associated with RA irrespective of RF status, while the association of RF with 
disease relied on its interaction with ACPAs.
Conclusion 
The fine specificity and isotype usage of the ACPA response are qualitatively dif-
ferent in health and disease. Epitope spreading and expansion of the isotype rep-
ertoire might be necessary for development of RA, and this could be facilitated by 
the presence of RF antibodies.
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INTRODUCTION
Autoantibodies are characteristic of a large number of autoimmune diseases. De-
termining the pathogenicity of autoantibodies by showing their capacity to transfer 
disease, however, is complicated by ethical and practical difficulties. Therefore, 
only a small minority of autoantibodies, such as antiplatelet antibodies in idiopath-
ic thrombocytopenia purpura or the antidesmoglein antibodies in pemphigus vul-
garis, were convincingly shown to mediate a pathogenetic effect through placental 
transfer1 or transfer into experimental animals2, respectively. 
Autoantibodies sometimes are found in healthy individuals as well and often are 
present years before the disease presentation. A detailed understanding of the 
characteristics of the autoantibody response that render it pathogenic is, there-
fore, of utmost importance, because such an understanding would allow targeted 
intervention in individuals at risk, before disease onset. Several characteristics of 
autoantibodies have been associated with pathogenicity. In pemphigus vulgaris, a 
skin disease, reactivity to different desmoglein epitopes is associated with different 
disease outcomes.3 In antibody-mediated models of arthritis in mice, a combina-
tion of antibodies with different fine specificities and isotypes was found to be more 
efficient than a single antibody in inducing disease.4, 5 Moreover, in these models, 
soluble immune complexes were shown to facilitate the access of pathogenic an-
tibodies to the joint.6
 Rheumatoid Arthritis (RA) is strongly associated with the presence of auto-
antibodies. Although the involvement of autoantibodies in RA is poorly understood, 
studies in several mouse models of arthritis indicate that autoantibodies are cru-
cial to disease induction and progression.7, 8 Among the different autoantibodies 
described in patients with RA, the anti-citrullinated peptide antibodies (ACPA) dis-
play the strongest RA specificity for RA (95-98%), with 70–80% sensitivity.9 The 
presence of ACPA in patients with recent-onset RA is predictive for progression to 
erosive RA10, 11 and their presence in patients diagnosed with undifferentiated ar-
thritis is highly predictive of progression to RA.12 Likewise, ACPAs were shown to 
contribute to disease progression in a mouse model of arthritis.13 Taken together, 
data from human and mouse studies indicate that ACPAs are a possible pathoge-
netic mechanism in RA. 
 The prevalence of the ACPA response in healthy Caucasians is estimated to 
be 1-2% of the population.14 Information about ACPAs in unaffected individuals is 
therefore scarce in the literature, and originates from retrospective studies that 
involve serum samples collected from patients with RA before disease onset.15, 
16 These studies, however, did not investigate the characteristics of the ACPA re-
sponse in health versus disease. Characterization of the ACPA response, including 
isotype usage and fine specificity, in healthy individuals and patients with RA would 
provide valuable information about features of the ACPA response that could be 
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associated with pathogenicity and could indicate the biological pathways involved 
in disease development. 
 North American Natives have previously been reported to have a younger 
age at disease onset and an increased prevalence and severity of RA. Genetic stud-
ies have also revealed a higher prevalence of shared epitope (SE) alleles in North 
American Natives and increased frequency of rheumatoid factor (RF) positivity in 
patients with RA in several North American native populations.17 The high predis-
position to RA prompted us to investigate the presence of the ACPA response in a 
unique population of patients with RA and their unaffected relatives from a North 
American native population in Central Canada. 
 Surprisingly, our results show a high prevalence of ACPAs in unaffected 
relatives of patients with RA in this population. This remarkable feature of this 
population allowed us, for the first time, to extensively study and compare the 
main characteristics of the ACPA response in health and disease and to identify the 
features that could confer its pathogenicity.
PATIENTS AND METHODS 
Patients, relatives and control subjects
Patients with RA were selected from a Cree and Ojibway population in Central 
Canada. Probands visiting rheumatology clinics in urban (Winnipeg, Saskatoon) 
and rural (Norway House, St Theresa’s Point) locations were recruited, and each 
patient was asked to bring along unaffected relatives who were willing to partici-
pate in this study. The unaffected population consisted mainly of first-degree rela-
tives (75.5%), with the remainder being second-degree relatives. Additionally, 91 
unrelated healthy controls were recruited from the same populations. Eighty-five 
families were included, comprising 76 probands and 208 relatives. Serum samples 
from 9 probands are missing. The largest family consisted of 1 proband and 13 
relatives. 
The characteristics of the patients with RA and their healthy relatives who were 
included in this study are shown in Table 1. RA was diagnosed according to the 
American College of Rheumatology (formerly, the American Rheumatism Asso-
ciation) 1987 revised criteria.18 Clinical assessment of swollen, stiff and painful 
joints of all patients and relatives was performed by a rheumatologist at the time 
of inclusion in the study. The number of swollen joints is available for 62 probands 
(76.3%). Of these patients, 9 had no swollen joints at the first visit. Among the 
relatives, 5 were found to have RA, and 3 of these patients were also currently re-
ceiving disease modifying antirheumatic drugs. These 5 individuals were analyzed 
as part of the RA population. Of the remaining group of relatives, 8 presented with 
>1 swollen joint at the time inclusion but did not meet the criteria for RA or any 
other rheumatic disease and were classified as having undifferentiated arthritis. 
2
ACPA characteristics in health and disease 37
The 91 unrelated controls had no swollen joints at the time of inclusion and no 
first-degree relative with RA. Their median age was 30 years (range 18-88 years) 
and 39.6% were women. Written consent was obtained from all participants, and 
the protocol was approved by the Biomedical Research Ethics Boards of the Univer-
sity of Manitoba and by the Band Councils of each rural community.  
ACPA isotypes
ACPA isotypes (IgA, IgG1, IgG2, IgG3, IgG4 and IgM) were measured in base-
line serum samples obtained from patients with RA, their healthy relatives and 
unrelated healthy control subjects, using CCP2 plates (Euro-Diagnostica, Arnhem, 
The Netherlands) and a previously described enzyme-linked immunosorbent assay 
(ELISA).19 A successive dilution of one reference standard, consisting of a pool of 
20 ACPA-positive samples, was used in all plates. Distinct dilutions of this standard 
(for IgA and IgM, 1:12.5; for IgG1, 1:400; for IgG2, 1:6.25; for IgG3 and IgG4, 
1:12.5) were defined as containing 1,000 arbitrary units (AU) per milliliter. 
Fine-specificity measurements
Antibodies against the Sa antigen were detected by ELISA as anti-citrullinated 
myelin basic protein and confirmed by Western blot analysis as anti-citrullinat-
ed vimentin, as previously described.20 The screening dilutions ensuring 99% RA 
specificity were 1:300 in ELISA and 1:100 in Western blot analysis. The anti-Sa 
ELISA cutoff is based on 2 SD of the value for non-RA Caucasian control subjects 
with connective tissue diseases. Human fibrinogen (Sigma-Aldrich, Zwijndrecht, 
The Netherlands) was also citrullinated as previously described21, under nonde-
naturing conditions. For detection of antibodies against citrullinated fibrinogen, 
MaxiSorp microtiter plates (Nunc, Sanbio, The Netherlands) were coated with 1 
µg/well citrullinated fibrinogen or native fibrinogen in phosphate buffered saline 
(PBS)(pH 9.0) and were incubated overnight at 4°C. Plates were washed 4 times 
with PBS/0.05% Tween-20 after this and all other incubation steps. After blocking 
with 2% Bovine serum albumin (BSA)/PBS (pH 9.0) for 2 hours at room tempera-
ture, plates were incubated with serum samples diluted 1:50 in radioimmuno-
assay (RIA) buffer/5% normal sheep serum (Sigma-Aldrich), for 1 hour at room 
temperature. Antibodies to citrullinated fibrinogen/fibrinogen were detected using 
rabbit anti-human IgG-horseradish peroxidise (DAKO, Glostrup, Denmark), diluted 
1:10,000 in RIA buffer, by incubating the plate for 1 hour at room temperature. 
Bound antibodies were visualized using avidin-biotinylated enzyme complex. 
The same reference standard as that used for measurements of ACPA isotypes 
was used in the citrullinated fibrinogen ELISA. The 1:12.5 dilution was defined as 
containing 1,000 AU/ml of antibody. For the anti-Sa ELISA, reference standards 
are based on optical density (OD) values given by low, medium and high serum 
titers at a 1:300 dilution in 1% BSA.20
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The following linear citrullinated peptides and their native counterparts were 
used for fine-specificity studies: C2 (vim) (STCit SVS SSS YCitCit MFG G)22 and C3 
(vim) (VYA TCitS SAV CitLCit SSV P)23 derived from human vimentin, C4 (fib) (NEE 
GFF SACit GHR PLD KK)23 and C5 (fib) (FLA EGG GVCit GPR VVE RH) (unpublished 
data) derived from human fibrinogen, and C6 (enolase) (KIH ACitE IFD SCitG NPT 
V)24 derived from human non-neuronal enolase. All synthetic peptides were coated 
on streptavidin-coated plates (Fisher, Winnipeg, Manitoba, Canada) via a C-ter-
minal long-chain biotin. Detection of antibodies recognizing these peptides was 
performed as described.23
A successive dilution of one serum sample reactive with all vimentin and fibrino-
gen peptides was used as reference standard for these peptides. The 1:25 dilution 
of the reference sera was defined as containing 1,000 AU/ml of antibody. 
Determination of cut-off values for ACPA ELISA assays
The level of specific antibodies in each serum sample was determined using the 
reference standard curve. Cutoff values for the citrulline-specific responses were 
calculated in each assay and were defined as 2 SDs above the mean concentration 
of serum samples obtained from 30 healthy Caucasian control subjects. In case 
the concentrations of several control samples were below the detection limit of 
the ELISA, the cutoff was calculated as the lowest concentration situated on the 
ascending region of the standard curve. Borderline samples (with concentrations 
between 10 AU above and 10 AU below the cut-off value) were tested at least twice 
for IgA ACPA and all IgG isotypes. All samples that reacted with the citrullinated 
peptides in fine specificity assays were retested. Only samples that were positive 
every time tested were considered positive. 
In fine-specificity studies, citrulline-specific signals were defined as a positive 
signal against the citrullinated antigen and a negative signal against the uncitrulli-
nated antigen, with a minimum difference of 0.1 in OD values. For uncitrullinated 
control antigens, a signal higher than 2 SDs above the average OD value for at 
least 4 Caucasian control subjects tested on the same plate was considered posi-
tive. Samples were tested on the same plate for citrullinated and control antigens 
to minimize experimental variations in OD measurements. 
Rheumatoid Factor measurements
IgM RF values reported throughout the study were determined by nephelome-
try. IgA-RF and IgM-RF were also measured by ELISA, using human IgG1 as the 
capture antigen and F(ab’)2 fragments of peroxidise-conjugated anti-human IgA 
or IgM, as previously described.25 The cutoff values used to assign positivity were 
based on 60 Caucasian controls. The IgM-RF values as determined by ELISA were 
comparable to those obtained by nephelometry. 
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Statistical analysis
Statistical analyses were performed using SPSS version 14.0 software (SPSS, 
Chicago, IL). Differences in the distribution of the ACPA isotypes between patients 
with RA and their healthy relatives were calculated using the chi-square test. The 
chi square test was also used for calculating odds ratios (ORs) with 95% confi-
dence intervals (95% CIs), and P values were used for the association of RF and 
ACPA with RA. When a cell contained fewer than 5 individuals, the P value was 
calculated with Fisher’s 2-tailed exact test. P values less than 0.05 and 95% CIs 
which excluded the value of 1 were considered significant. Multivariate logistic re-
gression analyses with IgM-RF and ACPAs or IgA RF and ACPAs as covariates were 
performed for testing the interaction between RF and ACPAs. 
Moreover, the individual variables significantly associated with RA were also 
tested in a multivariate and conditional logistic regression with age and sex as 
possible confounders (data not shown). These analyses were performed using the 
Stata 9.0 software (StataCorp, College Station, TX). 
RESULTS
The characteristics of the patients with RA and their healthy relatives included 
in this study are shown in Table 1. The patients were significantly older than the 
healthy relatives (median 52 years versus 35 years; p<10-8 by Mann-Whitney-
test) and were more likely to be females (p=0.001 by Chi-square test). Correction 
for these variables, as described in Materials and Methods, did not result in signif-
icant changes in ORs and P values (data not shown). 
We first determined the prevalence of ACPA in the patients with RA and their 
relatives (Table 2). The prevalence of ACPAs was 91.4% in the patients with RA. 
Intriguingly, an unusually high prevalence of ACPAs (19.0%) was also found in the 
healthy relatives. Of the unrelated healthy control subjects, 8.8% were positive 
for ACPAs; this prevalence was significantly lower than the prevalence in relatives 
(P=0.03 by chi-square test), although it was still higher than the prevalence re-
ported in healthy Caucasians. These data suggest that there is a high background 
frequency of ACPAs in this healthy North American native population, which is 
higher in the relatives of patients with RA compared with unrelated healthy indi-
viduals. Of note, the small subset of relatives who presented with undifferentiated 
arthritis at baseline, the frequency of ACPAs was intermediate (37.5%). This group 
was excluded from further analyses, due do its small size.
The most prevalent isotypes were IgG1 and IgA, with a higher prevalence in 
patients with RA than in control subjects (Table 2) (for IgG1, 98.6% versus 62.2% 
[P<10-6]; for IgA, 82.4% versus 32.4% [P<10-6] for ACPA-positive patients with 







Age, median (range) years 52 (19-76) 35 (18-78)




  Norway House
















No. of DMARDS, mean   
(range)  
3.1 (0-8) 0 (0-0)
Erosions 40.3 Not tested
No. of swollen joints, median 
(range) 
3.5 (0-36) 0 (0-0)
Diagnosis     
  RA








Table 1. Clinical characteristics of the study populations. Except where indicated oth-
erwise, values are the percent of patients with rheumatoid arthritis (RA) and their healthy 
relatives. Health Assessment Questionnaire (HAQ) scores were determined in 70 patients 
with RA. The use of disease-modifying antirheumatic drugs (DMARDs) was assessed in 71 
patients. The presence of erosions was determined in 67 patients with RA. The number of 
swollen joints was determined in 62 patients with RA and in 187 healthy relatives.
detectable in a significant percentage of patients with RA, but were virtually unde-
tectable in the healthy relatives (Table 2). As a consequence, the total number of 
isotypes used (Table 3) was also markedly different in patients with RA compared 
with their healthy relatives. Although many serum samples from patients with RA 
(n=20) were positive for all 6 ACPA isotypes, sear from healthy ACPA-positive rela-
tives showed usage of mostly 1 isotype (n=30) or a maximum of 2 (n=7). These data 
indicate the presence of a broader ACPA response in patients with RA compared with 
their healthy relatives, suggesting that the immune response to citrullinated antigens 
in the healthy relatives is relatively limited compared with that in the patients. 
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Table 2. Percentage of individuals positive for ACPAs and for isotypes of ACPAs 
and RF in the healthy and affected population. IgA rheumatoid factor (IgA-RF) pos-
itivity was determined in 185 healthy relatives, 7 relatives with undifferentiated arthritis, 
and 79 patients with rheumatoid arthritis (RA). ACPA = anti–citrullinated protein antibody; 
ND = not determined.

























Table 3. ACPA isotype usage in probands and relatives. For differences between the 
distribution of the number of isotypes used in healthy relatives and patients with rheuma-
toid arthritis (RA), P< 10-35; for differences among patients with RA, P= 0.20, by chi-square 
test. ACPA = anti–citrullinated protein antibody.
Expansion and maturation of antibody responses include not only extended 
isotype usage but also intramolecular and intermolecular epitope spreading.3 We 
therefore studied the fine specificity of the IgG ACPA response in paitents with RA 
and their healthy relatives. We specifically examined the recognition of citrullinated 
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fibrinogen and vimentin (the Sa-antigen), autoantigens expressed in the inflamed 
joint that have been shown to be recognized by IgG ACPAs from patients with RA.26 
27 The results depicted in Table 4 show that although citrullinated fibrinogen and 
Sa were recognized by IgG ACPAs from more than half of the patients with RA, vir-
tually none of the IgG ACPA-positive sera from healthy relatives recognized these 
antigens. (The results described in Table 4 were obtained with a linear α-enolase 
peptide containing a small difference in sequence compared with the peptide used 
by Lundberg et al, whose report appears elsewhere in this issue28). Interestingly, 
most of the RA sera that reacted with citrullinated antigens recognized both citrul-






    Anti-Sa
    Anti-Citrullinated fibrinogen
    Anti-Sa and anti-citrullinated fibrinogen
Peptides
    C2 (vim)
    C3 (vim)
    C4 (fib)
    C5 (fib)
    C6 (enolase)
0.0                                
3.7                                
0.0                                
0.0                                 
0.0                               
0.0                               
0.0                                 









Table 4. Percentage of IgG ACPA-positive individuals whose sera recognized ci-
trullinated vimentin/SA and/or fibrinogen or citrullinated peptides derived from 
these antigens. Sera from individuals positive for IgG anti–citrullinated protein antibodies 
(ACPAs) were tested for recognition of citrullinated vimentin (anti-Sa) or anti–citrullinated 
fibrinogen or peptides derived from citrullinated vimentin (C2 [vim] and C3 [vim]), ci-
trullinated fibrinogen (C4 [fib] and C5 [fib]), or citrullinated enolase (C6 [enolase]). RA= 
rheumatoid arthritis.
Furthermore, a spectrum of citrullinated epitopes previously shown to be rec-
ognized by sera from patients with RA, were also tested for recognition by the 
IgG ACPA-positive sera in this study. The vimentin and fibrinogen epitopes were 
selected from larger sets of peptides that were derived from the amino acid se-
quences of human vimentin and the α- and β-chains of human fibrinogen. The pep-
tides were selected from these sets based on the fact that they allowed adequate 
differentiation of ACPA fine specificities. The α-enolase peptide was synthesized 
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based on a study demonstrating that this is the most frequently recognized epitope 
of that protein.24 We observed the same striking difference between reactivities, 
with a significant proportion of RA sera recognizing 1 or more citrullinated epi-
topes (41.1% of IgG ACPA-positive patients), while virtually none of the sera from 
healthy relatives reacted against the citrullinated peptides tested. Taken together, 
these data indicate a markedly different recognition of citrullinated antigens by 
ACPAs in health and disease.
Previous retrospective studies have shown that the specificity and positive pre-
dictive value of ACPAs for RA are increased when ACPAs are combined with RF 
antibodies, especially of the IgM and IgA isotypes.14-16 Therefore, we also studied 
the association of IgM-RF and IgA-RF with the ACPA response in health and dis-
ease. The data shown in Table 5 indicate that having both IgM-RF and ACPAs is a 
characteristic feature of RA (present in 65 of 81 patients with RA), although pos-
itivity for both IgM-RF and ACPAs was rare in healthy relatives (7 of 195 healthy 
relatives) (OR 209, 95% CI 68–647 [P< 10-35] for IgM-RF-negative ACPA-negative 
versus IgM-RF-positive ACPA-positive). Similar data were obtained for IgA-RF and 
ACPAs (OR 63, 95% CI 22–179 [P<10-22] for IgA-RF-negative ACPA-negative ver-
sus IgA-RF-positive ACPA-positive) (Table 6).
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Table 5. Association of ACPAs and IgM-RF with RA. Values are the number of healthy 
relatives and patients with rheumatoid arthritis (RA) positive for IgM rheumatoid factor 
(IgM-RF) and/or anti–citrullinated protein antibodies (ACPAs). P values were calculated by 
chi-square test or, when a cell contained fewer than 5 events, by Fisher’s exact test. OR = 
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Table 6. Association of ACPAs and IgA RF with RA. Values are the number of healthy 
relatives and patients with rheumatoid arthritis (RA) positive for IgA rheumatoid factor 
(IgA-RF) and/or anti–citrullinated protein antibodies (ACPAs). P values were calculated by 
chi-square test or, when a cell contained fewer than 5 events, by Fisher’s exact test. OR= 
odds ratio; 95% CI= 95% confidence interval.    
Furthermore, after stratification for the presence of either IgM-RF or IgA-RF and 
ACPAs, we observed that the presence of ACPAs was significantly associated with 
RA, irrespective of IgM-RF. However, this association became stronger in the pres-
ence of IgM-RF. Intriguingly, IgM-RF was not associated with RA in the absence 
of ACPAs, but the association became significant when ACPAs were also present. 
These results suggest that the association of IgM-RF with RA is attributable to an 
interaction with ACPAs. This was further supported by a multiple logistic regression 
analysis indicating that the odds for having RA when both antibodies were present 
was 31.64 times higher than expected based on the ORs for the individual anti-
bodies (P=0.005). 
When we stratified for the presence of IgA-RF and ACPAs, we observed that 
ACPAs were associated with RA irrespective of positivity for IgA-RF, but this asso-
ciation is stronger in the presence of IgA-RF. Furthermore, an association between 
IgA-RF and RA was present only in the presence of ACPAs, but it did not reach 
the level of significance. Likewise, a logistic regression analysis indicated a trend 
toward an interaction between IgA-RF and ACPAs (exp(B)=2.79; P=0.276); how-
ever, this trend did not reach the level of significance. 
Taken together, these data confirm the previously recognized association of IgM/
IgA-RF with RA, but this study is the first to show that this association is attribut-
able to an interaction with ACPAs.  
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DISCUSSION
In this study, we have characterized the ACPA response in a unique population 
of patients with RA and their unaffected relatives. The cohort was derived from 
the North American native populations in Central Canada, characterized by a high 
prevalence of RA and frequent multicase families (29 and Peschken C et al, unpub-
lished data). We detected a surprisingly high frequency of ACPAs in the unaffected 
relatives. This offered us the opportunity to study and compare the characteristics 
of the ACPA response in health and disease. Our data indicate the presence of a 
qualitatively different ACPA response in the 2 populations, characterized by more 
extensive isotype usage and recognition of citrullinated antigens present in the 
inflamed joints exclusively by sera from patients with RA. Moreover, by studying 
ACPAs in relation to IgM-RF and IgA-RF, we found that ACPAs are associated with 
RA independently of RF, while RF is associated with RA only in the presence of 
ACPAs. Our data indicate the presence of an interaction between these risk factors, 
with high odds for having RA when both antibodies are present. 
To our knowledge, this is the first report of such a high prevalence of ACPAs in 
an unaffected population. Although the cause of this phenomenon is unknown, it 
has previously been shown that the Cree and Ojibway populations have a high fre-
quency of disease predisposing SE alleles (59%).30 Furthermore, we have shown in 
a Dutch population that SE alleles are a risk factor for the development of ACPAs 
rather than an independent risk factor for RA.31 We are currently investigating 
whether this is also true for our North American native population of healthy rel-
atives of patients with RA. 
Previous retrospective studies have indicated that the presence of ACPA often 
precede disease onset. Considering that the unaffected relatives are, on average, 
younger than patients with RA, it is conceivable that disease will develop in the 
future in at least some of the ACPA-positive relatives. Follow-up studies are cur-
rently under way and will provide valuable information about changes in antibody 
characteristics that may be associated with disease development.  
Although we detected a relatively high prevalence of ACPAs in the population 
of healthy relatives, our data indicate that the mere presence of ACPAs is not 
enough to induce disease. The limited ACPA isotype usage in the healthy relatives 
is consistent with a relatively immature autoantibody response. In patients with 
RA, chronic exposure to citrullinated antigens in the joint conceivably results in 
continuous (re)activation of antigen-specific B cells and favors isotype switching. 
This hypothesis is also supported by the low frequency of IgM ACPAs in healthy rel-
atives (4 of 37 ACPA-positive individuals), as IgM is indicative of ongoing immune 
responses. 
The fine-specificity data indicate that ACPAs recognize at least partially different 
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antigens in patients with RA and their healthy relatives, with responses against 
citrullinated fibrinogen and citrullinated vimentin/ Sa being present in more than 
half of the patients while being virtually undetectable in their healthy relatives. 
These citrullinated antigens are present in the inflamed joint and may serve as an 
important source of continuous antigen stimulation in RA synovium.26, 27 In con-
trast, the antigens that stimulate the ACPA response in healthy individuals and are 
responsible for the initial loss of immune tolerance are currently not known. Based 
on observations made in several populations, it has been hypothesized that the as-
sociation between smoking and ACPAs may be attributable to increased expression 
of citrullinated antigens in the lungs of smokers.32-34 Alternatively, it has been pro-
posed that the oral pathogen porphyromonas gingivalis, which is capable of citrul-
linating endogenous antigens, may be involved in the initial breaking of immune 
tolerance.35 To address these hypotheses, a spectrum of environmental stimuli 
and their association with fine-specificity of ACPAs will need to be systematically 
examined in multiple populations, particularly genetically susceptible populations, 
such as North American natives.       
An important observation made in this study is that the ACPA and RF respons-
es are closely associated in the patients with RA while being discordant in their 
healthy relatives. Although IgG-RF was not tested in this study due to technical 
difficulties, these results are consistent with results from earlier studies indicating 
that IgM-RF and IgA-RF are risk factors for RA.15, 16 Additionally, this study is the 
first to demonstrate that this association is confined to the ACPA-positive individ-
uals, indicating that the contribution of RF antibodies to RA is dependent on their 
interaction with ACPAs. 
The interaction between RF and ACPAs implies that these autoimmune respons-
es may converge to precipitate disease. Although the biological mechanism under-
lying this observation is unknown, this association could be explained by a model 
proposed in a recent study, suggesting that that autoantibody-mediated articular 
inflammation in mice may be facilitated by soluble immune complexes that en-
able the access of pathogenic antibodies into the joint.6 Because RF antibodies 
recognize IgG molecules, they can form soluble immune complexes, which could 
facilitate access of ACPAs joints. An alternative explanation is that RF could amplify 
the effector mechanisms induced by ACPAs in the joint, thereby exacerbating joint 
inflammation.
In summary, our data indicate a diversification of the ACPA response in patients 
with RA when compared with that in healthy individuals who are at risk of disease. 
We speculate that the relatively limited ACPA response in healthy individuals will 
change over time, leading to disease manifestations. These changes likely involve 
broader isotype usage and/or epitope spreading and could be facilitated by RF an-
tibodies that may allow access of ACPAs into the joint or amplify their effects. Un-
2
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derstanding the pathways responsible for the diversification of the ACPA response 
in RA is important, because such an understanding could provide new treatment 





1.   Bussel JB. Immune thrombocytopenia in pregnancy: autoimmune and allo-
immune. J Reprod Immunol 1997;37(1):35-61.
2.   Rock B, Martins CR, Theofilopoulos AN et al. The pathogenic effect of IgG4 
autoantibodies in endemic pemphigus foliaceus (fogo selvagem). N Engl J 
Med 1989;320(22):1463-1469.
3.   Li N, Aoki V, Hans-Filho G, Rivitti EA, Diaz LA. The role of intramolecu-
lar epitope spreading in the pathogenesis of endemic pemphigus foliaceus 
(fogo selvagem). J Exp Med 2003;197(11):1501-1510.
4.   Maccioni M, Zeder-Lutz G, Huang H et al. Arthritogenic monoclonal anti-
bodies from K/BxN mice. J Exp Med 2002;195(8):1071-1077.
5.   Terato K, Hasty KA, Reife RA, Cremer MA, Kang AH, Stuart JM. Induc-
tion of arthritis with monoclonal antibodies to collagen. J Immunol 
1992;148(7):2103-2108.
6.   Wipke BT, Wang Z, Nagengast W, Reichert DE, Allen PM. Staging the initia-
tion of autoantibody-induced arthritis: a critical role for immune complex-
es. J Immunol 2004;172(12):7694-7702.
7.   Stuart JM, Dixon FJ. Serum transfer of collagen-induced arthritis in mice. J 
Exp Med 1983;158(2):378-392.
8.   Kouskoff V, Korganow AS, Duchatelle V, Degott C, Benoist C, Mathis 
D. Organ-specific disease provoked by systemic autoimmunity. Cell 
1996;87(5):811-822.
9.   van Boekel MA, Vossenaar ER, van den Hoogen FH, van Venrooij WJ. Auto-
antibody systems in rheumatoid arthritis: specificity, sensitivity and diag-
nostic value. Arthritis Res 2002;4(2):87-93.
10.   Meyer O, Labarre C, Dougados M et al. Anticitrullinated protein/peptide 
antibody assays in early rheumatoid arthritis for predicting five year radio-
graphic damage. Ann Rheum Dis 2003;62(2):120-126.
11.   Visser H, le Cessie S, Vos K, Breedveld FC, Hazes JM. How to diagnose 
rheumatoid arthritis early: a prediction model for persistent (erosive) ar-
thritis. Arthritis Rheum 2002;46(2):357-365.
12.   van Gaalen FA, Linn-Rasker SP, van Venrooij WJ et al. Autoantibodies to 
cyclic citrullinated peptides predict progression to rheumatoid arthritis in 
patients with undifferentiated arthritis: a prospective cohort study. Arthritis 
Rheum 2004;50(3):709-715.
13.   Kuhn KA, Kulik L, Tomooka B et al. Antibodies against citrullinated proteins 




ACPA characteristics in health and disease 49
14.   Schellekens GA, Visser H, de Jong BA et al. The diagnostic properties of 
rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. 
Arthritis Rheum 2000;43(1):155-163.
15.   Rantapaa-Dahlqvist S, de Jong BA, Berglin E et al. Antibodies against cyclic 
citrullinated peptide and IgA rheumatoid factor predict the development of 
rheumatoid arthritis. Arthritis Rheum 2003;48(10):2741-2749.
16.   Nielen MM, van Schaardenburg D, Reesink HW et al. Specific autoantibod-
ies precede the symptoms of rheumatoid arthritis: a study of serial mea-
surements in blood donors. Arthritis Rheum 2004;50(2):380-386.
17.   Peschken CA, Esdaile JM. Rheumatic diseases in North America’s indige-
nous peoples. Semin Arthritis Rheum 1999;28(6):368-391.
18.   Arnett FC, Edworthy SM, Bloch DA et al. The American Rheumatism Asso-
ciation 1987 revised criteria for the classification of rheumatoid arthritis. 
Arthritis Rheum 1988;31(3):315-324.
19.   Verpoort KN, Jol-van der Zijde CM, Papendrecht-van der Voort EA et al. 
Isotype distribution of anti-cyclic citrullinated peptide antibodies in undif-
ferentiated arthritis and rheumatoid arthritis reflects an ongoing immune 
response. Arthritis Rheum 2006;54(12):3799-3808.
20.   Boire G, Cossette P, Brum-Fernandes AJ et al. Anti-Sa antibodies and anti-
bodies against cyclic citrullinated peptide are not equivalent as predictors 
of severe outcomes in patients with recent-onset polyarthritis. Arthritis Res 
Ther 2005;7(3):R592-R603.
21.   Vossenaar ER, Nijenhuis S, Helsen MM et al. Citrullination of synovi-
al proteins in murine models of rheumatoid arthritis. Arthritis Rheum 
2003;48(9):2489-2500.
22.   Hueber W, Kidd BA, Tomooka BH et al. Antigen microarray profiling of au-
toantibodies in rheumatoid arthritis. Arthritis Rheum 2005;52(9):2645-
2655.
23.   Verpoort KN, Cheung K, Ioan-Facsinay A et al. Fine specificity of the anti-ci-
trullinated protein antibody response is influenced by the shared epitope 
alleles. Arthritis Rheum 2007;56(12):3949-3952.
24.   Lundberg K, Fisher B, Kinloch A, Venables PJ. Rheumatoid arthritis-specific 
autoantibodies to an immunodominant epitope in citrullinated alpha-eno-
lase cross-react with bacterial enolase. Arthritis Rheum. 56. 2008. 2007. 
 Ref Type: Generic
25.   Newkirk MM, Goldbach-Mansky R, Senior BW, Klippel J, Schumacher HR, 
Jr., El Gabalawy HS. Elevated levels of IgM and IgA antibodies to Proteus 
mirabilis and IgM antibodies to Escherichia coli are associated with early 





26.   Masson-Bessiere C, Sebbag M, Girbal-Neuhauser E et al. The major syno-
vial targets of the rheumatoid arthritis-specifi c antifi laggrin autoantibodies 
are deiminated forms of the alpha- and beta-chains of fi brin. J Immunol 
2001;166(6):4177-4184.
27.   Despres N, Boire G, Lopez-Longo FJ, Menard HA. The Sa system: a nov-
el antigen-antibody system specifi c for rheumatoid arthritis. J Rheumatol 
1994;21(6):1027-1033.
28.   Lundberg K, Kinloch A, Fisher BA et al. Antibodies to citrullinated alpha-eno-
lase peptide 1 are specifi c for rheumatoid arthritis and cross-react with 
bacterial enolase. Arthritis Rheum 2008;58(10):3009-3019.
29.   Oen K, Robinson DB, Nickerson P et al. Familial seropositive rheumatoid 
arthritis in north american native families: effects of shared epitope and 
cytokine genotypes. J Rheumatol 2005;32(6):983-991.
30.   Oen K, Schroeder M, Jacobson K et al. Juvenile rheumatoid arthritis in a 
Canadian First Nations (aboriginal) population: onset subtypes and HLA 
associations. J Rheumatol 1998;25(4):783-790.
31.   van der Helm-van Mil AH, Verpoort KN, Breedveld FC, Huizinga TW, Toes 
RE, de Vries RR. The HLA-DRB1 shared epitope alleles are primarily a risk 
factor for anti-cyclic citrullinated peptide antibodies and are not an indepen-
dent risk factor for development of rheumatoid arthritis. Arthritis Rheum 
2006;54(4):1117-1121.
32.   Klareskog L, Stolt P, Lundberg K et al. A new model for an etiology of rheu-
matoid arthritis: smoking may trigger HLA-DR (shared epitope)-restrict-
ed immune reactions to autoantigens modifi ed by citrullination. Arthritis 
Rheum 2006;54(1):38-46.
33.   Pedersen M, Jacobsen S, Garred P et al. Strong combined gene-environ-
ment effects in anti-cyclic citrullinated peptide-positive rheumatoid ar-
thritis: a nationwide case-control study in Denmark. Arthritis Rheum 
2007;56(5):1446-1453.
34.   van der Helm-van Mil AH, Verpoort KN, le Cessie S, Huizinga TW, de Vries 
RR, Toes RE. The HLA-DRB1 shared epitope alleles differ in the interaction 
with smoking and predisposition to antibodies to cyclic citrullinated pep-
tide. Arthritis Rheum 2007;56(2):425-432.
35.   Rosenstein ED, Greenwald RA, Kushner LJ, Weissmann G. Hypothesis: the 
humoral immune response to oral bacteria provides a stimulus for the de-
velopment of rheumatoid arthritis. Infl ammation 2004;28(6):311-318.
Anti-citrullinated protein 
antibody response associated 
with synovial immune deposits 
in a patient with suspected 
early rheumatoid arthritis
J Rheumatol. 2008 Nov;35(11):2282-2284






Anti-citrullinated protein antibodies (ACPA) are highly specific for rheumatoid 
arthritis (RA) and precede the onset of clinical symptoms by several years, with 
increasing titers as patients approach disease onset.1, 2 The synovium is the pri-
mary site of pathology in RA, and ACPA are readily detectable in the synovial fluid 
and tissue of patients with RA.3 The transition from asymptomatic autoimmunity 
to clinically detectable synovitis is not well understood. We describe the serological 
and synovial features of a young woman from a multi-case RA family who initially 
had asymptomatic autoimmunity, then subsequently developed clinical features 
suggestive of early RA. 
An 18-year-old Native North American (Cree) woman from Central Canada was 
recruited to a study that aimed to identify high-risk family members of RA probands 
and follow them longitudinally for disease onset. This study was approved by the 
Research Ethics Board of the University of Manitoba, and by the Band Councils of 
the First Nations communities. At baseline she was asymptomatic and had an en-
tirely normal joint examination. Within 6 months of enrolment she developed pain 
and stiffness in her left knee and left wrist. Examination revealed joint-line ten-
derness in these 2 joints, along with several small joints of the hands, although no 
effusion was detectable. She was suspected of having early RA and started taking 
hydroxychloroquine and naproxen. After informed consent, at that time she also 
underwent a Parker-Pearson synovial biopsy of the knee, per an established study 
protocol. With treatment, her symptoms rapidly improved, and within 3 months 
she spontaneously discontinued the medications, as she had become pregnant for 
the first time. She continued to be free of synovitis throughout the pregnancy. Af-
ter delivering a healthy baby she once again developed tenderness and swelling in 
the left wrist and left knee, and was again given hydroxychloroquine and naprox-
en, with improvement in the symptoms over the ensuing 2 months. To date, her 
symptoms continue to be well controlled with this regimen.
The investigations at baseline had revealed that she was negative for IgM and 
IgA rheumatoid factor (RF), but was positive for anti-CCP2 (Eurodiagnostica) and 
anti-CCP3 (Inova) antibodies, at a titer of 52 and 38 units respectively. C-reactive 
protein and erythrocyte sedimentation rate were in the normal range. HLA testing 
showed her to have the HLA- DRB1*0901 and *1402 alleles. Her serum sam-
ples were tested for ACPA isotypes (IgM, IgA, IgG1-4) using ELISA as described.4 
Anti-Sa was tested by ELISA as described.5 Response to citrullinated fibrinogen 
(cit-fib), and 5 different linear citrullinated peptides, including C2 (vim), C3 (vim) 
derived from human vimentin, C4 (fb) and C5 (fb) derived from human fibrino-
gen, and C6 (en) derived from human enolase, were assessed by ELISA with 2 
non-citrullinated peptides as controls. Cutoff level was established on the basis of 
the mean + 2 standard deviations of the values obtained from testing 30 healthy 
Caucasian controls. RF and acute-phase reactants remained negative throughout 
the study period. IgG1-ACPA was positive the first visit (151 AU), with increasing 
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titers during followup (Figure 1). IgA-ACPA was initially negative, but became pos-
itive with increasing titers after symptom onset. IgM-ACPA, IgG2, IgG3, and IgG4 
remained negative throughout the study period. After being initially negative, she 
developed increasing titers of antibodies against citrullinated fibrinogen, but re-
mained negative for anti-Sa and all of the linear citrullinated peptides tested.
These data suggest that onset of clinical synovitis was heralded by an expansion 
in ACPA isotype usage, along with epitope spreading to nonlinear cit-fibrinogen-as-
sociated antigens. Interestingly, as shown in Figure 1, the autoantibody levels con-
tinued to rise despite amelioration of the clinical symptoms with pregnancy. This 
observation implies that the clinical improvement typically seen during RA preg-
nancy may not necessarily reflect an attenuation of the underlying autoimmune 
mechanisms, at least at this early stage of the process.
Figure 1. Development of ACPA response over a 2-year period in relation to clini-
cal features in suspected early RA. Levels of all ACPA isotypes and specificity are shown 
as arbitrary units (AU), with levels of IgA-ACPA and anti-citrullinated-fibrinogen (cit-fib) 
shown on Y1 axis, and levels of IgG1-ACPA and anti-CCP2 shown on Y2 axis. Approximate 
cutoff level determined using 30 healthy controls is indicated by broken line. There is an 
increase in the titers of all ACPA over the study period, with IgA-ACPA and anti-cit-fib both 
becoming positive after onset of articular symptoms. 
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In contrast to the findings reported in studies of early RA, the synovium demon-
strated normal sublining architecture and minimal microvascular changes. The sy-
novial lining layer was markedly abnormal throughout multiple samples, with the 
lining cells appearing to float in an amorphous extracellular matrix (Figure 2A). 
Immunoperoxidase staining revealed the presence of an occasional CD3-positive 
cell without aggregates, but no CD19 cells. CD68 and CD55 staining were present 
in the lining layer, and CD86-positive cells were scattered throughout the sub-
lining. Staining using a polyclonal anti-citrulline antibody (AP064, GemacBio) to 
detect citrullinated proteins demonstrated intense staining of the synovial lining 
cells (Figure 2B). Immunofluorescence studies showed staining of the lining layer 
for IgG, IgA, C3, and fibrin (Figure 2C), suggesting that the synovial lining layer 
may have been the target of an antibody-mediated immune response with com-
plement activation and deposition. Although the specific target of this immune re-
sponse was not directly tested, the colocalization of citrullinated antigens in lining 
cells with the immune deposits is consistent with the possibility that the response 
is directed towards a citrullinated antigen(s). TdT-mediated dUTP-biotin nick-end 
labeling (TUNEL) demonstrated extensive staining of the synovial lining cells (Fig-
ure 2D) compared to that seen in a normal synovial membrane (data not shown), 
indicating that the lining cells were undergoing wide- spread apoptosis.
We describe a case where there was a transition from asymptomatic autoimmu-
nity to clinically evident synovitis. At this point, it is not possible to determine with 
certainty whether this patient’s synovitis represents the earliest clinical evidence 
of RA, since she has yet to meet the American College of Rheumatology criteria 
set. On the other hand, it is possible that the very early use of antimalarials may 
indeed serve to prevent the full expression of the clinical RA syndrome. This has 
been shown with the use of methotrexate in anti-cyclic citrullinated peptide-posi-
tive patients with undifferentiated arthritis6. The serological evolution and synovial 
features are consistent with the hypothesis that isotype expansion and epitope 
spreading of ACPA responses to synovial autoantigens are associated with the on-
set of synovitis in an individual who is genetically susceptible to RA.
3
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Figure 2. Synovial tissue analysis of biopsy material from a symptomatic knee 
joint shortly after onset of articular symptoms. A. H&E light microscopy showing 
marked disruption of the synovial lining cell layer. Lining cells appear to be floating in an 
amorphous extracellular matrix. Sublining stroma is relatively unremarkable with minimal 
evidence of inflammatory infiltration. B. Intracellular citrullinated antigens are detected 
by intense staining of the synovial lining cells using a polyclonal anticitrulline antibody. 
There is less intense staining of the surrounding matrix. C. Immunofluoresence staining 
of synovial tissue for C3 showing positive staining in lining layer. Similar results were seen 
with IgG, IgA, and fibrin staining. D. Synovial lining cells exhibit evidence for widespread 
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Recent data suggest that a gene–environment interaction between smoking and 
the HLA shared epitope alleles plays a role in shaping the autoimmune reaction 
to specific citrullinated antigens. This study was undertaken to determine the ef-
fects of HLA shared epitope alleles and tobacco exposure on the immune response 
against various citrullinated antigens. These associations were analyzed in the 
anti–citrullinated protein antibody (ACPA)–positive stratum to control for the pos-
sibility that the associations found are explained by the known interaction between 
HLA shared epitope alleles and tobacco exposure on ACPA status.
Methods
In 661 patients with rheumatoid arthritis, reactivity against several citrullinated 
antigens from vimentin, fibrinogen, enolase, and myelin basic protein was de-
termined by enzyme-linked immunosorbent assay. The effects of the HLA shared 
epitope alleles and tobacco exposure were assessed by logistic regression analysis. 
Biologic interaction was analyzed by investigating whether the effects of the risk 
factors combined exhibited departure from additivity.
Results
A significant interaction between tobacco exposure and HLA shared epitope alleles 
was found for the presence of ACPA as reported previously. When these interaction 
effects were studied for several ACPA “fine specificities,” significant interactions 
were noted for several citrullinated peptides. However, these interactions were not 
present after stratification for ACPA status, indicating that the interaction between 
tobacco exposure and HLA shared epitope alleles influences autoimmunity not to 
specific citrullinated antigens, but rather to ACPA development.
Conclusion
Our data indicate that the gene–environment interaction between HLA shared epi-
tope alleles and smoking does not appear to shape the reactivity of the ACPA 
response. These data suggest that smoking promotes nonspecific citrullination 
rather than citrullination of specific antigens.
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INTRODUCTION
Rheumatoid arthritis (RA) is a systemic autoimmune disease involving inflam-
mation of the joints. The detection of anti–citrullinated protein antibodies (ACPAs), 
often measured by an anti–citrullinated antibody assay (anti–cyclic citrullinated pep-
tide 2 [anti–CCP-2]), is an accepted diagnostic tool for RA.1 Anti-CCP antibodies are 
highly specific for RA, can be detected years before the first clinical manifestation of 
RA2,3, and are reported to be a good predictor of the development of RA.4 Anti-CCP 
antibodies recognize multiple citrullinated peptides and proteins and are thus a col-
lection of ACPAs.5 Likewise, ACPAs have been shown to initiate and enhance arthritis 
in murine models6,7, and human ACPAs are able to activate both Fc receptor–positive 
cells8,9 and the complement system, indicating that they could play a role in disease 
pathogenesis.10
ACPA-positive and ACPA-negative disease have been shown to be associated with 
different genetic and environmental risk factors, fueling the hypothesis that different 
pathophysiologic mechanisms underlie these 2 separate disease subsets.11,12 Some 
types of HLA alleles, particularly HLA–DRB1 alleles encoding an amino acid sequence 
called the shared epitope, are known to be associated with RA susceptibility13, spe-
cifically susceptibility to ACPA-positive RA.14
It has been shown that ACPAs can recognize a variety of citrullinated antigens, 
including citrullinated fibrinogen and citrullinated vimentin, which is also known as 
the Sa antigen.15 However, not all ACPA-positive sera will recognize all citrullinated 
antigens, as has been shown by analyzing the reactivity against different citrullinat-
ed peptide antigens.5,16 In ACPA-positive patients, HLA shared epitope alleles have 
been shown to predispose to the development of antibodies against a peptide from 
citrullinated vimentin, but not to the development of antibodies recognizing a pep-
tide from citrullinated fibrinogen. These data indicate that HLA shared epitope alleles 
influence not only the magnitude, but also the specificity, of the ACPA response.17
Like the HLA shared epitope alleles, the environmental factor tobacco exposure is 
also known to predispose mainly to autoantibody-positive disease.18 The combined 
effect of HLA shared epitope alleles and tobacco exposure has been shown to exceed 
the sum of their single effects, a phenomenon known as biologic interaction.19–21 A 
gene–environment interaction thus exists between the HLA shared epitope alleles 
and tobacco exposure with regard to the development of ACPA-positive RA. This 
interaction displays a dose-dependent effect, as there is an even stronger gene-en-
vironment interaction present for heavy cigarette smoking.22
Recently, it has been reported that a specific interaction exists between the pres-
ence of HLA–DRB1*04, tobacco exposure, and the specific recognition of a peptide 
derived from citrullinated enolase.23 Such epidemiologic studies might be of rele-
vance as they link established genetic and environmental risk factors to an auto-
immune response against specific citrullinated antigens that are expressed in the 
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inflamed joints of RA patients. Therefore, such findings might provide relevant clues 
to aid in the understanding of the pathologic mechanism underlying RA development 
and progression. More recently, however, we have reported a similar interaction for 2 
peptides derived from 2 other citrullinated proteins, citrullinated vimentin and citrul-
linated fibrinogen.24 These latter data indicate that the observed interaction might 
not be confined to an auto-immune response against a specific citrullinated antigen. 
Rather, these findings indicate that these interaction effects extend to several citrul-
linated autoantigens, which might even be explained by a general predisposition to 
ACPA development. In this study, we aimed to analyze in greater detail the extent 
of the interaction between HLA shared epitope alleles and tobacco exposure on the 
antigen-recognition profile of ACPA, especially in ACPA-positive patients in order to 
exclude the possibility that the association is caused by the presence of ACPA rather 
than by the presence of an autoimmune reaction to specific citrullinated epitopes.
PATIENTS AND METHODS
Patient population 
The patients who were analyzed in this study were derived from the Leiden Ear-
ly Arthritis Clinic (EAC) cohort (n = 661). The Leiden EAC cohort is an inception 
cohort of patients with recent-onset arthritis (symptom duration of <2 years) that 
was started at the Department of Rheumatology of the Leiden University Medical 
Center in 1993 and has been described in detail previously.25 All patients fulfilled 
the American College of Rheumatology 1987 revised criteria for the classification 
of RA26 within the first year of follow-up. At baseline, patients were asked by 
trained research nurses if they had ever or never smoked. Cumulative smoking 
data were not included in these analyses, due to insufficient power. The protocols 
were approved by the relevant local ethics committee, and informed consent was 
obtained from all participants.
Genotyping 
DNA was collected at baseline for genotyping of the HLA–DRB1 region by poly-
merase chain reaction and hybridization to sequence-specific oligonucleotides as 
described previously.27 The HLA–DRB1*01:01, *01:02, *04:01, *04:04, *04:05, 
*04:08, *10:01, and *14:02 alleles were classified as the shared epitope alleles.
Anti–CCP-2 assays 
Total IgG anti–CCP-2 in sera collected at baseline was measured by en-
zyme-linked immunosorbent assay (ELISA) (Immunoscan RA [Mark 2]; Euro-di-
agnostica). Samples with a value of >25 units/ml were considered positive accord-
ing to the recommendations of the manufacturer. Patients with antibodies against 
CCP-2 were considered ACPA positive.
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ACPA fine specificity assays 
ELISAs were developed, as previously described17, against peptides derived 
from citrullinated vimentin, citrullinated fibrinogen, and citrullinated α-enolase 
5–20. Antibody reactivity against both the citrullinated and the noncitrullinated 
form of 2 linear peptides derived from vimentin (vimentin 1–16 [STCitS VSSS SY-
CitCit MFGG] and vimentin 59–74 [VYAT CitSSA VCitLCit SSVP]), 2 linear peptides 
derived from fibrinogen (fibrinogen α 27–43 [FLAE GGGV Cit GPR VVER H] and fi-
brinogen β 36–52 [NEEG FFSA CitGHR PLDK K]), and 1 linear peptide derived from 
α-enolase (enolase 5–20 [KIHA CitEIF DSCitG NPTV]) was determined by ELISA.28
Briefly, streptavidin-coated preblocked microtiter plates (Thermo Scientific) 
were coated with the different fibrinogen, vimentin, and enolase peptides, fol-
lowed by incubation with the serum samples. After washing, antibodies were de-
tected with a rabbit anti-human IgG horseradish peroxidase–conjugated antibody 
(P0214; Dako) and ABTS as the coloring substrate, according to the recommenda-
tions of the manufacturer (Sigma-Aldrich).
Citrullination of myelin basic protein (MBP; Sigma-Aldrich) and the specific ELI-
SA were performed as previously described.29 Antibodies reactive with citrullinated 
MBP were determined in sera diluted 1:100.
Although there are other targets for ACPA30,31 we chose to primarily investigate 
epitopes from these proteins because they have been most consistently identified 
as citrullinated autoantigens.15,32,33 We elected to use citrullinated MBP as a citrul-
linated protein antigen, since its ELISA has previously been standardized to be the 
clinical equivalent (positive versus negative) of the original anti-Sa (citrullinated 
vimentin) Western blot assay.29
Cutoff values for the citrulline-specific responses were calculated in each assay 
as previously described and were defined as 3 SD above the value of the mean 
concentration of the serum samples obtained from 41 control patients with gout. 
In fine specificity studies, citrulline-specific signals were defined as a positive sig-
nal (above the cutoff value based on findings in patients with gout) against the ci-
trullinated antigen and a minimum difference of 0.1 in delta optical density values 
compared to the noncitrullinated antigen.34
The fine specificity reactivity was confined to the subset of ACPA-positive pa-
tients. More than 98% of the patients displaying antibodies against a specific fine 
specificity epitope were also anti–CCP-2 positive; therefore, we did not analyze all 
of the anti–CCP-2–negative patients for fine specificity repertoire.
IgM rheumatoid factor was determined by ELISA. Anti-CCP2 autoantibodies (IgA 
and IgG subforms) and anti-mutated citrullinated vimentin (anti-MCV) Autoanti-
bodies were also measured by ELISA (Quanta Lite CCP version 3.1 for IgG/IgA 
from Inova Diagnostics and ELISAs from orgentec Diagnostika). The cutoff level 
for both the anti–CCP-3 test and the anti-MCV test was set at 20 arbitrary units, 
according to the recommendations of the manufacturers. Sera were tested for an-
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tinuclear factor using indirect immuno-fluorescence at a 1:40 dilution on Hep-2000 
cells (Biomedical Diagnostics).
Statistical analysis 
Logistic regression analysis was performed to determine the odds ratios (ORs) 
and 95% confidence intervals (95% CIs) of developing autoantibody-positive RA 
relative to autoantibody-negative RA for the risk factors HLA shared epitope alleles 
and smoking. The association between the recognition of different citrullinated 
epitopes and a gene–environment interaction was analyzed using the same meth-
od. To take into account the effect of the known association of HLA shared epitope 
alleles and tobacco exposure with ACPA status, stratified analyses in ACPA-positive 
patients only were performed.
Biologic interaction, defined as the deviation from additivity, was evaluated by 
3 measures: relative excess risk due to interaction (RERI), the attributable pro-
portion due to interaction (AP), and the synergy index. These measures indicate 
significant biologic interaction if they differ from 0 (RERI and AP) or 1 (synergy 
index). RERI can be interpreted as the excess risk due to interaction relative to the 
risk without exposure. AP is interpreted as the attributable proportion of disease 
that is due to interaction, among persons with both exposures.  The synergy index 
can be interpreted as the excess risk from exposure (to both exposures) when 
there is interaction, relative to the excess risk from exposure (to both exposures) 
without interaction.35 (For a more detailed definition of these measures, see ref. 
36). To obtain the parameter estimates needed for calculating these 3 measures, 
a logistic regression model was fitted.21 Data were analyzed using SPSS, version 
17.0. P values less than 0.05 were considered significant.
RESULTS
Effect of single risk factors on ACPA fine specificity
To  investigate whether HLA shared epitope alleles and tobacco exposure are as-
sociated with specific reactivities within the total ACPA response, CCP-2 status was 
determined in 661 RA patients, of whom 348 were found to be anti–CCP-2 positive 
(Table 1). In baseline sera from 345 of these ACPA-positive RA patients, as well as 
in sera from 92 ACPA-negative RA patients,  we determined reactivity against 2 ci-
trullinated vimentin peptides (citrullinated vimentin 1–16 and citrullinated vimentin 
59–74), 2 citrullinated fibrinogen peptides (citrullinated fibrinogen α and citrullinat-
ed fibrinogen β), citrullinated a-enolase peptide, and citrullinated MBP. More than 
98% of the patients who were positive for a specific citrullinated epitope were also 
ACPA positive (Table 2). Among ACPA-positive RA patients, 50% displayed anti-
bodies against citrullinated vimentin 59–74 and 12% against citrullinated vimentin 
1–16. The highest percentage of reactivity was found for citrullinated fibrinogen 
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β, for which 70% of the ACPA-positive RA patients displayed reactivity. Reactivity 
against the citrullinated α-enolase peptide was found in 34% of the ACPA-positive 
patients, and reactivity against citrullinated MBP was found in 65% of the ACPA-pos-
itive patients. Almost all ACPA-positive patients were also positive for anti-MCV and 
anti–CCP-3, as previously described.37
An association between the presence of HLA shared epitope alleles and the recog-
nition of virtually all citrullinated peptides was found when analyzing all RA patients, 
both ACPA-positive and ACPA-negative (Table 3). The strongest association for HLA 
shared epitope alleles was found for the recognition of the vimentin 59–74 peptide 
(OR 8.4 [95% CI 4.8, 14.8]). Similar associations were found for other citrullinated 
antigen reactivities. To determine whether the presence of the HLA shared epitope 
alleles influences the recognition of specific citrullinated epitopes, we performed 
similar analyses in the subset of ACPA-positive patients. In doing so, we controlled 
for the possibility that the results described above are explained by the known as-
sociation between HLA shared epitope alleles and ACPA status, rather than by an 
influence of the HLA shared epitope alleles on specific epitope recognition. Within 
the subset of ACPA-positive patients, we still found a significant association between 
HLA shared epitope alleles and some, but not all, citrullinated epitopes (Table 4). 
This suggests that HLA shared epitope alleles are involved in shaping the immune 
response against specific citrullinated antigens.
Likewise, we performed a similar analysis to investigate the association between 
tobacco exposure and the recognition of citrullinated peptides. This analysis re-
vealed smaller but similar associations (Table 3). The strongest association was 
found between citrullinated α-enolase recognition and tobacco exposure, with an OR 
of 3.0 (95% CI 1.9, 4.9). To analyze whether the observed association between to-
bacco exposure and the recognition of citrullinated epitopes was also specific for the 
recognition of certain epitopes, rather than due to the known association between 
tobacco exposure and ACPA status, we analyzed the association within the subset of 
ACPA-positive patients. An association between tobacco exposure and citrullinated 
α-enolase recognition remained (OR 1.7 [95% CI 1.1, 2.8]), while other citrullinated 
epitopes were no longer significantly associated with tobacco exposure (Table 4). 
This may indicate that tobacco exposure plays a modest role in broadening the im-
mune response against some, but not all, citrullinated antigens.
Effect of risk factor interaction on ACPA fine specificity
Next, we investigated the effect of biologic interaction between HLA shared epitope 
alleles and smoking with regard to ACPA fine specificity. The recognition of most fine 
specificity peptides indicated biologic interaction between those 2 risk factors when 
using ACPA-negative patients as reference (Table 5). Significant interaction was ob-
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served for the recognition of citrullinated vimentin 59–74, citrullinated fibrinogen β, 
and citrullinated MBP. The interaction effects were most prominent in the subset of 
patients with reactivity against citrullinated α-enolase (OR 16 [95% CI 6.1, 42.7], 
RERI 9.8 [95% CI -0.5, 20.1]) and citrullinated vimentin 59–74 molecules (OR  14 
[95% CI 6.3, 31.5], RERI 7.8 [95% CI 0.5, 15.1]) (Figure 1A). Even stronger effects 
were observed when patients carrying 2 HLA shared epitope alleles were analyzed 
for citrullinated vimentin 59–74, yielding an OR of 32.0 (95% CI 10.9, 94.1) and an 
RERI of 19.7 (95% CI-10.3, 49.7) as depicted in figure 2. 
Intriguingly, interaction effects were also noted in the subset of ACPA-positive 
patients who did not show reactivity against, for example, citrullinated vimentin 
1–16. This observation indicated that the interactions detected are mainly explained 
by the known effects between HLA shared epitope alleles and tobacco exposure on 
ACPA status. To control for this possibility, we next stratified the patients with regard 
to ACPA status and performed similar analyses in the ACPA-positive patients only. 
We reasoned that if the interaction only affected specific reactivities, the interaction 
should be detectable in the total subset of ACPA-positive patients as well. Notably, 
no significant effects were observed after stratification for ACPA status (Table 6). 
For example, HLA shared epitope alleles and tobacco exposure no longer showed a 
significant interaction on the recognition of citrullinated vimentin 59–74, with a com-
bined effect OR of 4.0 (95% CI 1.7, 9.6) and RERI of 0.3 (95% CI -2.0, 2.6), which 
is comparable to the association found for HLA shared epitope alleles and citrullinat-
ed vimentin 59–74 recognition only (OR 3.7 [95% CI 2.0, 6.8]). Similar effects were 
observed for the other fine specificity reactivities (Figure 1B).
Consistent with the results presented above, the AP due to interaction was com-
parable among reactivities against all of the citrullinated antigens and ACPA (Figure 
3). Since the AP was calculated before stratification for ACPA, these results indicate 
that the interaction effects between tobacco exposure and HLA shared epitope   al-
leles did not affect the fine specificity, but rather affected the ACPA status. Only 
citrullinated vimentin 1–16 displayed a slightly higher AP, but this might be a spu-
rious finding due to the small number of RA patients displaying antibodies against 
citrullinated vimentin 1–16 (6%).
An analysis of the interaction between tobacco exposure and only HLA DRB1*04 
shared epitope alleles resulted in similar findings, with strong interactive effects dis-
appearing after stratification for ACPA status (data not shown). Moreover, the inter-
action effects between HLA shared epitope status and tobacco exposure observed in 
the unstratified analysis for recognition of >3 citrullinated epitopes (OR 9.7 [95% CI 
4.9, 19.1], RERI 5.1 [95% CI 0.7, 9.4]) also became smaller and nonsignificant af-
ter stratification for ACPA (OR 3.1 [95% CI 1.3, 7.3], RERI -0.4 [95% CI -3.0, 2.2]).
Similarly, the subset of patients carrying 2 HLA shared epitope alleles displaying 
antibodies against, for example, citrullinated vimentin 59–74 did not show signs of 
interaction after stratification (figure 4). Taken together, these data indicate that an 
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interaction between HLA shared epitope alleles and tobacco exposure contributes to 








Gender (female) 450/661 (68.1%) 228/348 (65.5%) 222/313 (70.9%)
Mean age at inclu-
sion (mean ± SD)
55.8± 16 54.7± 15 57.1± 16
CCP2+ 348/661 (52.6%) 348/348 (100%) 0/313 (0%)
RF+ 321/537 (59.8%) 267/305 (87.5%) 54/232 (23.3%)
Table 1. Baseline characteristics. Except where indicated otherwise, values are the 
number (%) of patients. Data on rheumatoid factor (RF) status were available for 537 pa-
tients with rheumatoid arthritis (RA), 305 patients with anti–cyclic citrullinated peptide 2 














0-3 cit reactivities #
4-8 cit reactivities #
  42/652    (6%)
172/658  (26%)







  42/342  (12%)
171/345  (50%)





 84/284   (30%)
200/284  (70%)
  0/89  (0%) 
  1/92  (1%)
  0/92  (0%)
  1/89  (1%)
  2/92  (2%)
  1/92  (1%)
 42/88 (48%)
 91/92 (99%)
  1/92    (1%)
Table 2. Percentage of individuals positive for different fine specificity epitopes. 
Number of different citrullinated epitopes for which each patient displayed antibodies, in-
cluding citrullinated vimentin 1–16, citrullinated vimentin 59–74, citrullinated fibrinogen 
α, citrullinated fibrinogen β, citrullinated enolase 5–20, citrullinated myelin basic protein 
(MBP), mutated citrullinated vimentin, and anti–cyclic citrullinated peptide 3 (anti–CCP-
3). Almost all patients who were negative for anti–CCP-2 were negative for the measured 
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Figure 1. Risk of autoantibody-positive disease conferred by HLA SE positivity, TE 
and their interaction. Bars are depicted black from OR 0 to 1, light grey to indicate the 
risk conferred by the presence (1 or 2 alleles) of HLA SE alleles, white for the risk conferred 
by TE and dark grey for the interaction. Analyses were performed using the ACPA-negative 
individuals as reference group (1A) and the same analysis was performed within the AC-
PA-positive stratum (1B). 
Figure 2. Risk of autoantibody-positive disease conferred by HLA SE homozy-
gosity (SESE), TE and their interaction. Bars are depicted black from OR 0 to 1, light 
grey to indicate the risk conferred by the presence of two HLA SE alleles, white for the 
risk conferred by TE and dark grey for the interaction. Analyses were performed using the 
ACPA-negative individuals as reference group (bars 1 and 2) and the same analysis was 
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Figure 3. Attributable proportion due to interaction between HLA SE alleles and 
TE. Attributable proportion due to interaction was calculated by dividing the relative excess 
risk due to interaction by the total risk of autoantibody positive disease in patients with 
1 or 2 HLA SE alleles and TE (AP=RERI/R11) for the different fine specificity reactivities. 
All the reactivities show a similar attributable proportion compared to anti-CCP2 positive 




























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 4. Risk of autoantibody-positive disease with recognition of a limited or 
extended number of citrullinated epitopes conferred by HLA SE-alleles, TE and 
their interaction. Bars are depicted black from OR 0 to 1, light grey to indicate the risk 
conferred by the presence of (1 or 2) HLA SE alleles or HLA SE homozygosity (SESE), white 
for the risk conferred by TE and dark grey for the interaction. Analyses were performed 
using the ACPA-negative individuals as reference group (bars 1 and 2) and the same anal-
ysis was performed within the ACPA-positive stratum (bar 3). Recognising 0-3 citrullinated 
epitopes was considered limited recognition and recognising 4-8 citrullinated peptides as 
extended recognition. Eight epitopes were included in this analysis (cVim1-16, cVim59-74, 
cFibα, cFibβ, cEno5-20, cMBP, CCP3 and MCV). 
DISCUSSION
Our results show that the apparent interaction between HLA shared epitope al-
leles and tobacco exposure for ACPA fine specificity disappears after stratification 
for ACPA status, indicating that this interaction does not greatly affect the fine 
specificity of the ACPA response. Recently, it has been suggested that a gene–en-
vironment interaction between HLA shared epitope alleles and tobacco exposure 
plays a role in shaping an autoimmune response specifically directed against a 
peptide derived from enolase.23 Further experimentation resulted in similar find-
ings for the recognition of other citrullinated epitopes that were derived from vi-
mentin and fibrinogen.24 These findings could be of relevance, since interactions 
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between genotype, smoking, and autoimmunity to certain citrullinated antigens 
could further  expand our understanding of RA  pathogenesis.
However, no stratification for ACPA status was performed in previous studies, 
allowing the possibility that the interaction effects were not explained by their 
influence on the formation of autoimmune reactions against specific citrullinated 
antigens, but rather by their influence on the formation of ACPA. In the pres-
ent study, we specifically investigated this possibility. Careful analyses of original 
data previously published by our group and by Mahdi et al23,24 suggested that no 
such interaction effects were present, since, for example, the AP was similar for 
ACPA-positive disease in the presence and, importantly, also in the absence of a 
specific ACPA reactivity. Therefore, we reasoned that if such interaction effects 
only shaped the response to certain specific epitopes and not to other citrullinated 
epitopes, these effects should still be observed among the subset of ACPA-positive 
patients. We showed that this is not the case; the ORs observed in the interaction 
analysis were similar to the ORs observed for the presence of HLA shared epitope 
alleles only after stratification for ACPA status.
Taken together, these data indicate that the gene–environment interaction be-
tween tobacco exposure and HLA shared epitope alleles does not influence the 
reactivity of the ACPA response. Rather, the presence of HLA shared epitope alleles 
seems to be the main factor in shaping the antigen recognition of the ACPA re-
sponse. This is evidenced by the fact that the association between HLA shared epi-
tope alleles and certain fine specificities, such as citrullinated vimentin 59–74 and 
citrullinated α-enolase, remained after stratification for ACPA status, as has been 
demonstrated previously.17 Thus, these results suggest that ACPA fine specificity 
recognition is mainly dependent on HLA shared epitope status and that tobacco ex-
posure and the interaction between HLA shared epitope alleles and tobacco expo-
sure contribute little. These data also suggest that smoking promotes nonspecific 
citrullination rather than citrullination of specific antigens.
The findings of this study add to the discussion on the role of tobacco exposure 
and possibly other environmental triggers, such as infection with certain patho-
gens, in the pathogenesis of RA. For example, it has been postulated that the fact 
that immunity to some citrullinated antigens is strongly associated with both to-
bacco exposure and shared epitope alleles supports the hypothesis that smoking 
may induce citrullination of certainproteins in the lungs and that immunity to these 
posttranslationally modified proteins may be determined by certain HLA alleles.38 
This hypothesis is intriguing and warrants further investigation; it would also in-
criminate certain citrullinated proteins and/or epitopes in the break of tolerance 
against citrullinated antigens. However, the findings of the present study indicate 
that the presumed interaction effects previously described by our group and by 
Mahdi et al23,24 should not be taken as evidence supporting this hypothesis, but 
rather as evidence that the main driver of ACPA fine specificity is found in the HLA 
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shared epitope alleles. In contrast, the interaction effects between HLA shared 
epitope alleles and smoking are more likely to be confined to the predisposition to 
ACPA-positive disease.
A potential limitation of our study is that the results were not corrected for mul-
tiple testing, allowing the possibility that some associations are false-positives. 
However, the large ORs found are consistent with previously published data.17,23 
Likewise, we cannot formally exclude the presence  of an interaction between HLA 
shared epitope alleles and tobacco exposure for the peptides analyzed, due to in-
sufficient power. The observed RERI for, e.g., citrullinated vimentin 59–74 (0.29 
[95% CI -2.02, 2.59), is not statistically significant.39 Clearly, a large number of 
patients would be needed to obtain significant RERI values. The CI surrounding 
this RERI further indicates that it is unlikely that an RERI of >2.6 will be found in 
larger studies.
Thus, even if such an interaction existed, it would be modest compared to that 
found in previous analyses and would not have a very strong influence on the con-
stitution of the fine specificity repertoire. In contrast, the findings of the present 
study indicate that the HLA shared epitope status is mainly driving the result.
Although our data indicate that there is no clear link between environmental and 
genetic risk factors in the development of autoimmunity against specific citrullinat-
ed antigens, further study of other potential citrullinated autoantigens is needed. 
Clearly, we cannot exclude the possibility that such an interaction is involved in 
the development of antibodies against other citrullinated antigens. This would es-
pecially be the case in analyses that focus on “heavy smoking,” since cumulative 
smoking exposure might affect such presumed specific interaction. We did not 
perform such an analysis because of insufficient power.
Taken together, our findings indicate that gene–environment interactions play 
no major role in shaping the reactivity of the ACPA response by broadening the 
ACPA recognition profile, but rather   that the HLA shared epitope alleles make a 
significant contribution to the ACPA recognition profile.
4
HLA SE alleles, smoking and ACPA reactivity 77
REFERENCE LIST
1.  Van Venrooij  WJ, van Beers JJ, Pruijn GJ. Anti-CCP antibody, a marker for the 
early detection of rheumatoid arthritis. Ann N Y Acad Sci 2008;1143:268–
85.
2.  Nielen MM, van der Horst AR, van Schaardenburg D, van der Horst-Bruins-
ma IE, van de Stadt RJ, Aarden L, et al. Antibodies to citrullinated human 
fibrinogen (ACF) have diagnostic and prognostic value in early arthritis. 
Ann Rheum Dis 2005;64:1199–204.
3.  Rantapaa-Dahlqvist S, de Jong  BA,  Berglin E,  Hallmans G, Wadell G, 
Stenlund H, et al. Antibodies against cyclic citrullinated peptide  and IgA 
rheumatoid factor predict the development of rheumatoid arthritis. Arthri-
tis  Rheum 2003;48:2741–9.
4.  Van Gaalen FA, Linn-Rasker SP, van Venrooij WJ, de Jong BA, Breedveld  
FC, Verweij CL, et al. Autoantibodies to cyclic citrullinated peptides predict 
progression to rheumatoid arthritis in patients with undifferentiated arthri-
tis: a prospective cohort study. Arthritis  Rheum 2004;50:709–15.
5.  Ioan-Facsinay A, el-Bannoudi  H, Scherer HU, van der Woude D, Menard  
HA,  Lora  M, et al. Anti-cyclic citrullinated peptide antibodies  are a col-
lection of anti-citrullinated protein antibodies and contain overlapping and 
non-overlapping reactivities. Ann Rheum Dis 2011;70:188–93.
6.  Kuhn KA, Kulik L, Tomooka B, Braschler KJ, Arend WP, Robinson WH, et al. 
Antibodies against citrullinated proteins enhance tissue injury in experi-
mental autoimmune arthritis. J Clin Invest 2006;116:961–73.
7.  Uysal H, Bockermann R, Nandakumar KS, Sehnert B, Bajtner E, Engstrom  
A, et al. Structure and pathogenicity of antibodies specific for citrullinated 
collagen type II in experimental arthritis. J Exp Med 2009;206:449–62.
8.  Clavel C, Nogueira L, Laurent L, Iobagiu C, Vincent C, Sebbag M, et al. 
Induction of macrophage secretion of tumor necrosis factor α through Fcγ 
receptor IIa engagement by rheumatoid arthritis–specific autoantibod-
ies to citrullinated proteins complexed with fibrinogen. Arthritis Rheum  
2008;58:678–88.
9.  Schuerwegh AJ, Ioan-Facsinay A, Dorjee AL, Roos J, Bajema IM, van der 
Voort EI, et al. Evidence for a functional role of IgE anticitrullinated protein 
antibodies in rheumatoid arthritis. Proc Natl Acad Sci U S A 2010;107:2586–
91.
10.  Trouw LA, Haisma EM, Levarht EW, van der Woude D, Ioan- Facsinay A, 
Daha MR, et al. Anti–cyclic citrullinated peptide antibodies from rheumatoid 
arthritis patients activate complement via both the classical and alternative 




11.  Klareskog L, Ronnelid J, Lundberg K, Padyukov L, Alfredsson L. Immu-
nity to citrullinated proteins in rheumatoid arthritis. Annu Rev Immunol 
2008;26:651–75.
12.  Van der Helm-van Mil AH, Huizinga TW. Advances in the genetics of rheu-
matoid arthritis point to subclassification into distinct disease subsets. Ar-
thritis Res Ther 2008;10:205.
13.  Gregersen PK, Silver J, Winchester RJ. The shared epitope hypothesis: an 
approach to understanding the molecular genetics of susceptibility to rheu-
matoid arthritis. Arthritis Rheum 1987;30:1205–13.
14.  Van der Helm-van Mil AH, Verpoort KN, Breedveld FC, Huizinga TW, Toes 
RE, de Vries RR. The HLA–DRB1 shared epitope alleles are primarily a 
risk factor for anti–cyclic citrullinated peptide antibodies and are not an 
independent risk factor for development of  rheumatoid arthritis. Arthritis 
rheum 2006;54:1117–21.
15.  Vossenaar ER, Despres N, Lapointe E, van der Heijden A, Lora M, Senshu 
T, et al. Rheumatoid arthritis specific anti-Sa antibodies target citrullinated 
vimentin. Arthritis Res Ther 2004;6: R142–50.
16.  Schellekens GA, de Jong BA, van den Hoogen FH, van de Putte LB, van 
Venrooij WJ. Citrulline is an essential constituent of antigenic determinants 
recognized by rheumatoid arthritis-specific autoantibodies. J Clin Invest 
1998;101:273–81.
17.  Verpoort KN, Cheung K, Ioan-Facsinay  A, van der Helm-van Mil AH, de 
Vries-Bouwstra JK, Allaart CF, et al. Fine specificity of the anti–citrullinated 
protein antibody response is influenced by the shared epitope alleles. Ar-
thritis Rheum 2007;56:3949–52.
18.  Van der Helm-van Mil AH, Verpoort KN, le Cessie S, Huizinga TW, de Vries 
RR, Toes RE. The HLA–DRB1 shared epitope alleles differ in the interaction 
with smoking and predisposition to antibodies to cyclic citrullinated pep-
tide.  Arthritis Rheum 2007;56:425–32.
19.  Kallberg H, Padyukov L, Plenge RM, Ronnelid J, Gregersen PK, van der 
Helm-van Mil AH, et al, for the Epidemiological Investigation of Rheumatoid 
Arthritis (EIRA) study group. Gene-gene and gene-environment interac-
tions involving HLA-DRB1, PTPN22, and smoking in two subsets of rheuma-
toid arthritis. Am J Hum Genet 2007;80:867–75.
20.  Linn-Rasker SP, van der Helm-van Mil AH, van Gaalen FA, Kloppenburg M, 
de Vries RR, le Cessie S, et al. Smoking is a risk factor for anti-CCP anti-
bodies only in rheumatoid arthritis patients who carry HLA-DRB1 shared 
epitope alleles. Ann Rheum Dis 2006;65:366–71.
21.  Andersson T, Alfredsson L, Kallberg H, Zdravkovic S, Ahlbom A. Calculating 
measures of biological interaction. Eur J Epidemiol 2005;20:575–9.
 
4
HLA SE alleles, smoking and ACPA reactivity 79
22.  Karlson EW, Chang SC, Cui J, Chibnik LB, Fraser  PA, De Vivo I, et al. Gene–
environment interaction between HLA-DRB1 shared epitope and heavy cig-
arette smoking in predicting incident rheumatoid arthritis. Ann Rheum Dis 
2010;69:54–60.
23.  Mahdi H, Fisher BA, Kallberg H, Plant D, Malmstrom V, Ronnelid J, et al. 
Specific interaction between genotype, smoking and autoimmunity to ci-
trullinated a-enolase in the etiology of rheumatoid arthritis. Nat Genet  
2009;41:1319–24.
24.  Van der Woude D, Alemayehu WG, Verduijn W, de Vries RR, Houwing-Duis-
termaat JJ, Huizinga TW, et al. Gene–environment interaction influences 
the reactivity of autoantibodies to citrullinated antigens  in rheumatoid 
arthritis. Nat Genet 2010;42:814–6.
25.  De Rooy DP, van der Linden MP, Knevel R, Huizinga TW, van der Helm-van 
Mil AH. Predicting arthritis outcomes—what can be learned from the Leiden 
Early Arthritis Clinic? Rheumatology (Oxford) 2011;50:93–100.
26.  Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. 
The American Rheumatism Association 1987 revised criteria for the classi-
fication of rheumatoid arthritis. Arthritis Rheum 1988;31:315–24.
27.  Van der Horst-Bruinsma IE, Visser H, Hazes JM, Breedveld FC, Verduyn W, 
Schreuder GM, et al. HLA-DQ-associated predisposition to and dominant 
HLA-DR-associated protection against rheumatoid arthritis. Hum Immunol 
1999;60:152–8.
28.  Ioan-Facsinay A, Willemze A, Robinson DB, Peschken CA, Markland J, van 
der Woude D, et al. Marked differences in fine specificity and isotype usage 
of the anti–citrullinated protein antibody in health and disease. Arthritis 
Rheum 2008;58:3000–8.
29.  Boire G, Cossette P, de Brum-Fernandes AJ, Liang P, Niyonsenga T, Zhou  
ZJ, et al. Anti-Sa antibodies and antibodies against cyclic citrullinated pep-
tide  are not equivalent as predictors of severe outcomes in patients with 
recent-onset polyarthritis. Arthritis Res Ther 2005;7:R592–603.
30.  Koivula MK, Heliovaara M, Ramberg J, Knekt P, Rissanen H, Palosuo T, et al. 
Autoantibodies binding to citrullinated telopeptide of type II collagen and 
to cyclic citrullinated peptides predict synergistically the development of 
seropositive rheumatoid arthritis. Ann Rheum Dis 2007;66:1450–5.
31.  Tilleman K, Van Beneden K, Dhondt A, Hoffman I, De Keyser F, Veys E, et 
al. Chronically inflamed synovium from spondyloarthropathy and rheuma-
toid arthritis investigated by protein expression profiling followed by tan-




32.  Kinloch A, Tatzer V, Wait R, Peston D, Lundberg K, Donatien P, et al. Identi-
fi cation of citrullinated a-enolase as a candidate autoantigen in rheumatoid 
arthritis. Arthritis Res Ther 2005;7: R1421–9.
33.  Sebbag M, Moinard  N, Auger I, Clavel C, Arnaud J, Nogueira L, et  al. Epi-
topes of human fi brin recognized by the rheumatoid arthritis-specifi c auto-
antibodies to citrullinated proteins. Eur J Im- munol 2006;36:2250–63.
34.  Van der Woude D, Rantapaa-Dahlqvist S, Ioan-Facsinay A, Onnekink C, 
Schwarte CM, Verpoort KN, et al. Epitope spreading of the anti-citrullinated 
protein antibody response occurs before disease onset and is associated 
with the disease course of early arthritis. Ann Rheum Dis 2010;69:1554–
61.
35.  Skrondal A. Interaction as departure from additivity in case- control stud-
ies: a cautionary note. Am J Epidemiol 2003;158: 251–8.
36.  Rothman KJ. Measuring interactions. Epidemiology: an introduction. New 
York: Oxford University Press; 2002. p. 173–6.
37.  Damjanovska  L, Thabet MM, Levarth EW, Stoeken-Rijsbergen G, van der 
Voort EI, Toes RE, et al. Diagnostic value of anti-MCV antibodies in differ-
entiating early infl ammatory arthritis. Ann Rheum Dis 2010;69:730–2.
38.  Makrygiannakis D, af Klint E, Lundberg IE, Lofberg R, Ulfgren AK, Klareskog 
L, et al. Citrullination is an infl ammation-depen- dent  process. Ann Rheum 
Dis 2006;65:1219–22.
39.  Demidenko E. Sample size and optimal design for logistic regression with 
binary interaction. Stat Med 2008;27:36– 46.
Anti-citrullinated fibronectin 
antibodies in Rheumatoid Arthritis 
are associated with human leukocyte 
antigen-DRB1 shared epitope alleles
Arthritis Res Ther. 2012 Feb;14(1):R35
Joyce J.B.C. van Beers - Annemiek Willemze - Judith Stammen-Vogelzangs






Fibronectin is one of the most abundant proteins present in the inflamed joint. 
Here, we characterized the citrullination of fibronectin in the joints of rheuma-
toid arthritis (RA) patients and studied the prevalence, epitope specificity and 
human leukocyte antigen (HLA) association of autoantibodies against citrullinated 
fibronectin in RA.
Methods   
Citrullinated residues in fibronectin isolated from RA patient synovial fluid were 
identified by mass spectrometry. The corresponding citrullinated and non-citrulli-
nated peptides were synthesized and used to analyze the presence of autoantibod-
ies to these peptides in RA sera and sera from other diseases and healthy controls 
by ELISA. The data were compared with risk factors like shared epitope HLA alleles 
and smoking, and with clinical features.
Results   
Five citrullinated residues were identified in fibronectin from RA synovial fluid.  RA 
sera reacted in a citrulline-dependent manner with two out of four citrullinated 
fibronectin peptides, one of which contains two adjacent citrulline residues, in 
contrast to non-RA sera, which were not reactive. The most frequently recog-
nized peptide (FN-Cit1035,1036, LTVGLTXXGQPRQY, in which × represents citrulline) 
was primarily targeted by anti-CCP (cyclic citrullinated peptide) 2-positive RA pa-
tients. Anti-FN-Cit1035,1036 autoantibodies were detected in 50% of established an-
ti-CCP2-positive RA patients and in 45% of such patients from a early arthritis clin-
ic. These antibodies appeared to be predominantly of the immunoglobulin G (IgG) 
isotype and to be associated with HLA shared epitope alleles (odds ratio = 2.11).
Conclusions  
Fibronectin in the inflamed synovia of RA patients can be citrullinated at least at 
five positions. Together with the flanking amino acids, three of these citrullinated 
residues comprise two epitopes recognized by RA autoantibodies. Anti-citrullinated 
fibronectin peptide antibodies are associated with HLA shared epitope alleles.
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INTRODUCTION
Citrullination or deimination is a post-translational modification, in which a 
peptidylarginine is converted into a peptidylcitrulline by the enzyme family of 
peptidylarginine deiminases (PAD). Citrullinated proteins occur at inflamed sites 
in healthy individuals as well as in patients.1,2 However, autoantibodies direct-
ed against citrullinated proteins (anti-citrullinated protein/ peptide antibodies, 
ACPA) are very specific for rheumatoid arthritis (RA). More than 70% of RA pa-
tients display ACPA, measured via the anti-CCP2 (cyclic citrullinated peptide 2) 
test, in their sera.3,4 These antibodies are frequently present prior to disease onset 
and can predict the development of RA.5,6
It is still not fully understood how RA originates and develops, although there 
is experimental evidence for several steps in this process.7 Both genetic and en-
vironmental factors have been demonstrated to contribute to the development 
of the disease and ACPA production. The association of several HLA-DRB1 alleles, 
which all share  a highly conserved  motif that  is known  as the  shared  epitope 
(SE), has  already  been reported many years ago.8,9. Other genes that have been 
identified as risk factors for RA include PTPN22, the TRAF1-C5 locus, PADI4, STAT4, 
IRF5 and CTLA-4.10-15 Smoking has been demonstrated to be an environmental 
risk factor for RA and also for ACPA production in RA patients carrying SE al-
leles.16,17 Other environmental risk factors that have been suggested to enhance 
the chance of developing RA include the exposure to mineral oil, diet restrictions 
and coffee intake.18-20 However, these data still need confirmation.
Many citrullinated autoantigens (for example, fibrinogen, vimentin, α-enolase) 
and ACPA directed towards these citrullinated proteins have been identified in 
RA.21-26 Currently, the CCP2 test, which is based on a synthetic citrullinated pep-
tide not related to proteins occurring in the inflamed joints of RA patients, is 
the gold standard27-29 for ACPA testing. ACPA have recently been included in the 
new American College of Rheumatology/European League Against Rheumatism 
(ACR/EULAR) criteria for the classification of RA, because they are present early 
in the disease and can predict disease development and outcome.5,30 The ACPA 
response in established RA patients is very heterogeneous and includes antibodies 
directed to many citrullinated proteins.31-33
Because it has been suggested that ACPA play an important role in the de-
velopment of the disease, it is important to learn more about the autoantigens 
that could be involved in the generation of ACPA.7 Several citrullinated proteins 
occurring in the inflamed joints of RA patients have been identified previously. In 
part, their citrulline-containing epitopes have been mapped, particularly using 
synthetic peptides24,34 or material from cultured (non-synovial)  cells (for exam-
ple, HL-60 cells).23 It remains to be established whether these epitopes are rele-
vant from a pathophysiological point of view. ACPA tests  based  upon  citrullinated 
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autoantigenic proteins may provide information on ACPA fine-specificities35,36 
and may aid the differentiation  between  clinically distinct  RA patient  subgroups, 
although  so far no correlations between ACPA fine-specificities and clinical phe-
notypes  have been found.37-39
One of the citrullinated proteins in inflamed synovial tissue identified previously 
is fibronectin (FN).40,41 FN is a glycoprotein, which can be a component of the ex-
tracellular matrix (insoluble form) or present in body fluids (soluble form). FN is in-
volved in a variety of processes, such as wound healing, haemostasis, thrombosis 
and embryogenesis.42 Several findings have been published linking (citrullinated) 
FN with RA. For example, citrullinated FN was found to be present in synovial tis-
sue and synovial fluid (SF) of RA patients.41,43 It has also been detected in pannus 
tissue and in immune complexes present in sera of RA patients.44,45 FN might play 
a role in articular cartilage destruction, because it has been observed that FN frag-
ments can stimulate the production of multiple mediators of matrix destruction, 
such as various cytokines and metalloproteinases.46,47 However, the presence and 
characteristics of anti-citrullinated fibronectin antibodies in RA patients have not 
been studied yet.
In the current study, we have mapped citrullinated residues of FN isolated from 
the SF of RA patients and have used this information to investigate the B-cell re-
sponse to citrullinated FN in RA.
MATERIALS AND METHODS 
Patient material
Synovial fluid (SF) samples from RA patients were a kind gift from Prof. Dr. B. 
Bozic (Department of Rheumatology, University Medical Center, Ljubljana, Slove-
nia). After SF samples were obtained by joint punctures (arthrocentesis), using 
needles with a diameter from 1.6 to 2.2 mm, they were immediately centrifuged 
at 2,500× g for 10 minutes at 4°C to separate insoluble and soluble components 
into pellet and supernatant fractions, respectively. Supernatant and pellet fractions 
were separately stored at -80°C within two hours after taking the samples. The 
pellets were resuspended in EGTA lysis buffer (50 mM Tris-HCl, pH 7.4, 100 mM 
KCl, 1 mM DTE, 0.1% NP40, 10 mM EGTA, 0.5 mM PMSF and protease inhibitor 
cocktail). Supernatant fractions were diluted in five volumes of EGTA lysis buffer. 
After sonification, SDS was added (final concentration 2%) and the fractions were 
heated and centrifuged at 12,000× g. Supernatants were used for further analysis. 
Sera from (established) rheumatoid arthritis (RA; n = 110), systemic lupus 
erythematosus (SLE; n = 31), and primary Sjőgren’s syndrome (pSS; n = 31) pa-
tients were collected at the Department of Rheumatology of the University Medical 
Centre Nijmegen and the St. Maartenskliniek Nijmegen (The Netherlands). Sera 
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from multiple sclerosis (MS; n = 31) patients were collected at the MS Centrum 
Nijmegen (The Netherlands). Type 1 diabetes (T1D; n = 32) sera were obtained 
from the Department of Immunohaematology and Blood Transfusion of the Leiden 
University Medical Center (Leiden, The Netherlands). Early arthritis sera (EAC; n = 
301) were collected at the Department of Rheumatology of the Leiden University 
Medical Center (Leiden, The Netherlands).48 Tuberculosis (TB; n = 29) sera were 
collected at Department of Internal Medicine, Tel Aviv Medical Center, Israel. Sera 
from healthy individuals(NS; n = 32) were collected  at the Sanquin Blood Bank in 
Nijmegen. Sera were stored at -70°C until use.
ACPA levels in RA sera were measured using a commercial CCP2 ELISA kit (Eu-
ro-Diagnostica A.B., Malmo, Sweden).
These studies were approved by the local ethics committees; the need for pa-
tient consent was waived by the local ethics committees.
Sample preparation and tandem mass spectrometry analysis
Two SF samples from RA patients, the supernatant fraction of one and the pellet 
of the other, were depleted of albumin as described by Colantonio and coworkers49, 
separated by SDS-PAGE and stained with colloidal Coomassie Brilliant Blue. Each 
lane of the gel, containing material from an individual SF sample, was sliced into 
18 pieces and the polypeptides in these gel slices were digested after the addition 
of 20 µL trypsin solution (15 ng/µL trypsin in 25 mM NH4HCO3 and 5 mM n-octyl- 
pyranoglucoside).  Peptides were extracted by adding 50% acetonitril, 0.5% triflu-
oroacetic acid, 5 mM n-octylpyranoglucoside followed by sonication.  The protein 
digests resulting from each of the gel slices were separately analyzed by nano-
LC-MS/MS (using a LTQ (linear trap quadrupole) Fourier Transform Ion Cyclotron 
Resonance mass spectrometer (LTQ FT, Thermo Scientific, Waltham, MA, USA)). 
Data were converted by BioWorks SEQUEST (Thermo Electron, Waltham, MA, USA) 
into a peak list, which allowed peptide identification with the Mascot Search data-
base. Additionally, citrullination sites were checked manually. Mass deviations for 
precursor ions were set to 20 ppm and deviations for the mass of fragment ions 
were set at 0.8 Da. Fixed modifications, besides citrullination, such as oxidation 
and methylation, were taken along during the analysis.
Synthesis of citrullinated fibronectin peptides
Peptides (Table 1) were synthesized by a solid-phase procedure using Fmoc 
chemistry as described previously.50 The peptides were at least 90% pure as de-




Enzyme-linked immunosorbent assays (ELISA) with fibronectin peptides 
were performed as described previously. Briefly, each well of a microtiter plate 
(Streptawell, Roche, Basel, Switzerland) was coated with 1 µg biotinylated peptide 
in 0.1 mL PBS/0.1% BSA overnight at 4°C. After washing three times with PBST0.1 
(PBS, 0.1% Tween20), wells were incubated with serum samples 100-fold diluted 
at in PBST0.05 (PBS, 0.05% Tween20) containing 1% BSA for one hour at 37°C. 
After incubation, plates were washed three times with PBST0.1, followed by an 
incubation at 37°C with HRP-conjugated goat anti-human IgG, IgM, IgA, kappa, 
lambda (DAKO, Glostrup, Denmark) or with either HRP-conjugated rabbit anti-hu-
man IgG, rabbit anti-human IgM or rabbit  anti-human IgA (DAKO, Glostrup,  Den-
mark). Bound antibodies were detected by the conversion of 3,3’,5,5’-tetramethyl-
benzidine (TMB) and, after terminating the reaction by the addition of sulfuric acid, 
the  absorbance  was measured  at 450 nm. Cut-off values were determined as the 
mean value plus two times the standard deviation of normal human control sera.
ACPA fine specificity ELISA assays using peptides derived from citrullinated 
vimentin, fibrinogen and α-enolase were performed as described previously.39,51 
Supplementary Figure 1. Overview of the handling of synovial fluid samples.
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Statistics
A two-tailed unpaired t-test with a CI of 95% was used to observe differences 
in reactivity between RA sera and non-RA sera with respect to the citrullinated 
peptides.
Univariate logistic regression analyses were performed for testing the associa-
tion between several single risk factors (SE alleles as well as smoking) and anti-ci-
trullinated fibronectin peptide antibodies in early arthritis patients. A Mann-Whit-
ney U test was performed to address associations with the clinical phenotype (HAQ 
(health assessment questionnaire) score, VAS (visual analog scale) score, swollen 
joint count and Ritchie index) of the early arthritis patients.
RESULTS
Citrullinated fibronectin in synovial fluid samples of RA patients
To study the immune response to citrullinated FN in RA, first the positions of 
the citrulline residues in FN isolated from the inflamed joints of RA patients were 
mapped. One supernatant fraction and one pellet fraction from SF samples ob-
tained from two different RA patients (RA1 and RA2, respectively) were depleted 
of albumin by a differential precipitation procedure as described previously.49 This 
resulted in two pellet fractions for each RA SF sample, which were separated by 
SDS-PAGE and stained with colloidal Coomassie Brilliant Blue (CBB) (Supplemen-
tary Figure S1). Subsequently, 18 equal slices, covering the largest polypeptides 
(slice number 1, molecular weight >94,000) to the smallest polypeptides (slice 
number 18, molecular weight < 14,000) were excised from the stained gel for both 
samples (Figure 1A). The polypeptides present in the slices were digested with 
trypsin and analyzed by LC-MS/MS.  The identity of polypeptides and the positions 
of citrullinated residues were determined by database searches using Mascot (Ver-
sion 2.1.03, Matrix Science Inc, Boston, MA, USA). 
To confirm the presence of citrullinated residues and to distinguish from deam-
idation of glutamine or asparagine residues, the peptide fragmentation patterns 
were inspected manually. One of the citrullinated proteins found in the SF of both 
patients was FN. Figure 1B shows a schematic overview of all the FN peptide se-
quences obtained. This indicates that (fragments of) FN were present in material 
from many gel slices, indicative of a large variety of FN polypeptide lengths in SF 
samples. FN is a protein for which at least 15 different isoforms exist Figure 1C); 
the canonical isoform (FN1) comprises a polypeptide of 2,386 amino acids, in 
which three repeats can be discerned.52 FN-derived peptides that were found by 
these analyses covered most of the FN1 isoform, although for several regions no 
peptides were detected, which may at least in part be due to poor ionization effi-
ciencies. For one of the alternatively spliced segments, extra domain A (EDA), no 
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peptides were found in the data obtained, whereas several peptides demonstrating 
the absence of EDA were present. For IIICS, another alternatively spliced region, 
some peptide sequences were obtained with material from the high molecular 
weight fractions. Altogether, the mass spectrometry data covered 53% and 28% 
of the FN iso- form 1 sequence for RA1 and RA2, respectively (Figure 1B and Sup-
plementary Figure S2).
Figure 1. Identification of (citrullinated) FN in RA synovial fluid. A. RA synovial fluid 
samples were depleted of albumin and separated by SDS-PAGE and stained with colloidal 
Coomassie Brilliant Blue. Subsequently, 18 equal slices were excised from the stained gel 
for both samples. The polypeptides present in the slices were digested with trypsin and 
analyzed by LC-MS/MS. The presence of citrullinated proteins in the gel was visualized by 
western blotting using anti-modified citrulline (AMC) antibodies after modification of the 
proteins on the blot. The positions of molecular mass markers are indicated on the left 
(kDa). B. The positions of FN peptides detected in RA SF with LC-MS/MS for each of the 18 
gel slices of both patient samples are schematically aligned with isoform 1 of fibronectin 
(FN1). The white bars represent peptides detected in RA1, the black bars peptides detected 
in RA2 and the grey bars peptides detected in both patients. The positions of the citrullinat-
ed residues detected are marked with asterisks. C. Schematic overview of the 15 different 
FN isoforms, resulting from alternative splicing events, documented in the UniProtKB da-
tabase. The positions of the main alternatively spliced segments EDA, EDB and IIICS are 
indicated. 
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Supplementary Figure 2. Fibronectin-derived peptides identified in the synovial fluid of 
RA patients. The fibronectin peptides detected in synovial fluid samples of RA patients are 
indicated by lines above and below the amino acid sequence of human fibronectin (for RA1 
and RA2, respectively) and the citrullinated residues present in these peptides are marked 
with a grey box. The extra domain A (EDA) is represented by the amino acids 1631 till 
1720. A tryptic peptide (amino acids 1589-1629), beginning and ending with an asterisk 
was detected as a single peptide sequence. 
   4  
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      361 VLPFTYNGRT FYSCTTEGRQ DGHLWCSTTS NYEQDQKYSF CTDHTVLVQT RGGNSNGALC HFPFLYNNHN YTDCTSEGRR DNMKWCGTTQ   
      451 NYDADQKFGF CPMAAHEEIC TTNEGVMYRI GDQWDKQHDM GHMMRCTCVG NGRGEWTCIA YSQLRDQCIV DDITYNVNDT FHKRHEEGHM 
      541 LNCTCFGQGR GRWKCDPVDQ CQDSETGTFY QIGDSWEKYV HGVRYQCYCY GRGIGEWHCQ PLQTYPSSSG PVEVFITETP SQPNSHPIQW                
      631 NAPQPSHISK YILRWRPKNS VGRWKEATIP GHLNSYTIKG LKPGVVYEGQ LISIQQYGHQ EVTRFDFTTT STSTPVTSNT VTGETTPFSP 
      721 LVATSESVTE ITASSFVVSW VSASDTVSGF RVEYELSEEG DEPQYLDLPS TATSVNIPDL LPGRKYIVNV YQISEDGEQS LILSTSQTTA     
      811 PDAPPDPTVD QVDDTSIVVR WSRPQAPITG YRIVYSPSVE GSSTELNLPE TANSVTLSDL QPGVQYNITI YAVEENQEST PVVIQQETTG 
      901 TPRSDTVPSP RDLQFVEVTD VKVTIMWTPP ESAVTGYRVD VIPVNLPGEH GQRLPISRNT FAEVTGLSPG VTYYFKVFAV SHGRESKPLT    
      991 AQQTTKLDAP TNLQFVNETD STVLVRWTPP RAQITGYRLT VGLTRRGQPR QYNVGPSVSK YPLRNLQPAS EYTVSLVAIK GNQESPKATG 
     1081 VFTTLQPGSS IPPYNTEVTE TTIVITWTPA PRIGFKLGVR PSQGGEAPRE VTSDSGSIVV SGLTPGVEYV YTIQVLRDGQ ERDAPIVNKV   
     1171 VTPLSPPTNL HLEANPDTGV LTVSWERSTT PDITGYRITT TPTNGQQGNS LEEVVHADQS SCTFDNLSPG LEYNVSVYTV KDDKESVPIS 
     1261 DTIIPAVPPP TDLRFTNIGP DTMRVTWAPP PSIDLTNFLV RYSPVKNEED VAELSISPSD NAVVLTNLLP GTEYVVSVSS VYEQHESTPL  
     1351 RGRQKTGLDS PTGIDFSDIT ANSFTVHWIA PRATITGYRI RHHPEHFSGR PREDRVPHSR NSITLTNLTP GTEYVVSIVA LNGREESPLL 
     1441 IGQQSTVSDV PRDLEVVAAT PTSLLISWDA PAVTVRYYRI TYGETGGNSP VQEFTVPGSK STATISGLKP GVDYTITVYA VTGRGDSPAS  
     1531 SKPISINYRT EIDKPSQMQV TDVQDNSISV KWLPSSSPVT GYRVTTTPKN GPGPTKTKTA GPDQTEMTIE GLQPTVEYVV SVYAQNPSGE 
     1621 SQPLVQTAVT NIDRPKGLAF TDVDVDSIKI AWESPQGQVS RYRVTYSSPE DGIHELFPAP DGEEDTAELQ GLRPGSEYTV SVVALHDDME 
     1711 SQPLIGTQST AIPAPTDLKF TQVTPTSLSA QWTPPNVQLT GYRVRVTPKE KTGPMKEINL APDSSSVVVS GLMVATKYEV SVYALKDTLT 
     1801 SRPAQGVVTT LENVSPPRRA RVTDATETTI TISWRTKTET ITGFQVDAVP ANGQTPIQRT IKPDVRSYTI TGLQPGTDYK IYLYTLNDNA 
     1891 RSSPVVIDAS TAIDAPSNLR FLATTPNSLL VSWQPPRARI TGYIIKYEKP GSPPREVVPR PRPGVTEATI TGLEPGTEYT IYVIALKNNQ  
     1981 KSEPLIGRKK TDELPQLVTL PHPNLHGPEI LDVPSTVQKT PFVTHPGYDT GNGIQLPGTS GQQPSVGQQM IFEEHGFRRT TPPTTATPIR 
     2071 HRPRPYPPNV GEEIQIGHIP REDVDYHLYP HGPGLNPNAS TGQEALSQTT ISWAPFQDTS EYIISCHPVG TDEEPLQFRV PGTSTSATLT 
     2161 GLTRGATYNI IVEALKDQQR HKVREEVVTV GNSVNEGLNQ PTDDSCFDPY TVSHYAVGDE WERMSESGFK LLCQCLGFGS GHFRCDSSRW 
     2251 CHDNGVNYKI GEKWDRQGEN GQMMSCTCLG NGKGEFKCDP HEATCYDDGK TYHVGEQWQK EYLGAICSCT CFGGQRGWRC DNCRRPGGEP 





Figure 2. Recognition of citrullinated fibronectin peptides by RA sera. The four fi-
bronectin peptide sets (A, FN-Arg/Cit241; B, FN-Arg/Cit1035,1036; C, FN-Arg/Cit1162; D, FN-Arg/
Cit2356) were analyzed by ELISA with 23 sera from established RA patients. Two peptide sets 
(E, FN-Arg/Cit1035,1036; F, FN-Arg/Cit2356) were analyzed with a larger cohort obtained from 
established RA sera (n=80). OD450 = optical density at 450 nm. 
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A search for deiminated  arginines identified four citrullinated  FN regions  con-
taining  five citrullinated residues,  located  at  amino  acid positions  241, 1035, 
1036, 1162 and 2356 (Figure 1B). In RA1, four citrullinated residues were identi-
fied (positions 241, 1035, 1036 and 1162), whereas in the second patient (RA2) 
four citrullinated residues were identified (positions 241, 1035, 1162 and 2356) 
(Figure 1A and Table 1).
Anti-citrullinated fibronectin peptide antibodies are specific for RA and 
are associated with the ACPA response
To investigate the antigenicity of citrullinated FN, peptides comprising the ci-
trullination sites identified were synthesized, as well as their arginine-containing 
counterparts (Table 1). A single peptide was synthesized for the flanking citrulli-
nation sites at positions 1035 and 1036, similar to the peptide identified in RA SF. 
The recognition of these peptides by antibodies in established RA patient sera (n 
= 23) was analyzed by ELISA. Two of these peptides, which contained either a ci-
trulline at position 241 or at position 1162 (FN-Cit241 and FN-Cit1162, respectively), 
were not recognized by RA sera. In contrast, the other two peptides (FN-Cit1035,1036 
and FN-Cit2356) were reactive with RA sera, and for both this reactivity appeared 
to be citrulline-dependent (Figure 2A-D). To substantiate these data and to obtain 
an indication of the frequency by which these peptides are recognized, sera from a 
second, larger cohort of 80 established RA patients were analyzed. Also these  sera 
were  found  to  be  frequently  reactive with the FN-Cit1035,1036  and  FN-Cit2356 
peptides (Figure 2E, F). 
Forty-three percent of these sera appeared to recognize FN-Cit1035,1036, whereas 
eight percent  was reactive with FN-Cit2356. To analyze the disease-specificity of 
antibodies to these citrullinated FN peptides, sera from 31 multiple sclerosis (MS), 
32 type 1 diabetes (T1D), 31 primary Sjőgren’s syndrome (pSS), 31 systemic  lu-
pus erythematosus (SLE) and 29 tuberculosis (TB) patients, and from 32 healthy 
individuals, in parallel with 75 established  RA sera, were analyzed by ELISA. The 
results showed that less than two percent of the control sera was reactive with 
FN-Cit1035,1036, whereas one percent displayed reactivity with FN-Cit2356 (Figure 3).
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Figure 3. Recognition of citrullinated fibronectin peptides by diseased and healthy 
control sera. The peptides FN-Arg/Cit1035,1036 and FN-Arg/Cit2356 were used to study the 
specificity of the anti-FN antibodies. A. Reactivity of RA sera and control sera to FN-
Cit1035,1036. B. Reactivity of RA sera and control sera to FN-Cit2356. C. Reactivity of RA sera 
and control sera to FN-Arg1035,1036. D. Reactivity of RA sera and control sera to FN-Arg2356. 
RA (n=75); pSS = primary Sjőgren’s syndrome (n=31); MS = multiple sclerosis (n=31); 
SLE = systemic lupus erythematosus (n=31); T1D = type 1 diabetes (n=32); TB = tu-
berculosis (n=29); NS = normal human sera (n = 32). Broken lines indicate cutoff values 
(mean + 2*SD of NS data); OD450 = optical density at 450 nm. 
Recently, it was shown that RA patients can be divided into two subsets based 
upon the presence or absence of ACPA in their sera and the CCP2 test appeared to 
be very suitable to differentiate between these subsets.53 The analysis of anti FN-
Cit1035,1036 reactivity in 131 anti-CCP2-positive and 28 anti-CCP2-negative RA sera 
(Figure 4) showed that  the anti-citrullinated fibronectin antibodies were hardly 
present in anti-CCP2-negative RA sera, corroborating the idea that these  antibod-
ies  are part of the ACPA response in anti-CCP2-positive RA patients. The combined 
analyses of the established RA sera resulted in a prevalence of 50 percent for the 
autoantibodies to peptide FN-Cit1035,1036 (Table 2), LTVGLTXXGQPRQY (X represents 
citrulline), in CCP2-positive established  RA sera (n = 82).
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Figure 4. Anti-citrullinated fibronectin peptide antibodies in relation to anti-CCP2 
positivity. The peptide set FN-Arg/Cit1035,1036 was used to study the presence of anti-FN an-
tibodies in anti-CCP2 positive (n=138) and anti-CCP2 negative (n=28) RA sera. The broken 
line indicates the cut-off value (mean + 2*SD of data obtained with normal human control 
sera); OD450 = optical density at 450 nm.
Autoantibodies against citrullinated fibronectin peptide are present early 
in the disease
Autoantibodies against CCP2 peptides have been demonstrated to be detectable 
very early in the disease. Moreover, their presence in pre-disease sera predicts the 
development of RA.5,6,54 The diversification of the ACPA response was found to oc-
cur mainly in the pre-disease stage. To investigate whether autoantibodies against 
citrullinated FN are also detectable in the early stages of RA development, a num-
ber of sera from early arthritis (EAC) patients (CCP2-negative, n = 23; CCP2-pos-
itive, n = 24) was analyzed. As observed before for the established RA sera, also 
the EAC sera reactive with the FN-Cit1035,1036 peptide represented a subgroup of the 
anti-CCP2-positive patients (Figure 5A). To substantiate these data and to obtain 
an indication of the frequency by which the FN-Cit1035,1036 peptide was recognized, 
additional CCP2-positive early arthritis sera (n = 278) were analyzed. Forty-five per-
cent of these CCP2-positive EAC sera appeared to be reactive with the citrullinated 
fibronectin peptide containing citrulline residues at positions 1035 and 1036 (Figure 
5B and Table 2). Only a small fraction of these early arthritis sera (4%) displayed 
some reactivity with the corresponding arginine-containing peptide (Figure 5B).
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Figure 5. Anti-citrullinated fibronectin peptide antibodies in early arthritis patient sera.
A. Sera from anti-CCP2-negative (n=23) and anti-CCP2-positive (n=24) early arthritis 
patients were analyzed in the FN-Cit1035,1036 ELISA. B. Sera from anti-CCP2-positive early 
arthritis patients (n=278) were analyzed in the FN-Cit1035,1036 ELISA. The broken line indi-
cates the cut-off value (mean + 2*SD of data obtained with normal human control sera); 
OD450 = optical density at 450 nm. 
It is known that after disease onset ACPA isotype switching may occur.55 To inves-
tigate isotype switching of antibodies to citrullinated FN, 23 anti-FN-Cit1035,1036-pos-
itive sera for which both samples taken at baseline and approximately  seven years 
after disease onset were avail- able, were selected and analyzed in ELISA with 
isotype-specific (IgG, IgM and IgA) secondary  antibody  conjugates.  At baseline 
(t = 0), 87% of the reactive sera contained immunoglobulins of the IgG isotype 
(Figure 6A), whereas 13% contained IgM (Figure 6C) and 4% contained IgA (Fig-
ure 6E) type reactivities. 
After a median follow-up time of seven years (t = 7) the frequency of IgG type 
antibodies to FN-Cit1035,1036 was slightly decreased to 74% (Figure 6B). In these 
patients the frequency of IgM type anti-FN-Cit1035,1036 antibodies decreased to 4% 
(Figure 6D) In contrast, at this stage the frequency of IgA type antibodies to this 
citrullinated FN peptide increased to 13% (Figure 6F). All IgM- and IgA-positive 
patients were also positive for IgG, whereas the simultaneous presence of IgM 
and IgA reactivities in the same patients was observed in one patient. Except for 
two patients, in which the IgG type anti-FN-Cit1035,1036 antibodies disappeared, the 
presence of these IgG antibodies  did not markedly change in time (Figure 6G).
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Figure 6. Anti-FN-Cit1035,1036 antibodies are predominantly of the IgG isotype.
Sera from a subset of anti-FN-Cit1035,1036-positive early arthritis patients (n=23) taken at 
baseline (t=0) and after a median follow-up of seven years later (t=7) were analyzed for 
different anti-FN-Cit1035,1036 antibody isotypes in ELISA. A.  IgG isotype reactivity at t=0. B. 
IgG isotype reactivity at t=7. C. IgM isotype reactivity at t=0. D. IgM isotype reactivity at 
t=7. E. IgA isotype reactivity at t=0. F. IgA isotype reactivity at t=7. G. Anti-FN-Cit1035,1036 
IgG reactivity at t=0 and t=7. The broken lines indicate the cut-off values determined by 
normal human control sera. 
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Anti-citrullinated fibronectin peptide antibodies are associated with HLA 
SE alleles
The HLA-DRB1*01, HLA-DRB1*04, HLA-DRB1*10 and HLA-DRB1*14 alleles 
comprise the group of HLA SE alleles, which are associated with RA.56 The reactivity 
to FN-Cit1035,1036 was compared  with the HLA-DRB1 alleles of the 278 early arthritis 
patients. The results showed that the presence of HLA SE alleles is associated with 
the production of anti-citrullinated fibronectin antibodies, because patients  car-
rying HLA SE alleles are more than two times more likely to have autoantibodies 
against citrullinated fibronectin (OR = 2.11; Table 3 and Supplementary Table S1). 
When addressing individual HLA-DRB1 alleles, only HLA-DRB1*04 (OR = 1.5), and 
HLA-DRB1*10 (OR = 1.57) showed a weak to moderate association with the pres-
ence of anti-FN-Cit1035,1036 antibodies. Although a more pronounced association was 
observed with HLA-DRB1*08 (OR = 2.45) and HLA-DRB1*16 (OR = 2.43), these 
data should be interpreted with care because the carriage of these alleles is rare 
and the data are based on only a low number of patients. Interestingly, a negative 
association was observed between the presence of anti-citrullinated fibronectin 
antibodies and two additional HLA-DRB1 alleles, HLA-DRB1*09 and HLA-DRB1*11 
(OR = 0.19 and OR = 0.41, respectively) (Supplementary Table S1).
In addition, the potential relationship of smoking with the production of anti-ci-
trullinated fibronectin antibodies was assessed and a weak association was found 
(OR = 1.42). We did not observe significant associations between the presence of 
anti-citrullinated fibronectin antibodies and clinical parameters, such as VAS score, 
HAQ score, Ritchie index or swollen joint count at baseline (data not shown).
Peptide 
name
Peptides identified in 
RA SFa






















Table 1. Sequences of synthetic fibronectin peptides. a X: citrulline; Z: aminohexano-
ic acid; O: biotinylated lysine. b Only citrulline at position 1035 was identified
5
Anti-citrullinated fibronectin and HLA SE alleles 97





established RAa 82 41 50.0
early RAa 278 124 44.6
Controls 186 3 1.6 98.4
       non-RA 154 3 1.9 98.1
       Healthy 32 0 0 100
Table 2. Sensitivity and specificity of anti-citrullinated fibronectin antibodies. 
a Based upon CCP2-positive sera
Anti-cit FN neg. (%)d Anti-cit FN pos. (%)d OR  (95% CI)
Smokinga
- 63 (46.7) 40 (38.1)
1.42 (0.85 - 2.39)
+ 72 (53.3) 65 (61.9)
HLA SE allelesb
- 39 (26.5) 57 (14.6)
2.11 (1.13 - 3.92)
+ 108 (73.5) 213 (85.4)
Table 3. Association of anti-citrullinated fibronectin antibodies with smoking and 
SE alleles in anti-CCP2-positive early arthritis patients. a Based upon information 
obtained from 240 RA patients. b Based upon information obtained from 270 RA patients. 
OR = odds ratio; 95% CI = 95% confidence interval.
DISCUSSION
The analysis of citrullinated proteins in the synovial fluids of two rheumatoid 
arthritis patients revealed fibronectin as one of the multiply citrullinated proteins 
in both patients.  Two of the four synthetic peptides that were derived from the 
citrullinated regions of FN appeared to be reactive with ACPA in the sera of RA 
patients. The most frequently targeted FN peptide, FN-Cit1035,1036, which contains 
two adjacent  citrullines, was recognized by 50% of established and 45% of early 
ACPA-positive RA patients. Like ACPA in general, anti-FN-Cit1035,1036 antibodies ap-
peared to be associated with HLA-DRB1 shared epitope  alleles.
FN is a complex protein, characterized by the presence of three types of repeats 
in its polypeptide sequence, for which many isoforms resulting from alternative 
splicing events have been described (Figure 1C). The UniProtKB database pro-
vides details of 15 isoforms, with isoform 1 (FN1 in Figure 1C) as the canonical 
sequence. The overall sequence coverage of the mass spectrometry datasets rela-
tive to FN1 comprises 53% and 28% for both synovial fluid samples, respectively. 
It is likely that multiple FN isoforms are expressed in the inflamed synovia of RA 
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patients and our data do not allow drawing conclusions on their relative abun-
dance. Three regions of FN are especially prone to alternative splicing; at the pro-
tein level these are termed extra domain A (EDA), extra domain B (EDB) and type 
III connecting segment (IIICS). Although peptides were found that match part of 
the IIICS sequence, no peptides were detected for EDA and EDB. Moreover, a few 
peptides provide evidence for the absence of EDA and EDB in the isoform(s) they 
originate from, because their sequences covered the regions immediately N- and 
C-terminal from EDA or from EDB. The EDA domain, also designated EIIIA, has 
been implicated in inflammation, because it was shown to be involved in Toll-like 
receptor (TLR) 4 activation.57 Although our data do not support the presence of 
EDA-containing FN isoforms in the synovial fluid of RA patients, it has been demon-
strated previously that EDA-containing FN is produced in the RA synovium and is 
expressed abundantly in RA SF.58,59 Moreover, recently Lefebvre and colleagues 
showed that EDA-containing FN stimulated leukotriene synthesis and neutrophil 
recruitment via TLR activation in a mouse model.60 Although we could not detect 
any peptides in the EDA region, our data do not exclude the presence of EDA-con-
taining FN isoforms in RA synovial fluid samples, because we have only analyzed 
a limited number of patients or because of technical limitations, such as ionization 
efficiencies. The interpretation of the data is further complicated by the fact that 
FN-derived peptides were found in material from many gel slices, which indicates 
a high heterogeneity of FN polypeptide lengths. It is likely that this is at least in 
part due to the presence of proteolytic enzymes in the synovial fluid from inflamed 
joints, which cleave the FN polypeptides in different fragments. It is known that 
during inflammation proteases are active in synovial fluid and can contribute to RA 
pathogenesis.61,62 Indeed, the fragmentation of FN in inflammatory SF63, as well as 
in cartilage of RA and osteoarthritis patients64 has been reported previously. Our 
analyses identified five citrullinated residues in FN from RA patient SF. Except for 
two adjacent citrullines, these residues are found in distant regions of the FN poly-
peptide chain. Our data do not provide information on the extent to which these 
residues are citrullinated in RA SF and it is likely that differences between patients 
exist. This is substantiated by the observation that in material from RA2 for the re-
gion containing the two adjacent citrullines only one of these two residues (1035) 
was found to be citrullinated, whereas both were citrullinated in RA1. Two other 
studies have previously reported the presence of citrullinated FN in SF and synovial 
tissue of RA patients.41,43 However, these studies did not reveal the positions of the 
citrullinated residues.  Our data do not exclude the possibility that FN is also citrul-
linated at other positions in RA SF, because material from only two patients was 
analyzed in detail and the sequence coverage was not more than 53%. Moreover, 
if citrullination enhances FN’s susceptibility to proteolytic cleavage, citrullinated 
peptides may have escaped detection as a result of cleavages by endogenous pro-
teases that cleave the polypeptide close to the citrullinated residue.
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A synthetic peptide approach to investigate the recognition of citrullinated epi-
topes of FN by RA autoantibodies revealed that the major auto-epitope is located 
in the region containing the two adjacent  citrullines (amino acids 1035 and 1036). 
Only one of the other three citrullinated peptides was recognized by some RA sera. 
The fact that RA sera were only reactive with two of these peptides is consistent 
with the results of other studies showing that the amino acids flanking the citrulline 
residue contribute to the formation of auto-epitopes.1 Several studies24,34,65 with 
synthetic citrullinated peptides (derived from vimentin, fibrinogen and α-enolase) 
showed that not all peptides containing citrullinated residues are recognized by 
patient sera, indicating that not only the citrulline is important, but also the amino 
acids surrounding the citrullinated residue. However, it should be noted that the 
use of synthetic peptides in general does not allow the identification of reactivities 
with conformational and/or discontinuous epitopes. Therefore, our data do not 
exclude the possibility that the citrullinated residues identified are part of confor-
mational epitopes and that autoantibodies to these epitopes may be present in 
RA patient sera. Although autoantibodies to FN have been detected in RA as well 
as SLE patients before66,67, our data are the first to describe antibodies that  tar-
get FN in a citrulline-dependent manner. The autoantibodies that can be detected 
with the FN-Cit1035,1036 peptide represent a subset of ACPA, which is substantiated 
by the lack of correlation between the  levels of reactivity with CCP2 and with FN-
Cit1035,1036 (Supplementary Figure S3). In total, 50% of the (anti-CCP2-positive) es-
tablished RA patients  showed reactivity to FN-Cit1035,1036, compared to two percent 
of the controls (non-RA and healthy individuals; Table 2).
Supplementary Figure 3. Correlation between anti-CCP2 and anti-FN-Cit1035,1036 reactivi-
ties. Cor0lation diagram showing the levels of anti-FN-Cit1035,1036 and anti-CCP2 reactivities 
of (established) RA sera (n=110). Broken lines represent the cut-off values. OD450 = op-
tical density at 450 nm. 
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Supplementary Figure 3. Correlation between anti-CCP2 and anti-FN-Cit1035,1036 
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Figure 7. Anti-FN-Cit1035,1036 in relation to other ACPA. The reactivity of EAC sera 
(n=228) with FN-Cit1035,1036 was compared with the presence of antibodies to other citrul-
linated peptides, which are derived from vimentin (1-16: STCitSVSSSSYCitCitMFGG and 
59-74: VYATCitSSAVCitLCitSSVP), fibrinogen (α-fibrinogen 27-43: FLAEGGGVCitGPRV-
VERH; β-fibrinogen 36-52: NEEGFFSACitGHRPLDKK) and α-enolase (5-20: KIHACitEIFD-
SCitGNPTV) 1. A. Fraction of patients recognizing 0 – 6 citrullinated peptides. B. Heat map 
showing the presence of antibodies to the citrullinated peptides obtained by an unsuper-
vised cluster analysis. Red and green mark positive and negative sera, respectively. Miss-
ing values are depicted in grey. 
The possibility existed that the anti-FN-Cit1035,1036 subset of ACPA overlapped 
with another  subset that  has been identified  previously, as a result of epi-
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tope similarities. ACPA fine-specificity data were available for most of the EAC 
patient sera. The reactivity of these sera with FN-Cit1035,1036 was compared with 
their reactivity with two citrullinated peptides derived from vimentin (vimen-
tin-1-16: STCitSVSSSSYCitCitMFGG; vimentin-59-74: VYATCitSSAVCitLCitSSVP), 
two peptides derived from fibrinogen (α-fibrinogen-27-43: FLAEGGGVCitGPRV-
VERH; β-fibrinogen-36-52: NEEGFFSACitGHRPLDKK) and one peptide derived from 
α-enolase (α-enolase-5-20: KIHACitEIFDS- CitGNPTV).39 These analyses showed 
that most of the EAC sera recognized multiple citrullinated epitopes (Figure 7A). 
A large overlap of anti-FN-Cit1035,1036  with reactivities to any of the other  peptides 
was observed, as might  be expected  from previous  data.26,68 However, some sera 
appeared to react exclusively with FN- Cit1035,1036 and not with the other citrullinated 
epitopes (Figure 7B). These data are underscoring the large heterogeneity of the 
ACPA response in RA and indicate that the anti-FN-Cit1035,1036 antibodies are one of 
the most abundant ACPA subclasses that can be detected with synthetic  peptides 
derived from citrullinated synovial proteins. Taken together, these data indicate 
that this citrullinated FN peptide may be used to investigate the fine-specificity of 
ACPA in more detail and may be complementary to other citrullinated molecules in 
ACPA profiling.
The anti-FN-Cit1035,1036 antibodies present in early arthritis  patients  appeared to 
be predominantly of the IgG isotype. Only a small percentage of sera was found 
to contain IgM or IgA type anti-FN-Cit1035,1036  antibodies. After a median follow-up 
of seven years, the IgG type reactivities were hardly changed, whereas the prev-
alence of IgM reactivity against FN-Cit1035,1036 was decreased, and that of IgA was 
somewhat increased. Similar observations have been reported for samples from 
undifferentiated arthritis patients (who developed RA) taken either at baseline or 
after one year follow-up.36 It remains an open question whether the anti-citrulli-
nated FN antibodies play a pathophysiological role. FN-containing immune com-
plexes are likely to be formed in the inflamed joints of RA patients and this may 
occur already early during disease development. Further studies will be required to 
elucidate whether citrullinated FN is involved in the inflammatory process.
The presence of anti-citrullinated FN antibodies in the early arthritis patients 
was associated with HLA SE alleles (OR = 2.11). Of the individual SE alleles, only 
HLA-DRB1*04 and HLA-DRB1*10 showed a weak association with the presence of 
anti-citrullinated FN peptide antibodies (Supplementary Table S1). Previously, Snir 
and co-workers  demonstrated that antibodies against multiple citrullinated anti-
gens (for example, vimentin,  fibrinogen,  α-enolase  and  the  C1-epitope  of type 
II collagen) were associated with SE alleles, particularly with HLA-DRB1*04.26,69 
Our data show a negative association of HLA-DRB1*09 and HLA-DRB1*11 with the 
presence of anti-citrullinated FN peptide antibodies (OR = 0.19 and OR = 0.41, 
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Anti-cit FN neg. (%)d Anti-cit FN pos. (%)d OR  (95% CI)
Smokinga - 63 (46.7) 40 (38.1) 1.42 (0.85-2.39)
+ 72 (53.3) 65 (61.9)
HLA SE allelesb - 39 (26.5) 57 (14.6) 2.11 (1.13-3.92)
+ 108 (73.5) 213 (85.4)
HLA-DRB1*01c - 112 (75.2) 93 (75.0) 1.01 (0.58-1.75)
+ 37 (24.8) 31 (25.0)
HLA-DRB1*03c -  118 (79.2) 105 (84.7) 0.69 (0.37-1.29)
+ 31 (20.8) 19 (15.3)
HLA-DRB1*04c - 70 (47.0) 46 (37.1) 1.5 (0.92-2.44)
+ 79 (53.0) 78 (62.9)
HLA-DRB1*07c - 131 (87.9) 110 (88.7) 0.93 (0.44-1.95)
+ 18 (12.1) 14 (11.3)
HLA-DRB1*08c - 147 (98.7) 120 (96.8) 2.45 (0.44-13.61)
+ 2 (1.3) 4 (3.2)
HLA-DRB1*09c - 137 (91.9) 122 (98.4) 0.19 (0.04-0.85)
+ 12 (8.1) 2 (1.6)
HLA-DRB1*10c - 137 (91.9) 109 (87.9) 1.57 (0.71-3.5)
+ 12 (8.1) 15 (12.1)
HLA-DRB1*11c - 125 (83.9) 115 (92.7) 0.41 (0.18-0.91)
+ 24 (16.1) 9 (7.3)
HLA-DRB1*12c - 145 (97.3) 121 (97.6) 0.9 (0.20-4.09)
+ 4 (2.7) 3 (2.4)
HLA-DRB1-13c - 129 (86.6) 113 (91.1) 0.63 (0.29-1.37)
+ 20 (13.4) 11 (8.9)
HLA-DRB1-14c - 144 (96.6) 120 (96.8) 0.96 (0.25-3.66)
+ 5 (3.4) 4 (3.2)
HLA-DRB1*15c - 113 (75.8) 91 (73.4) 1.14 (0.66-1.97)
+ 36 (24.2) 33 (26.6)
HLA-DRB1*16c - 148 (99.3) 122 (98.4) 2.43 (0.22-27.08)
+ 1 (0.7) 2 (1.6)
 Supplementary Table 1. Association of anti-citrullinated fibronectin antibodies and HLA-
DRB1 alleles in anti-CCP2-positive early arthritis patients. a Based upon information ob-
tained from 240 RA patients. b Based upon information obtained from 270 RA patients. c 
Based upon information obtained from 278 RA patients. dValues are the number and per-
centages of early arthritis patients (EAC) negative or positive (cut-off = mean + 2*SD) for 
anti-FN-Cit1035,1036 antibodies. OR = odds ratio; 95% CI = 95% confidence interval. 
a Based upon information obtained from 240 RA patients.
b Based upon information obtained from 270 RA patients.
c Based upon information obtained from 278 RA patients.
dValues are the number and percentages of early arthritis patients (EAC) negative or 
positive (cut-off = mean + 2*SD) for anti-FN-Cit1035,1036 antibodies.
OR = odds ratio; 95% CI = 95% confidence interval.
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respectively). This may be in agreement with the previously reported association 
of the HLA-DRB1*0901 haplotype with reduced levels of anti-CCP antibodies.70 Par-
adoxically, HLA-DRB1*09 has been reported previously to be associated with RA in 
Asian as well as Caucasian individuals.71,72 In addition, it should be noted that, be-
cause ACPA-positive RA patients  comprise a strong prevalence for SE-alleles, oth-
er  HLA-DRB1 alleles are less frequently  present  than  SE-alleles and, therefore, 
might seem to be protective. As a consequence, the negative association observed 
with HLA-DRB1*09 and HLA- DRB1*11 might also be the result of skewing.73
We did not detect a significant association between clinical phenotype and the 
presence of anti-citrullinated fibronectin in ACPA-positive RA patients. Recently, 
Scherer and colleagues also observed no effect on radiographic joint damage in 
patients that were positive for several citrullinated epitopes.37 Nevertheless, a 
weak correlation between the presence of autoantibodies against citrullinated FN 
and smoking, a risk factor for ACPA generation, particularly in individuals  that 
carry the SE alleles16,17 was observed.
CONCLUSION
Five citrullinated residues were identified in fibronectin isolated from the in-
flamed joints of RA patients. An epitope containing two adjacent citrullines at po-
sitions corresponding to residues 1035 and 1036 appeared to be most frequently 
recognized by RA sera. Our data  not only show that antibodies against citrullinat-
ed FN are present  in RA patients,  but  also demonstrate that  the anti-FN  anti-
bodies  represent a subgroup of anti-CCP2 antibodies and that they can already 
be detected  very early in the disease. Moreover, anti-FN-Cit1035,1036 antibodies are 
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Human leucocyte antigen shared epitope (SE) alleles are associated with joint 
destruction, the presence of anti-citrullinated protein antibodies (ACPA) and the 
ACPA fine specificity repertoire in rheumatoid arthritis (RA). A large variation in 
joint destruction is seen within the ACPA-positive patient population, and it is 
conceivable that certain ACPA reactivities contribute to radiological damage. The 
authors investigated whether ACPA fine specificities, which are formed under the 
influence of SE alleles, associate with the extent of radiographic joint damage. 
Methods 
Antibodies recognizing six citrullinated epitopes were determined in sera of 330 
ACPA-positive RA patients genotyped for SE alleles. The association between SE 
alleles, ACPA fine specificity and radiographic joint damage was assessed using ra-
diographic follow-up data. A second cohort of 154 RA patients with 5 and 10-year 
radiographic follow-up was used for replication.
Results 
SE alleles predisposed to the recognition of certain citrullinated epitopes. However, 
none of the ACPA fine specificities studied influenced radiographic joint damage. 
Importantly, although SE alleles associated with radiographic damage in the total 
RA population, this association was no longer detectable after stratification for the 
presence of ACPA.
Conclusions  
SE alleles are instrumental in shaping the ACPA repertoire. However, ACPA fine 
specificities formed under the influence of SE alleles do not seem to affect joint 
destruction.  
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INTRODUCTION
Human leucocyte antigen (HLA) shared epitope (SE) encoding genes are the 
most prominent genetic risk factor for rheumatoid arthritis (RA). SE alleles exert 
their risk effect by predisposing for anti-citrullinated protein antibody (ACPA)-pos-
itive RA,1 This and other findings have led to the concept that RA represents at 
least two distinct disease entities (ACPA-positive and negative RA) with different 
pathogenetic mechanisms.2, 3
The strength of the SE effect on susceptibility to ACPA-positive disease depends 
on the number of SE alleles present, with two alleles conferring a higher risk of 
disease than one allele. The fact that ACPA are also found in SE-negative patients, 
albeit in lower frequency, indicates that SE alleles are not absolutely required for 
the development of ACPA.1 It has been postulated that SE alleles primarily facil-
itate priming and activation of T helper cells, which can then provide help to AC-
PA-producing B cells. Such help is required for isotype switching and generation of 
a potent and long-lasting antibody response. 
It is conceivable that certain citrullinated antigens are more potent than others 
in activating T cells in the context of SE alleles. Only very few T-cell epitopes have 
so far been found, and no skewing of T-cell responses has been described. How-
ever, SE alleles were found to associate with antibodies targeting peptides from 
citrullinated vimentin, but not with the presence of antibodies recognizing citrulli-
nated fibrinogen.4 This differential modulation of the ACPA response by SE alleles, 
and the fact that disease phenotypes vary greatly among ACPA-positive patients, 
has raised the question whether certain ACPA fine specificities might associate 
with a more severe disease phenotype. If so, designing assays that test for these 
specificities would be of prognostic value and could influence treatment decisions 
in the clinic. 
In the present study, we analysed the relation between SE alleles, different 
ACPA fine specificities and their independent effects on disease outcome. 
METHODS
Patients and Radiographs
ACPA fine specificity was determined on baseline serum samples of RA patients 
participating in the Leiden Early Arthritis Clinic (EAC).5 The present study included 
patients who presented between March 1993 and November 2006 and who fulfilled 
the 1987 revised ACR criteria for RA within the first year of follow-up. Annual ra-
diographs of hands and feet were assessed as previously described.6
Replication of the association between SE alleles and radiographic progression 
in relation to ACPA status was performed using data of Norwegian RA patients 
with a maximum disease duration of 4 years included in 1992-3 in the Europe-
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an Research on Incapacitating Disease and Social Support (EURIDISS) project.7,8 
Radiographs of the hands were available for 154 patients at baseline and assessed 
according to the Sharp-van der Heijde method9 by one experienced reader with 
known time order.
Anti-CCP2 assays 
Anticyclic citrullinated peptide 2 (anti-CCP2) antibody levels were measured by 
ELISA (EAC: Immunoscan RA Mark 2; Eurodiagnostica, Arnhem, The Netherlands; 
EURIDISS: INOVA Diagnostics, San Diego, CA, USA).
 
ACPA fine specificity assays
Antibodies against the citrullinated (Cit) and the arginine-containing form of 
two peptides derived from vimentin (Vim1-16; Vim59-74), two peptides derived 
from fibrinogen (Fibα 27-43; Fibβ 36-52), one peptide derived from α-enolase (Eno 
5-20) and against citrullinated myelin basic protein (MBP) were determined by in-
house ELISA as previously described.4, 10 
Cut-off values were defined as the mean plus three times the standard deviation 
of the values of 30 control subjects (anti-CCP-negative EAC patients diagnosed 
with gout). Recognition was deemed to be citrulline-specific when the following 
requirements were met: (1) OD value citrullinated peptide greater than cut-off and 
(2) OD difference (OD citrullinated peptide – OD arginine-containing peptide) of 
0.1 or greater. The number of patients recognizing both the citrullinated and the 
arginine-variant above cut-off levels was small (~ 3%). 
Statistical analysis
Association between fine specificity recognition and SE alleles was assessed us-
ing chi-square tests. Association of fine specificities with the rate of joint destruc-
tion was assessed using a repeated measurement analysis on log-transformed 
radiological data. Adjustments were made for age, gender and treatment strategy 
used at the time of inclusion as previously described.5, 6 No association between 
inclusion period and recognition of separate ACPA fine specificities was found (data 
not shown). For the EURIDISS cohort, non-parametric Mann-Whitney U-test was 
used because of non-normal distribution of the data despite log-transformation. 
For comparison, Mann-Whitney U-test was also applied to the Leiden EAC where 
indicated.
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RESULTS
HLA SE alleles associate with several ACPA fine specificities
SE alleles associate with the presence of certain ACPA fine specificities.4 We first 
extended these findings by analyzing reactivity to more citrullinated epitopes, by 
increasing the number of patients studied, and by analyzing the effect of the SE 
gene dose on ACPA fine specificity. Three out of six citrullinated epitopes studied 
associated with the presence of SE alleles (table 1). Reactivity to citrullinated vi-
mentin 59-74, citrullinated α-enolase 5-20 and citrullinated MBP was found in sig-
nificantly increased frequency in SE positive patients, whereas no such effect was 
observed for the other three antigens. The effect was independent of the number 
of SE alleles, as patients with one or two SE alleles displayed a comparable profile 
of ACPA epitope recognition. These data indicate that one SE allele is sufficient to 
facilitate the development of certain ACPA fine specificities, and that presence of 
a second SE allele does not further skew the ACPA profile towards more frequent 
recognition of a specific epitope. 
The ACPA fine specificity repertoire does not predict future radiographic 
progression
ACPA-positive patients suffer from more severe disease than ACPA-negative pa-
tients. However, it is unknown whether distinct ACPA fine specificities are pathoge-
netically driving the inflammatory process and thus lead to a more severe disease 
outcome. Considering radiographic joint damage as the most objective sign of dis-
ease severity in RA, we analyzed the association between baseline recognition of 
specific citrullinated antigens and progression of radiographic joint damage in AC-
PA-positive patients over the course of 5 years (figure 1A,B). The ACPA fine spec-
ificity repertoire in individual patients did not change during this time period.11 We 
did not detect a difference in radiographic outcome in patients who harbour ACPA 
of one of the fine specificities tested. Also, patients with ACPA that recognized 
more citrullinated peptides did not suffer from a higher degree of progression of 
joint damage than patients with a limited ACPA repertoire (figure 1C). These data 
indicate that harbouring ACPA of any of the specificities tested has no direct influ-
ence on the progression of radiographic joint damage. 
Stratification for ACPA status abolishes the effect of HLA SE alleles on 
radiographic joint damage
None of the fine specificities tested was found to associate with radiographic 
progression. A drawback of this analysis is that lack of association does not ex-
clude that the investigation of other citrullinated peptides would have revealed a 
positive association with long-term joint damage. As this limitation can persist in 
case more (non-associating) reactivities would be analyzed, we reasoned that an 
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additional way to investigate the relationship between the ACPA recognition profile 
and radiographic outcome is to study the effect of SE alleles on joint damage in 
ACPA-positive disease only. As SE alleles affect the recognition of certain citrulli-
nated epitopes (table 1), SE alleles can be interpreted as a surrogate marker for 
the constitution of the ACPA response. 
While SE alleles associated with the degree of radiographic joint damage in the 
total RA population (figure 2A), they no longer contributed to radiographic joint 
damage in ACPA-positive disease (figure 2B). We sought replication of this obser-
vation in the Norwegian EURIDISS cohort. The findings in this cohort with 5 and 
10-year radiographic follow-up confirmed our results: there was no association 
between the presence of SE alleles and radiographic damage in ACPA-positive dis-
ease (figure 2C and D).
Figure 1. Association between different ACPA fine specificities and radiographic 
progression. (A,B) Median Sharp-van der Heijde scores (SHS) during 5 year follow-up 
of ACPA positive patients from the Leiden EAC testing positive or negative for six differ-
ent ACPA fine specificities at baseline. (C) Median SHS in ACPA-positive patients grouped 
by the number of ACPA fine specificities recognized. All statistical comparisons (repeated 
measurement analysis) were non-significant (p>0.05). Numbers of patients in each group 
are given in the table below each figure. The line representing the group of patients recog-
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nizing six fine specificities diverts from the rest due to the low number of patients in this 
group. In order to highlight this, this group is depicted with a dotted line. Radiographic data 
was available for n=266 ACPA-positive patients at baseline and n=132 at year 5. 
Figure 2. Shared epitope (SE) alleles exert no effect on radiographic progression 
after stratification for ACPA. Median Sharp-van der Heijde scores (SHS) in relation to 
SE positivity in the entire RA population and after stratification for ACPA-positive disease 
in patients of the Leiden Early Arthritis Clinic (A/B) and of the EURIDISS cohort (C/D). 
For the Leiden EAC: radiographic data was available for n=481 patients at baseline and 
n=214 at year 5, of which n=266 were ACPA-positive (data for n=132 available at year 5). 
(A) Repeated measurement analysis: p = 0.013; Mann-Whitney U test p < 0.001 at year 
1, p < 0.001 at year 2, p = 0.007 at year 3, p = 0.005 at year 4, p = 0.012 at year 5; 
(B) repeated measurement analysis: p > 0.05; all Mann-Whitney U p-values > 0.05. For 
the EURIDISS cohort: radiographic data was available for n=154 patients at baseline and 
n=142 at year 10, of which n=94 were ACPA-positive (data for n=83 available at year 10). 
(C) Mann-Whitney U test p = 0.029 at baseline, p < 0.001 at year 5, p < 0.001 at year 10; 
(D) Mann-Whitney U test p = 0.36 at baseline, p = 0.93 at year 5, p = 0.97 at year 10.
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Vimentin 1-16 8/63 (13%) 25/188 (13%) 8/73 (11%) 41/324 (13%)
Vimentin 59-74 16/64 (25%) 100/190 (53%) 46/73 (63%) 162/327 (50%)
Fibrinogen-α 27-43 20/64 (31%) 51/190 (27%) 15/73 (21%) 86/327 (26%)
Fibrinogen-β 36-52 43/63 (68%) 128/181 (71%) 52/73 (71%) 223/317 (70%)
α –enolase 5-20 12/64 (19%) 70/190 (37%) 27/73 (37%) 109/327 (33%)
MBP 30/64 (47%) 128/190 (67%) 51/73 (64%) 209/327 (64%)
Table 1. Association of HLA SE alleles with ACPA fine specificity. Displayed is the 
number of patients within the ACPA-positive patient population who harbor ACPA recog-
nizing defined citrullinated antigens. Chi-squared test over all 3 allelic groups (Vim 1-16: 
p = 0.88; Vim 59-74: p < 0.001; Fib-α: p = 0.35; Fib-β: p = 0.92; α-enolase: p = 0.022; 
MBP: p = 0.006).
DISCUSSION
Recent findings on ACPA fine specificity and its association with SE alleles have 
fuelled a hypothesis in which ACPA are pathogenetically driving the disease and in 
which certain ACPA fine specificities (developing preferentially under the influence 
of SE alleles) could be more pathogenic than others, leading to more severe joint 
destruction over time .4, 12 Further insights into which ACPA fine specificities might 
be associated with disease severity could therefore have prognostic value and con-
tribute to our understanding of disease pathogenesis. 
In this study, we could not detect an association between ACPA fine specificities 
and radiographic joint damage. An anti-citrulline immune response to 3 out of 6 of 
the epitopes studied developed preferentially in patients harboring SE alleles, but 
this did not translate into more severe radiographic outcome. Also, the number of 
citrullinated epitopes recognized by an individual patient did not influence the de-
gree of joint destruction. Although we accounted for baseline treatment strategy in 
this analysis, and although no association between year of inclusion and recogni-
tion of the separate ACPA fine specificities was found, we cannot fully exclude that 
treatment effects later in the disease course could have influenced our results. The 
number of citrullinated epitopes also limits our study, and it cannot be excluded 
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that other epitopes would have been more useful for this purpose. We addressed 
this issue by using SE alleles as a surrogate marker for those ACPA fine specifici-
ties that develop under the influence of SE alleles. After stratification for ACPA, SE 
alleles no longer contributed to joint damage. Based on this finding, we consider 
it unlikely that a SE associated ACPA fine specificity can be identified that predicts 
disease course in RA. If such a predictive recognition profile exists, antibodies rec-
ognizing this epitope are likely to be generated independent of SE alleles. 
Our findings are relevant for strategies aimed at identifying patients that are 
at risk for rapidly progressive disease and provide evidence that the recognition 
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Anticitrullinated protein antibodies (ACPA) are the most predictive factor for the 
development of rheumatoid arthritis (RA). Epitope spreading towards more ci-
trullinated epitopes occurs before the onset of RA. Here, the authors investigated 
whether specific epitope recognition allows the identification of specific RA sub-
groups and whether it is associated with clinical features of RA.
Methods 
The reactivity of 661 patients with RA from the Leiden Early Arthritis Clinic against 
several citrullinated antigens was determined by ELISA. Cluster analyses were 
performed to identify subgroups of patients on the basis of their ACPA recognition 
profile. The association of the specific reactivities with clinical characteristics was 
studied. 
Results
ACPA-positive patients displayed a heterogeneous ACPA recognition profile. After 
performing cluster analyses, no apparent clustering of patients was found, and 
on the basis of the reactivities analysed, 64 different subgroups could already be 
identified. The extent of epitope recognition was associated with anticyclic citrul-
linated peptide-2 levels. The recognition of specific citrullinated epitopes was not 
associated with baseline characteristics. Likewise, patients with an extended fine 
specificity repertoire did not display differences in baseline characteristics or joint 
damage after 7 years of follow-up using cyclic citrullinated peptide-2 levels as a 
proxy, compared to ACPA-positive patients recognising fewer peptides.
Conclusion 
These data show that the ACPA response is highly diverse with respect to recog-
nition of specific citrullinated epitopes. Furthermore, the authors’ data indicate 
that clinical correlates in established ACPA- positive RA are independent from the 
specific (group of) citrullinated peptides recognised.
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INTRODUCTION
Anticitrullinated protein antibodies (ACPA) have been shown to be able to initi-
ate and enhance arthritis in murine models of arthritis1,2 and are able to activate 
Fc Receptor-positive cells3,4 and the complement system, leading to the argument 
that they could play a role in disease pathogenesis.5
The detection of ACPA, which is most commonly assessed by reactivity against 
cyclic citrullinated peptide (CCP)-2, is an accepted diagnostic tool for rheumatoid 
arthritis (RA).6 ACPA are highly specific for RA, can be detected years before the 
first clinical manifestation of RA7,8 and are reported to be a good predictor for the 
development of RA.9 Anti-CCP antibodies recognise multiple citrullinated peptides 
and proteins and are thus a collection of ACPA.10
Some types of human leucocyte antigens (HLA) alleles, particularly HLA-DRB1 
alleles encoding the shared epitope sequence, are known to be associated with RA 
susceptibility,11 more specifically susceptibility to ACPA-positive RA.12 ACPA-pos-
itive and ACPA-negative disease have been shown to be associated with differ-
ent genetic and environmental risk factors, fuelling the hypothesis that different 
pathophysiological mechanisms are underlying these two separate disease sub-
sets.13,14 Next to isotype usage15 and avidity16, the fine specificity of an antibody 
response is also thought to contribute in determining its efficacy.17 It has been 
shown that ACPA can recognise a variety of citrullinated antigens, including citrulli-
nated fibrinogen (cFib), α-enolase18, citrullinated vimentin (cVim) and citrullinated 
myelin-binding protein (cMBP)—the latter mimicking the Sa antigen.19,20
Levels of specific ACPA are elevated in synovial fluid, suggesting local antibody 
production and/or retention of ACPA at the site of inflammation.21
However, not all ACPA-positive sera will recognise all citrullinated antigens, as 
has been shown by analysing the reactivity against different citrullinated peptide 
antigens.10,22
It has been shown that patients with RA display a much more extended citrulli-
nated epitope recognition pattern compared to ACPA-positive first-degree relatives 
without symptoms.23 Indeed, epitope spreading with an increase in the recognition 
of citrullinated antigens occurs before the patients fulfil the 1987 classification cri-
teria of RA. Differences in ACPA fine specificity between patients having undiffer-
entiated arthritis who do or do not develop RA after 1 year are already present at 
baseline.24 Likewise, patients with arthralgia and with an extended ACPA repertoire 
have a higher risk of developing arthritis.25
It is conceivable that a certain ACPA recognition profile is associated with the 
emergence of certain clinical features and possibly pathogenicity, as has been 
shown in other autoimmune diseases. For example, in pemphigus the reactivity 
against different desmoglein epitopes is associated with different outcomes.26
Here, we determined the association between the ACPA fine specificity and phe-
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notypic characteristics within ACPA-positive RA and investigated whether specific 
subsets of RA patients can be distinguished on the basis of their epitope recogni-
tion profile.
MATERIALS AND METHODS 
Patient population
All patients who fulfilled the American College of Rheumatology 1987 revised 
criteria for the classification of RA27 within 1 year of follow-up from the Leiden 
Early Arthritis Clinic were analysed (n=661). The Leiden Early Arthritis Clinic is an 
inception cohort of patients with recent onset arthritis (symptoms duration, <2 
years) that was started at the Department of Rheumatology of the Leiden Univer-
sity Medical Center in 1993 and was described in detail previously.28 Sustained dis-
ease-modifying antirheumatic drug (DMARD)-free remission was defined as hav-
ing no current use of DMARDs, no swollen joints and classification as DMARD-free 
remission by the patients’ rheumatologist.29
Anti-CCP2 assays
Total IgG anti-CCP2 was measured in baseline sera by ELISA (Immunoscan RA 
Mark 2; Eurodiagnostica, Arnhem, The Netherlands). Samples with a value >25 
units/ml were considered positive according to the manufacturer’s instructions. 
Individuals with antibodies against CCP2 were considered ACPA-positive. From pa-
tients with antibody levels reaching the plateau of the standard, we further diluted 
the serum to determine ACPA levels.
ACPA fine specificity assays
ELISA assays were developed, as previously described30, against peptides de-
rived from cVim, cFib and citrullinated α-enolase (cEno)5-20. Antibody reactivity 
against the citrullinated (Cit) and the uncitrullinated form of two linear peptides 
derived from vimentin (Vim 1-16: STCitS VSSS SYCitCit MFGG and Vim 59-74: 
VYAT CitSSA VCitLCit SSVP), two linear peptides derived from fibrinogen (Fibα 27-
43: FLAE GGGV Cit GPR VVER H and Fibβ 36-52: NEEG FFSA CitGHR PLDK K) and 
one linear peptide derived from α-enolase (Eno 5-20: KIHA CitEIF DSCitG NPTV) 
were determined by ELISA as described previously.23,31 Citrullination of myelin ba-
sic protein (MBP) (Sigma-Aldrich, Zwijndrecht, Netherlands) and the specific ELISA 
were performed as previously described.20 Antibodies reactive with citrullinated 
MBP were determined in 1:100 diluted sera.
Although there are also other targets for ACPA,32,33 we chose primarily to in-
vestigate epitopes from these proteins because they have been most consistently 
identified as citrullinated autoantigens.18, 19, 34 We analysed reactivity to citrullinat-
ed MBP, as its ELISA has been previously standardised to be the clinical equiva-
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lent (positive versus negative) of the original anti-Sa (cit-Vimentin) western blot 
assay.20
Cut-off values for the citrulline-specific responses were calculated as previously 
described.24,31 IgM-rheumatoid factor (RF), anti-CCP3 autoantibodies (IgA and IgG 
subforms) and anti-mutated citrullinated vimentin (MCV) autoantibodies were also 
measured by ELISA as described previously.31 Sera were tested for antinuclear fac-
tor (ANF) using indirect immunofluorescence at a 1:40 dilution on Hep-2000 cells 
(biomedical diagnostics). 
Statistical analysis
Differences between groups were analysed with the Mann– Whitney test or the 
t test, or χ² test where appropriate. Association between anti-CCP2 antibody levels 
and number of peptides recognised was studied by linear regression of log-trans-
formed anti-CCP2 antibody levels on number of recognised peptides. Principal 
component analyses (PCA)35 were applied to covariance matrices and included the 
different fine specificity epitopes. In order to normalise distributions, all variables 
were log-transformed concentration levels plus one. Based on scree plots and ei-
genvalues, components with an eigenvalue ≥0.4 were selected.
The association of the specific reactivities with baseline characteristics and joint 
damage over time was studied. Annual radiographs of hands and feet were as-
sessed chronologically for radiographic damage according to the Sharp–van der 
Heijde score36 by one experienced reader. For this, a repeated measurement anal-
ysis was applied. This method takes advantage of the longitudinal, repetitive char-
acter of the data and does not exclude patients with incomplete follow-up data, 
avoiding selection bias. In a multivariate normal regression model with radiolog-
ical score as response variable, the effect of time was entered as factor to fit the 
non-linear slope of joint destruction. The components were entered with an inter-
action term with time as continuous variable to test the effect of the components 
over time. Age, gender and inclusion period (a proxy for treatment strategy) were 
entered in the model to correct for possible confounding effects. Analyses were 
performed using SPSS version 17.0, and p values below 0.05 were considered to 
be statistically significant.
Cluster analyses were used to identify subgroups of patients on the basis of 
their ACPA recognition profile. Clustering illustrates the relationship between dif-
ferent patients and reactivities, as described by Eisen et al.37 Hierarchical cluster-
ing was performed using average linkage clustering where patient correlation was 
performed centred and the reactivities uncentred. To illustrate the influence on 
anti-CCP2 level, we performed a supervised cluster analysis where the patients 





Baseline characteristics of the 661 patients with RA who fulfil the American 
College of Rheumatology criteria 1987 are shown in table 1. To analyse whether 
the ACPA recognition profile would allow for the identification of specific antibody 
positive subgroups, we wished to perform cluster analyses as well as PCA to inves-
tigate whether specific subgroups can be identified on the basis of epitope recogni-
tion. If so, such subgroups could then be used to analyse possible clinical associa-
tion. First, we described patients on the basis of their ACPA status and their ability 
to recognise one specific citrullinated peptide (ie, cVim59-74 and cEno5-20). This 
analysis resulted in the identification of different subsets of patients (figure 1A,B). 
Combining the two reactivities against these two peptides resulted in more differ-
ent subgroups (figure 1C). Remarkably, when using all nine reactivities included in 
this study, 64 subgroups could already be identified (figure 1D).
Figure 1. Different subsets of patients based on the epitope recognition profile. 
Patients were grouped on the basis of recognition of CCP2 and cVim59-74 (depicted in 
black are patients CCP2-cVim-; in white, CCP2-cVim+; in light grey, CCP2+cVim-; and 
in dark grey, CCP2+cVim+ (figure 1A), grouped on the basis of recognition of CCP2 en 
cEno5-20 (depicted in black are patients CCP2-cEno-; in white, CCP2-cEno+; in light grey, 
CCP2+cVim-; and in dark grey, CCP2+cEno+ (figure 1B)) and on the combination of those 
two peptides (cVim59-74 and cEno5-20) and CCP2 (figure 1C). Dividing patients based 
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on all tested reactivities (including cVim1-16, cVim59-74, cFibα27-43, cFibβ36-52, cEno5-
20, MBP, MCV, CCP2 and CCP3, resulted in 64 different subsets of patients indicating a 
heterogeneous epitope recognition pattern. Depicted in black are patients negative for 
all the tested citrullinated antigens (figure 1D). CCP2, cyclic citrullinated peptide; cEno, 
citrullinated α-enolase; cVim, citrullinated vimentin; cFib, citrullinated fibrinogen; MBP; 
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Table 1. Baseline characteristics. CCP, cyclic citrullinated peptide; 
IgM-RF= IgM-rheumatoid factor. 
These data show that within ACPA-positive patients, a large heterogeneity is 
present in the ACPA recognition profile. More importantly, this large heterogene-
ity seems to preclude the identification of specific subgroups. To investigate the 
possibility that specific peptide reactivities would cluster together, we generated a 
heatmap after an unsupervised hierarchical cluster analysis. A heatmap groups pa-
tients who resemble each other the most, based on their fine specificity recognition 
repertoire. This analysis did not lead to the identification of apparent subgroups of 
patients harbouring a specific ACPA recognition profile (figure 2). Together, these 
analyses did not point to the presence of a clear pattern of recognition of citrulli-
nated peptides by ACPA.
Interestingly, when we performed a similar analysis in a supervised manner 
by ordering patients on anti-CCP2 levels and subsequently analysed the recog-
nition to specific peptides, an association was found between levels of anti-CCP2 
antibodies and the number of recognised peptides by ACPA-positive patients with 
RA (figure 3). The association between levels and the epitope recognition profile 
was also confirmed with a linear regression analysis (p<0.001). As control, the 
relation to RF or ANF status (figure 3) was also analysed. In this case, no rela-
tion between anti-CCP2 levels and the antibody status of RF and ANF was found. 
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Figure 2. Unsupervised cluster analysis. No apparent clusters of patients were visi-
ble after an unsupervised cluster analysis based the recognition of different citrullinated 
epitopes (including cVim1-16, cFibα27-43, cEno5-20, cVim59-74, cMBP, cFibβ27-43, CCP3 
and MCV). Each column represents one patient and each row one tested fine specificity 
peptide or protein. Depicted in red are patients being positive for the recognition of a 
specific reactivity, when depicted in green the patients did not recognise that epitope. 
cEno, citrullinated α-enolase; cFib, citrullinated fibrinogen; MBP; myelin-binding protein; 
cVim, citrullinated vimentin; MCV, mutated citrullinated vimentin. 
Likewise, no association was found between the presence of antibodies against 
citrullinated epitopes and antibody levels against tetanus (figure 4B) or total IgG 
levels (figure 4C). Together, these data indicate that anti-CCP2 antibody levels 
specifically correlate with the number of citrullinated epitopes recognised by ACPA 
(figure 4A).
As our analyses described above did not identify defined subgroups, we per-
formed PCA thereafter. PCA are an exploratory tool to unravel unknown trends in 
the data; however, this method also did not provide indications for the presence 
of patient subsets that can be grouped on the basis of the ACPA recognition profile 
(data not shown). Together, these analyses show that within these reactivities, no 
apparent patterns of recognition of citrullinated peptides by ACPA are present.
ACPA fine specificity and clinical characteristics
As outlined above, no specific subgroups of patients could be identified based 
on the presence of different ACPA characteristics. Therefore, we wished to analyse 
associations between baseline characteristics and the recognition of specific epi-
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topes. To determine whether the baseline characteristics are associated with the 
recognition of specific citrullinated epitopes, we performed these analyses in the 
ACPA-positive stratum only. In doing so, we control the possibility that the results 
described above are explained by the known association between baseline char-
acteristics and ACPA status, rather than by an influence of specific epitope recog-
nition on baseline characteristics (ie, all ACPA reactivities are almost exclusively 
found within the ACPA-positive stratum). 
Figure 3. The association between anti-CCP2 levels and the recognition of multi-
ple citrullinated epitopes. A supervised cluster-analysis showed an association between 
the anti-CCP2 levels and number of recognized peptides (including cVim1-16, cFibα27-43, 
cEno5-20, cVim59-74, cMBP, cFibβ36-52, CCP3 and MCV). There was no apparent 
association between levels and RF or ANF. Each column represents one patient and each 
row, one tested fine specificity peptide or protein. Depicted in red are patients being pos-
itive for the recognition of a specific reactivity; depicted in green are the patients who did 
not recognise that epitope. Depicted in grey are missing values. ANF, anticulear factor; 
cEno, citrullinated α-enolase; CCP, cyclic citrullinated peptide, cVim, citrullinated vimentin; 
cFib, citrullinated fibrinogen; MBP, myelin-binding protein; MCV, mutated citrullinated vi-
mentin; RF, rheumatoid factor. 
We observed essentially no association with any of the reactivities in relation to 
any of the baseline characteristics tested (figure 5 and figure 6). Although an as-
sociation between reactivity against anti-cMBP-reactivity and C reactive protein 
(CRP) was observed (p=0.008), this association did not remain after the Bonfer-
roni correction for multiple testing (figure 5). 
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Figure 4. Association between anti-CCP2 levels and number of citrullinated epi-
topes recognized. The number of epitopes recognized was positively associated with the 
anti-CCP2 levels (figure 4A). This association is citrulline-specific rather than antibody lev-
els specific, as it was not found for anti-tetanus antibody levels (figure 4B). Also total-IgG 
levels were not associated with the number of epitopes recognized by RA patients (figure 
4C). Graphs are depicted with mean ± standard error of the mean (SEM). Epitopes in-
cluded in these analyses were: cVim1-16, cVim59-74, cFibα27-43, cFibβ36-52, cEno5-20, 
7
ACPA recognition profile and subgrouping patients 133
cMBP, MCV, CCP2 and CCP3. CCP, cyclic citrullinated peptide; cEno, citrullinated α-enolase; 
cFib, citrullinated fibrinogen; MBP; myelin-binding protein; cVim, citrullinated vimentin; 
MCV, mutated citrullinated vimentin; RA, rheumatoid arthritis. 
In line with these data, patients with an extended fine specificity repertoire 
(defined by the recognition of more than two citrullinated epitopes) also did not 
display significant differences in baseline characteristics compared to ACPA-posi-
tive patients recognising fewer peptides (figure 5), as the difference in CRP levels 
(p=0.018) could not withstand correction for multiple testing.
Figure  5. The association between epitope recognition and baseline characteristics. 
We observed essentially no association with any of the reactivities in relation to any of the 
baseline characteristics tested. An association was found between the recognition of cMBP 
and higher CRP levels at baseline (p=0.008) and recognition of more citrullinated peptides 
with CRP levels (p=0.018). However, after correction for multiple testing, no association 
between the recognition of specific citrullinated epitopes and baseline characteristics re-
mained. Depicted are the mean and standard deviation between different citrullinated 
epitopes and baseline characteristics within ACPA positive patients. Age of inclusion is de-
picted, swollen joint count with number of swollen joints, morning stiffness in min, ESR in 
mm/h, CRP in mg/l and RF in percentage positivity. ACPA, anticitrullinated protein antibod-
ies; cMBP, citrullinated myelin-binding protein; CRP, C reactive protein; ESR, erythrocyte 
sedimentation rate; RF, rheumatoid factor; SJC, swollen joint count.
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Figure 6. The association between epitope recognition and baseline character-
istics. Depicted are the mean and standard deviation between different citrullinated epi-
topes and baseline characteristics within ACPA positive patients. Age of inclusion is de-
picted, swollen joint count with number of swollen joints, morning stiffness in min, ESR in 
mm/h, CRP in mg/l and RF in percentage positivity. ACPA, anticitrullinated protein antibod-
ies; cMBP, citrullinated myelin-binding protein; CRP, C reactive protein; ESR, erythrocyte 
sedimentation rate; RF, rheumatoid factor; SJC, swollen joint count. 
Another goal for making subgroups is to identify patients who will reach re-
mission or will develop more joint destruction over time. Therefore, we wished 
to analyse sustained DMARD-free remission and joint damage over time within 
the ACPA-positive stratum. Only nine out of 306 ACPA-positive patients with RA 
achieved remission. As a consequence of this low number of patients, we did not 
perform further analyses into the association of the ACPA recognition profile and 
remission. Recently, we have shown that different fine specificities or an extended 
ACPA recognition profile was not associated with joint destruction over time.38 We 
now extended these findings by analysing additional citrullinated epitopes, but this 
analysis also did not indicate an association between the recognition of a specific 
citrullinated epitope with radiological progression. Nonetheless, it is possible that 
an association exists for another, not in our study tested, epitope. Our data show a 
strong correlation between anti-CCP2 levels and the number of peptides recognised 
by patients (figures 3 and 4). Therefore, we wished to use anti-CCP2 levels as a 
proxy for the peptides that we did not analyse. Intriguingly, we did not observe an 
association between rate of joint destruction over time and the anti-CCP2 levels 
within the ACPA-positive patients (p=0.66) (figure 7).
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Together, our data indicate that although the ACPA recognition profile is highly 
diverse, the number of epitopes recognised correlates with ACPA level. Interest-
ingly, the recognition of these citrullinated peptides, irrespective of their differenc-
es in peptide-backbone structure, all correlated with similar clinical characteristics.
Figure 7. Rate of joint destruction over time and anti-CCP2 levels. Anti-CCP2 posi-
tive patients developed significantly more joint destruction over time (p <0.001) compared 
to anti-CCP2 negative patients. Within the anti-CCP2 positive patients that rate of joint de-
struction between patient with high levels (>620AU) and low levels (<620AU) did not differ 
(p=0.66). The ACPA positive patients were divided into 2 groups based on the median of 




Epitope spreading is a phenomenon in which the (auto)immune response is ex-
tended to include new epitopes within the same molecule or towards different mol-
ecules and is thought to be involved in disease onset of autoimmune disorders. For 
example, pemphigus is one of the most clearly defined autoimmune diseases medi-
ated by autoantibodies. The involvement of epitope spreading in pemphigus patho-
genesis was first demonstrated in endemic pemphigus foliaceous.26 Subjects in the 
preclinical stage harbour antibodies recognising different epitopes on desmoglein 1 
compared to patients after disease onset.39 In several cases of pemphigus, it has 
been described that intermolecular epitope shifting occurs along with the transition 
of pemphigus phenotype.
In RA, the association between epitope spreading in a predisease phase with RA 
development had been described as well. For example, it has been shown that epi-
tope spreading of the ACPA response occurs before clinical disease onset and that it 
is associated with the disease course of early arthritis.23 Likewise, at time of disease 
onset, ACPA-positive patients with undifferentiated arthritis who will subsequently 
develop RA and those that will not already have an immunological distinct immune 
response, although these differences were not confined to specific citrullinated epi-
topes. The relevance of epitope spreading before disease onset raised the question 
as to whether a different epitope recognition pattern would be associated with differ-
ent clinical phenotypes as has been described in pemphigus. This question was also 
based upon the findings that HLA shared epitope alleles predispose for the develop-
ment of antibodies against some but not for other citrullinated epitopes, suggesting 
that reactivity towards some epitopes plays a more relevant role than others in 
disease pathogenesis.30,40,41
Here, we investigated whether specific subsets of RA patients could be distin-
guished on the basis of an autoimmune response to specific citrullinated epitopes 
and investigated the effects of the ACPA fine specificity on clinical features of RA. 
The analyses were performed within the ACPA-positive stratum to exclude the in-
fluence of ACPA status on disease outcome, as published before.42
As subgrouping patients based on their epitope recognition profile could be po-
tentially useful to get more homogenous patient groups, we analysed different rec-
ognition profiles in detail. Unsupervised clustering of patients based on their epitope 
recognition resulted in many different subgroups, making it unrealistic to analyse all 
those subgroups in detail. Therefore we analysed the data with the use of several 
methods to obtain indications as to whether specific patient groups can be formed 
based upon the (cumulative) occurrence of specific antibody reactivities. The PCA 
did not point to specific reactivities as a discriminative factor within the variables. 
Likewise, the cluster analysis also did not result in clustering of specific patients. 
These data suggest that the recognition profile of patients with RA displays a large 
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heterogeneity and that patients are not characterised by a unique and specific epi-
tope recognition pattern.
The data described above might not be surprising, given the observation that 
even the baseline differences between ACPA- positive and ACPA-negative patients 
with RA are rather small. Nonetheless, these latter subgroups differ considerably 
with respect to disease course as measured by radiological progression.42 We feel 
that it is unlikely that ACPA fine specificity within ACPA-positive disease will have a 
similar impact as found for ACPA status within RA. This notion is supported by our 
observation that a similar rate of joint destruction is observed between ACPA-pos-
itive patients with high- and low-baseline anti-CCP2 levels as proxy for the extent 
of epitope recognition. Likewise, recent observations made by our group and others 
analysing the possible connection between reactivity against a specific citrullinated 
epitope provided similar indications.38,43
Remarkably, these findings contrast observations made in early/predisease RA, 
as it has been shown that ACPA-positive subjects who are still healthy or have early 
arthritis are more likely to develop arthritis when harbouring a more extended gen-
eralised citrullinated epitope recognition pattern.24 The reason why ‘maturation’ of 
the ACPA response with respect to its epitope recognition profile is associated with 
transition to disease but, once disease is established, not with disease outcome, 
is not known. However, it is tempting to speculate that once a certain threshold is 
reached, disease manifestations become apparent. In case ACPA would be involved 
in disease pathogenesis, it is conceivable that over this threshold, higher levels or 
a more extended recognition profile does not contribute further to disease progres-
sion, as the response is already maximally involved in creation of the harmful in-
flammatory milieu underlying the signs and symptoms associated with RA.
Although our data indicate that no clear link exists between clinical features and 
autoimmunity against specific citrullinated antigens, we cannot exclude that anti-
bodies against other citrullinated antigens will correlate with clinical outcome once 
the disease has emerged. Obviously this could lead to two phenotypically different 
subgroups. However, we feel that it is more likely that inclusion of more citrullinat-
ed epitopes will result in more subgroups as analysing nine reactivities already led 
to a division into 64 subgroups, each displaying a unique ACPA recognition profile. 
Likewise, we cannot exclude that associations could be found with a more extend-
ed samples size; however, based on our sample size, the effect would still remain 
small, and increasing sample size further will unlikely result in a meaningful clinical 
difference.
Altogether, our data indicate that the epitope recognition profile is highly diverse. 
The recognition of different citrullinated peptides at baseline correlated with similar 
clinical characteristics, irrespective of differences in peptide-backbone structure, in-
dicating that the breaking of tolerance towards citrullinated proteins as such provides 
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Very early therapy of Rheumatoid Arthritis (RA) with disease-modifying anti-
rheumatic drugs is associated with lower levels of joint destruction and a higher 
chance on achieving remission.1-5 Having symptoms for >12 weeks at treatment 
initiation is a strong and independent risk factors for a persistent disease course.1, 
3-5 These observations have led to the concept of the ‘window of opportunity’.2 This 
hypothesis presumes that underlying disease processes are not fully matured in 
the very early stage of arthritis, making modulation more successful. However, 
putative biological mechanisms remain unexplored. 
Figure 1 Joint destruction (Sharp/van der Heijde scores) over time in ACPA-positive RA 
patients with <12 or ≥12 weeks of symptoms at first presentation at the rheumatologist. 
The date of symptom onset is used as starting point. 70 ACPA-positive patients (22.7%) 
presented <12 weeks (median after 8 weeks of symptoms) and 239 ACPA-positive patients 
presented after ≥12 weeks of symptoms (median symptom duration at first presentation 
at 27 weeks). The RA patients studied were included in the Leiden Early Arthritis Clinic 
between 1993 and 2006. ACPA, anti-citrullinated protein antibodies; RA, rheumatoid ar-
thritis; SHS, sharp/van der Heijde score. 
Anti-citrullinated protein antibodies (ACPA) precede arthritis development and 
are associated with a severe disease course.6 We hypothesized that the ACPA 
response broadens within the very early phase of RA and in doing so limits the 
‘window of opportunity’. Therefore, it was examined whether patients who were 
assessed within 12 weeks of symptom onset have a less broadened ACPA response 
than patients with longer symptom duration. 
Three hundred and nine ACPA-positive patients (defined by anti-CCP2-positivi-
ty) fulfilling the 1987 ACR criteria for RA and included in the Leiden Early Arthritis 
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Clinic7 were studied on the association between symptom duration and the pro-
gression in joint destruction over 7.5 years, with symptom onset as starting point.3 
Yearly radiographs of hands and feet were scored according to the Sharp-van der 
Heijde method.7 A repeated measurement analysis was used with a random person 
and time effect; the fixed effect of time was modeled with linear spline functions 
with knots at each year.3 Adjustments were made for age, gender and treatment 
strategy. RA-patients that presented with <12 weeks or ≥12 weeks of symptoms 
were compared for level, isotype-usage and fine specificity of ACPA at inclusion. 
Antibody reactivity against peptides derived from human proteins (the citrullinat-
ed (Cit) and the uncitrullinated form of two linear peptides derived from vimentin 
(Vim1-16:STCitS VSSS SYCitCit MFGG  and Vim59-74:VYAT CitSSA VCitLCit SSVP), 
two linear peptides derived from fibrinogen (Fibα27-43:FLAE GGGV Cit GPR VVER 
H and Fibβ36-52:NEEG FFSA CitGHR PLDK K), one linear peptide derived from 
α-enolase (Eno5-20:KIHA CitEIF DSCitG NPTV) and Myelin Basic Protein (MBP)) 
were determined by ELISA and described previously.3, 7-9 Anti-CCP3 and anti-MCV 
were also measured by ELISA (Quanta Lite CCP version 3.1 for IgG/IgA, Inova Di-
agnostics San Diego, USA and Orgentec Diagnostika, Mainz, Germany). 
ACPA-positive RA patients who presented <12 weeks of symptom onset had less 
progression in joint destruction over 7.5 years (p=0.04) (Figure 1). Patients with 
symptoms <12 weeks revealed no differences in anti-CCP2 level, isotype usage 
or fine-specificity recognition profile compared to patients with longer symptom 
duration (Table 1). 
To our knowledge this is the first study investigating ACPA-characteristics in 
relation to the so-called ‘window of opportunity’. Recently published data showed 
a trend for less joint destruction in ACPA-positive RA patients presenting with 
symptoms <12weeks.3 In the present study the radiographic data were extended. 
No clear differences were observed with respect to ACPA characteristics in relation 
to symptom duration. Although it cannot be excluded that other ACPA-character-
istics, such as glycosylation patterns or other ‘fine-specificities’, would show dif-
ferences, our data indicate that the ‘window of opportunity’ is not reflected in the 
maturation of the ACPA-response.  
A longitudinal study-design with regular assessments of ACPA characteristics 
within the same patients would be more appropriate than a cross-sectional study. 
However, as ACPA-positive RA patients often present relatively late (only 22.7% 
of the ACPA-positive RA-patients visited a rheumatologist <12 weeks of symptom 
onset), it will be difficult to obtain adequate patient numbers. 
In conclusion, ACPA-positive RA patients with symptoms <12 weeks have less 
progressive disease than patients with a longer symptom duration. However, the 
broadness of the ACPA response is not different between these groups, indicating 
that maturation of the autoantibody response occurs even earlier.10 
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Table 1. ACPA characteristics at inclusion of ACPA-positive RA patients with 
symptoms for <12 or ≥ 12 weeks. Fine specificity data were assessed in patients in-
cluded between 1993 and 2006. Fine-specificity data were missing for 61 patients. Isotype 
data were determined previously in patients included between 1993 and March 2004 and 
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are therefore missing in 116 patients. * Difference in anti-CCP2 levels was analyzed using 
Mann-Whitney test. **8 peptides were included for the high versus low recognition analy-
ses: cVim1-16, cVim59-74, cFib-α, cFib-β, cEno5-20, MBP, MCV, CCP3. ***ACPA isotypes 
were measured using anti-CCP2 peptides. cEno5-20, citrullinated enolase; cFib, citrulli-
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The antigen recognition pattern of immunoglobulin M (IgM) could, when directed 
against protein antigens, provide an indication of the antigenic moieties triggering 
new B cells. The half-life of IgM is short and memory B cells against T-cell-depen-
dent protein antigens typically produce IgG and not IgM antibodies. In this study, 
we analyzed whether a difference exists between the fine specificity of IgM versus 
IgG anti-citrullinated protein antibodies (ACPAs).
Methods 
We determined the fine specificity of IgM and IgG ACPAs in 113 ACPA-positive 
rheumatoid arthritis patients with IgM cyclic citrullinated peptide 2 (CCP2) levels 
above 100 AU/ml. Fine specificity was assessed by performing ELISA using citrul-
linated peptides derived from vimentin, fibrinogen-β, fibrinogen-α and α-enolase, 
as well as citrullinated proteins fibrinogen and myelin basic protein. The arginine 
counterparts were used as controls.
Results 
Recognition of defined citrullinated antigens by IgM ACPA was confined to samples 
that also displayed recognition by IgG ACPA. However, the IgM ACPA response 
displayed a more restricted antigen recognition profile than IgG ACPA (OR = 0.26, 
P < 0.0001).
Conclusion
Our data show that several defined citrullinated antigens are recognized only by 
IgG ACPA, whereas others are also recognized by IgM ACPA. These observations 
suggest that not all citrullinated antigens are able to activate new B cells despite 
concurrent recognition by IgG ACPA.
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INTRODUCTION
Anti-citrullinated protein antibodies (ACPA) may be involved in the disease patho-
genesis of rheumatoid arthritis (RA). ACPA can be found early in the disease course1, 
even before disease onset2, and the presence of ACPA at the time of diagnosis can 
predict disease course.3 Moreover, ACPA can contribute to disease pathogenesis by 
activating immune cells4,5 and the complement system.6 The ACPA response likely 
represents a T-cell-dependent B-cell response, given the protein nature of the anti-
gen recognized and the strong association with the human leukocyte antigen shared 
epitope alleles. The evolution of such a response is typically characterized by a first 
wave of IgM antibodies after the first antigen contact, quickly followed by the pres-
ence of IgG. After repeated antigen exposure, the IgG responses are further boosted 
while the IgM peak declines. The latter observation is explained by the presence of 
Ig-switched, affinity matured, memory B cell that are formed in the presence of CD4+ 
T cells. These T cells provide the helper activity required for affinity maturation, iso-
type switching and memory cell formation. When such T-cell help cannot be provided, 
as in the case of hyper-IgM syndrome, IgG, IgA and IgE antibody levels are absent 
or severely reduced.7 The presence of IgG, IgA and IgE ACPAs5,8, therefore, provides 
another line of evidence for the T-cell-dependent nature of ACPA responses. 
To the best of our knowledge, IgM-producing memory B cells against T-cell-de-
pendent antigens have not been described, in contrast to T-cell-independent B-cell 
responses against, for example, repetitive sugar residues on bacteria.9,10 For these 
reasons, it is most conceivable that the presence of IgM ACPA suggests that activation 
of recently recruited naïve B cells recognize citrullinated antigens because the half-life 
of circulating IgM is short. In this study, we hypothesized that there might be certain 
antigens which drive the ACPA IgM response in RA. We therefore sought to determine 
whether there is a difference in the fine specificity of IgG and IgM ACPA. 
MATERIAL AND METHODS
Fine specificity of anti-citrullinated protein antibody immunoglobulin M
We determined the fine specificity of ACPA IgM and IgG in 113 serum sam-
ples of anti-cyclic citrullinated peptide (CCP2) IgG and IgM double-positive RA 
patients collected from the Leiden Early Arthritis Clinic (EAC), an inception cohort 
of recent-onset arthritis that was initiated at the Department of Rheumatology at 
Leiden University Medical Center in 1993.11 We selected those patients who had a 
relatively high titer of IgM CCP2 (levels ≥ 100 AU/ ml) to ensure that differences 
between IgG and IgM reactivity could not be explained by differences in the sensi-
tivity associated with the detection of IgG or IgM antibodies by ELISA. For the de-
termination of ACPA status and ACPA levels of IgM anti-CCP2, we used a commer-
cial immunoassay kit (Euro-Diagnostica, Malmö, Sweden) with minor modifications 
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for the detection of IgM. The collection and use of patient samples was approved 
by the local medical ethics committee and in compliance with the Declaration of 
Helsinki. All patients provided their written informed consent.
Demographic data (age, gender, disease duration and radiographic damage) of 
ACPA IgG-positive RA patients who had ACPA IgM ≥ 100 AU/ml were not different 
from patients displaying ACPA IgM levels < 100 AU/ml. The peptides used in this 
study are linear citrulline (Cit)-containing peptides, which are known ACPA IgG 
epitopes in RA, as well as their arginine counterparts12. Specifically, we used vi-
mentin (Vim) 59 to 74: VYAT CitSSAVCitLCitSSVP; fibrinogen-α (Fib-α) 27 to 43: 
FLAEGGGVCitGPRVVERH; Fib-β 36 to 52: NEEGFFSA CitGHRPLDKK; and α-enolase 
5 to 20: KIHACitEIFDS CitGNPTV.
In addition, we tested citrullinated protein antigens (Fib and myelin basic pro-
tein (MBP)) and all of their arginine counterparts. As described previously, the 
presence of anti-Cit-MBP antibodies on ELISA is clinically equivalent to the original 
anti-Sa (Cit-Vim) on Western blot assays.13
Fine specificity assays of ACPA IgG were performed essentially as described 
before12, with minor modifications for ACPA IgM.8 In brief, for IgM-, Cit- and argi-
nine-containing peptides (10µg/ml) were incubated on streptavidin coated plates. 
After being washed, sera were incubated at 1:25 dilution at 37°C for 1 hour, 
bound antibodies were detected using rabbit anti-human IgM (Dako Denmark 
A/S, Glostrup, Denmark), followed by washing with horseradish peroxidase-la-
beled goat anti-rabbit IgG (Dako Denmark A/S). 2,2’-azino-bis(3-ethyl-benzothi-
azoline-6-sulfonic acid) was used as a substrate, and absorbance was determined 
at 415 nm. In each ELISA plate, we included on the Cit-containing peptide eight 
representative gout controls and used these to calculate the cut-off for positivity.8 
These eight gout controls represent a set of fifty controls as established before8 
and were used on each plate to minimize plate-to-plate variation. This was defined 
as the mean ± 2 SD of the absorbance on the Cit-containing peptide. In addition, 
we verified that the difference in absorbance between wells coated with the Cit- 
and the arginine-containing peptide was at least 0.1 as previously described8,12 
Therefore, sera that fulfilled both criteria were considered positive.
Stability of the anti-citrullinated protein antibody I response
Samples from 18 patients were used to analyze the specific reactivity of IgM 
against CCP2, Fib-α and Fib-β over time. We used serum samples obtained at base-
line and at 1, 2 and 5 years of follow-up. Samples were tested by ELISA as described 
above. Samples were considered positive when they displayed an absorbance value 
higher than the cut-off and a difference of at least 0.1 absorbance units when com-
paring the reactivity against the Cit-containing peptide and its arginine-containing 
control peptide.
9
Fine specificity of IgM ACPA and IgG ACPA 153
Statistical analysis
Differences between groups were analyzed using the Mann-Whitney U test or 
analysis of variance. The associations between ACPA IgM and ACPA IgG positivity 
were evaluated by using 2 × 2 tables for the estimation of ORs and 95% CIs. The 
correlation between ACPA IgM and ACPA IgG responses were determined using 
Spearman’s rank-correlation coefficients. The c2 test was used to evaluate differ-
ences in the frequency distribution of ACPA IgG and IgM. All data were analyzed 
with GraphPad Prism version 4.0 software (GraphPad Software, San Diego, CA, 
USA) or SPSS for Windows release 16.0 software (SPSS Inc, Chicago, IL, USA). In 
all tests, P < 0.05 was considered significant. 
Figure 1. The fine specificity of immunoglobulin G (IgG) and IgM anticitrullinated 
protein antibodies (ACPAs). The absorbance (Abs) at 415 nm of ACPA IgG (A) and IgM 
(B) ACPA fine specificity. ***P < 0.001. Data for gout controls from three ELISA plates are 
depicted. α-eno = α-enolase; Arg = arginine; CCP2 = cyclic citrullinated peptide 2; Cit = 




Anti-citrullinated protein antibody fine specificity is different from IgG 
fine specificity
It has been shown that IgM ACPA can be detected in the sera of RA patients 
with established disease, suggesting an ongoing recruitment of new B cells into 
the ACPA response.8 If IgM is the result of triggering of naïve B cells, then the fine 
specificity of ACPA IgM might conceivably differ from ACPA IgG, as IgM will mainly 
be directed  against the antigens  that  have recently been detected by B cells.14 
Therefore, we determined the ACPA IgM and IgG responses against a set of citrul-
linated peptides from Fib, enolase and Vim, as well as the responses against two 
citrullinated proteins (Figures 1A and 1B). Our data show that some but not all 
citrullinated epitopes are recognized by IgM ACPA (Table 1 and Figure 1B). These 
data indicate a restricted epitope recognition profile by IgM ACPA, as some epi-
topes were not recognized by IgM in all analyzed patient sera. 
Figure 2. Positivity of immunoglobulin G (IgG) and IgM anticitrullinated protein 
antibodies (ACPAs). The citrullinated epitopes recognized by IgG and IgM ACPAs in each 
individual. The gray area represents positive reactivity, and the white area represents lack 
of reactivity. α-eno = α-enolase; CCP = cyclic citrullinated peptide; Fib = fibrinogen; MBP 
= myelin basic protein; Vim = vimentin. 
We next determined the recognition profile of IgG ACPA. Although not all patient 
sera recognized all citrullinated epitopes, the IgG ACPA epitope recognition pattern 
was clearly much broader than the epitope recognition profile of IgM ACPA (Figures 
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1A and 2). In fact, when all ACPA reactivities were analyzed as a group, the chance 
of having an IgM-positive response was four times lower compared to IgG (OR = 
0.26, P < 0.0001). For those reactivities where, next to IgG ACPA, IgM ACPA re-
sponses also were apparent, a correlation between the titers of IgG and IgM ACPAs 
was observed between the positive samples (data not shown). 
When reactivity patterns were directly compared at an individual level, we ob-
served that IgM ACPAs against some citrullinated epitopes, but not others, were 
present. However, in all cases, IgM positivity was paralleled by the presence of IgG 
recognizing the same epitopes. In contrast, patients can display certain IgG ACPA 
reactivities in the absence of IgM reactivities against the same antigen (Figure 2). 
Together, these data indicate that IgM ACPAs display a more restricted antigen 
recognition profiles as compared to IgG ACPAs.
Figure 3. Stability of the ACPA IgM response. Sera of 18 patients obtained at baseline 
(BL) and at 1, 2 and 5 years of follow up were analyzed by ELISA for reactivity against 
CCP2, Fib-α and Fib-β. (A,B,C) graphs display the IgM reactivity to the indicated peptides 
over time. Shown is the absorbance of the citrulline reactivity minus the absorbance of the 
arginine reactivity. (D) table shows the number of positive patients at baseline (BL) as well 
as the conversion towards negative or towards positive during one of the follow-up (FU) 
time points analyzed. 
IgM tested pos BL  neg FU pos FU
CCP2 18 18 3 0
Fib-α  18 7 3 0


























































Stability of the anti-citrullinated protein antibody I response
To address the question whether the observed differences between IgG and IgM 
reactivity are limited to baseline samples only or whether they are also present at 
later follow-up, we analyzed ACPA IgM reactivity against three peptides over time. 
The reactivity of ACPA IgM against CCP2, Fib-α and Fib-β at baseline and at 1, 2 
and 5 years of follow-up was analyzed in sera of 18 patients. We observed that 
the ACPA IgM levels against these peptides appeared rather stable (Figures 3A to 
3C). Some patients whose sera reacted with CCP2, Fib-α and Fib-β at baseline may 
over time become IgM-negative (Figure 3D). Importantly, none of the patients 
tested became IgM-seropositive against either Fib-α or Fib-β peptides. These data 
indicate that the observations made using the base- line samples (Figures 1 and 
2) would also be made at any of the follow-up time points. Collectively, these data 
therefore indicate that the ACPA IgM response is narrower than the ACPA IgG re-
sponse, an observation not applicable only to the baseline results but also during 
follow-up.








Table 1. Specific positivity of anticitrullinated protein antibody immunoglobulin 
G and immunoglobulin M in 113 rheumatoid arthritis patients directed against a 
set of defined specificities. CCP2 = cyclic citrullinated peptide 2; Fib = fibrinogen; IgG = 
immunoglobulin G; IgM = immunoglobulin M; MBP = myelin basic protein; Vim = vimentin.
DISCUSSION
In this study, we observed that ACPA IgM responses are different from ACPA IgG 
responses, as they display a more restricted antigen recognition pattern. These 
data are intriguing, as they indicate that the regulation of the IgM ACPA response 
differs from the regulation of B cells producing IgG-directed against citrullinated 
antigens. Although the reason for this difference is not known, we think it is most 
conceivable that these findings are explained by a limited recruitment of new B 
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cells into the ACPA response that is driven by some, but not other, citrullinated 
antigens. Given the short half-life of circulating IgM and the lack of memory B cells 
producing IgM against protein antigens, we think that the IgM ACPAs detected in 
this study are produced by new B cells that are recruited into the ACPA response 
against certain citrullinated antigens. Even in the case where ACPA IgM-producing 
memory B cells exist, it is still interesting that such cells are present only against 
certain citrullinated antigens. For this study, we selected patients who are dou-
ble-positive for IgG and IgM CCP2 reactivity. To exclude the possibility that dif-
ferences between IgG and IgM may be explained by differences in the sensitivity 
associated with the detection of IgG or IgM antibodies by ELISA, we selected only 
patients with an IgM level of at least 100 AU/ml. 
Indeed, in the setup we used, we observed that, although the IgG responses 
against the different citrullinated antigens were rather similar in absorbance units, 
IgM reactivity was detected only against some antigens but not others. This ob-
servation was made at baseline but appears also to be present at follow-up. To 
ensure that we did not introduce additional bias into our data, we compared the 
demographic data (age, gender, disease duration and radiographic damage) of 
ACPA IgG-positive RA patients who had ACPA IgM ≥ 100 AU/ml with those who had 
ACPA IgM < 100 AU/ml and observed no differences.
Since IgM rheumatoid factor (RF) could also be a confounding factor, we com-
pared RF levels between the patients who displayed ACPA IgM ≥ 100 AU/ml with 
those who had ACPA IgM < 100 AU/ml and observed that in RA patients with ACPA 
IgM ≥ 100 AU/ml, the levels of RF IgM were higher than in RA patients who had 
ACPA IgM < 100 AU/ml (RF IgM 50 AU/ml (25 to 118) and 28 AU/ml (12 to 60), 
respectively). To exclude the possibility that our findings were influenced by IgM 
RF, we analyzed ACPA IgM specificities in relation to IgM RF. We observed that IgM 
RF-positive samples can be negative for IgM ACPA reactivities and that, in the ab-
sence of IgM RF, IgM ACPA reactivities can be detected readily (data not shown). 
RF-positive samples that have IgG reactivity against all fine specificity epitopes 
may have IgM ACPA against only some antigens and not others, confirming that 
our assay did not merely detect IgM RF. Previously, we addressed this issue exper-
imentally.8 When RFs were depleted from RF IgM-positive, ACPA IgM-positive and 
ACPA IgG-positive sera using IgG-coated Cyanogen bromide-activated-Sepharose 
beads (Sigma-Aldrich, St Louis, MO, USA), there was no reduction of ACPA IgM 
levels. Moreover, after mixing sera which were highly positive for RF IgM but nega-
tive for ACPA IgG and ACPA IgM with sera which were RF IgM- and ACPA IgM-neg-
ative but ACPA IgG-positive, ACPA IgM could not be detected.8 Collectively, these 
observations support the notion that true IgM ACPA and not IgM RF bound to ACPA 
IgG were detected by the methods employed.
Although it is tempting to speculate, these studies should not be taken as an 
argument for the involvement of the antigens analyzed here in the recruitment of 
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new B cells into the ACPA response. Peptides are unlikely to reflect correctly the 
three-dimensional structure of citrullinated proteins that form the epitope for anti-
bodies. Moreover, ACPA IgG is cross-reactive to multiple citrullinated antigens15,16, 
and therefore recognition of a citrullinated antigen by ACPA IgG does not indi-
cate that this antigen is necessarily involved in the induction of B-cell responses. 
Nonetheless, our data do show that the IgM ACPA response is significantly more 
restricted than that of the IgG ACPA present in the same patient.
How IgM can be formed in the presence of an active IgG response against the 
same antigen is not clear. In other situations, as exemplified by the prophylactic 
administration of anti-Rhesus D antigen antibodies to pregnant women carrying 
a Rhesus D-positive child, the presence of IgG against a certain antigen will pre-
vent the induction of a novel IgM response. The mechanism behind this protective 
measure is thought to be mediated by either the capture and clearance of circulat-
ing Rhesus D antigen and/or by IgG-Rhesus D immune complexes that inactivate 
new Rhesus D-reactive B cells through FcgRIIB, the inhibitory Fcg IIB receptor17. 
Clearly, IgG ACPAs do not inhibit the activation of IgM-positive, citrullinated an-
tigen-reactive B cells. The reason for this finding is not known but could possibly 
be explained by the low avidity of the ACPA18, conceivably resulting in “nonstable” 
immune complexes unable to trigger FcgRIIB.
CONCLUSIONS 
Collectively, our data show that the immune response against one citrullinated 
antigen is different from the immune response against another citrullinated pro-
tein. Some responses are dominated by IgG, whereas both IgM and IgG responses 
were found for other ACPA antigens. Elucidation of the mechanism behind this ob-
servation could be of relevance to the identification of those citrullinated antigens 
that drive ACPA responses and could provide clues to how the continuous recruit-
ment of new B cells can be halted.
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Anticitrullinated protein antibodies (ACPA) are one of the best predictors for the 
development of rheumatoid arthritis. Nonetheless, relatively little information is 
present on the absolute concentration of ACPA in relation to total immunoglobulin 
(Ig) concentrations. Such information would be of relevance to compare ACPA lev-
els to other antibody levels. Here, we estimated the relative abundance of ACPA 
immunoglobulins in serum and synovial fluid using a quantitative approach.  
Methods  
ACPA were purified using HiTrap Streptavidin columns coupled with biotinylated 
cyclic citrullinated peptide (CCP2). Total Ig and anti-CCP2 isotype reactivities were 
measured by ELISA.
Results 
ACPA were successfully isolated as substantial antibody amounts were eluted from 
sera of ACPA positive patients and neglectable antibody amounts were eluted from 
sera of ACPA negative patients. Up to 1 in 80 IgG-molecules were estimated to be 
ACPA. Strikingly, IgM-ACPA was most abundant in synovial fluid (with the highest 
enrichment in the range of 1 IgM-ACPA for every 8 IgM-antibodies). 
Conclusion 
ACPA-IgG levels are estimated to be within the range of peak levels of protective 
antibody responses against recall antigens. IgM-ACPA is abundantly present in 
synovial fluid, suggesting the presence of a continuous ongoing autoimmune re-
sponse in the synovial compartment. 
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INTRODUCTION
Anti-citrullinated protein antibodies (ACPA) have been shown to initiate and 
enhance disease in murine models of arthritis1, 2 and to activate both FcR-posi-
tive cells3, 4 and the complement system,5 arguing that they could play a role in 
disease pathogenesis. ACPA are highly specific for RA and can be detected years 
before clinical manifestations.6, 7 Activation of naïve B-cells upon the first antigen 
encounter results in proliferation and differentiation in IgM-secreting cells. During 
their differentiation upon further contact with T cells, some B cells undergo iso-
type switching and affinity maturation. The ACPA response utilize all isotypes.4, 
8-10 Intriguingly, an expanded ACPA-isotype profile associates with more severe 
radiographic damage, indicating that the extent of the ACPA-response impacts on 
disease progression.11
It has been shown that anti-CCP2-antibody levels are higher in synovial-fluid 
than serum.12-14 However, limited information on absolute ACPA levels in either sy-
novial fluid or serum is present as the levels are generally expressed as arbitrary 
units. Nonetheless, information on the absolute concentration of ACPA is of inter-
est as it allows the comparison of the ACPA response to other antibody responses 
in quantitative terms. To quantitate ACPA levels it is required to isolate ACPA. Here 
we present data on the estimation of ACPA quantities in serum and synovial-fluid. 
MATERIALS AND METHODS
Patient population 
Patients analyzed were derived from the Leiden Early Arthritis clinic (EAC) co-
hort.15 All patients fulfilled the American College of Rheumatology 1987 revised 
criteria for the classification of RA.16 Serum samples of 10 ACPA-positive and 2 
ACPA-negative RA patients and 2 healthy controls were obtained for ACPA purifi-
cation. Knee synovial-fluid was obtained at the time of therapeutic arthrocentesis. 
Samples were obtained from 5 ACPA-positive (including 2 paired synovial-fluid-se-
rum samples selected for high IgM-ACPA levels) and 1 ACPA-negative RA patient 
and 1 patient with osteoarthritis, attending the outpatient clinic of the rheumatolo-
gy department in Leiden. The protocols were approved by the relevant local ethics 
committee and all participants provided informed consent.
Affinity-purification of ACPA
Synovial-fluid samples were treated with hyaluronidase type IV from bovine 
testes (Sigma Aldrich; 100 µg/ml) and protease-inhibitor (Sigma Aldrich; 1:50). 
ACPA from synovial-fluid and serum were purified using HiTrap-streptavidin HP 1 
ml columns (GE-Healthcare) coupled with biotinylated CCP2 peptides as described 
previously.17 The CCP2 peptide was obtained from Dr Drijfhout, Department of 
10
Chapter 10164
IHB, LUMC, The Netherlands. Antibodies were eluted with 0.1M Glycine Hydrogen 
Chloride pH2.5 and neutralized with 2 M Tris.  A control column coated with CCP2 
arginine was attached before the CCP2 citrulline column. This was necessary to 
control for non-specific adherence of antibodies to the bead material. We observed 
that, indeed, a considerable amount of IgG (mean: 10ug/ml) adhered to the con-
trol column (data not shown). After running the sample the columns were discon-
nected and eluted separately to guarantee the citrulline specificity of the purified 
antibodies.  
Anti-CCP2 assays
Anti-CCP2 IgG was measured by ELISA (Immunoscan RA Mark2; Eurodiagnosti-
ca, Arnhem, The Netherlands). Samples with values > 25 units/ml were considered 
positive according to the manufacturer’s instructions. Anti-CCP-positive individuals 
were considered ACPA-positive. 
Quantitative IgA, IgM, IgG ELISA
Quantitiative Ig analyses were performed using the Human IgA-ELISA, IgG-ELI-
SA and IgM-ELISA Quantitation Set (Bethyl Laboratories, Inc, USA) according to 
the manufacturer’s instructions. 
RESULTS
Affinity-purification of ACPA 
ACPA were successfully isolated using HiTrap Streptavidin columns loaded with 
CCP2 peptides as substantial amounts of antibodies were eluted from sera of ACPA 
positive RA patients and neglectable amounts from sera of ACPA-negative patients 
or healthy controls (range: 0-2.1 μg/ml) (table 1). Two affinity-columns, one coat-
ed with biotinylated CCP2 arginine and one coated with biotinylated CCP2 citrul-
line, were used to purify ACPA (figure 1A). The CCP2-arginine coated column was 
essential in the purification procedure, as considerable amounts of, most likely, 
non-specific antibodies were eluted from this control column (mean: 10µg IgG/
ml). The flow-through was collected and antibodies were eluted with glycine-HCl 
and directly neutralized. The flow-through was completely devoid of anti-CCP2-re-
activity, except for 4 high-titer samples (figure 1B), probably due to overloading 
of the column. Recovery of ACPA-activity was not complete. In some samples only 
20% of ACPA-activity could be detected. The recovery rate of ACPA of the different 
immunoglobulins (Ig) after purification was comparable. Together, these data indi-
cate that ACPA can be purified from ACPA-positive sera and indicate that numbers 
of absolute ACPA levels are possibly an underestimation as not all ACPA activity 
originally present in the samples has been recovered.
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Figure 1. Affinity-purification of ACPA. ACPA was purified using 2 affinity-col-
umns. A control column coated with CCP2-arginine was attached to the column with 
CCP2-cittrulline to guarantee the citrulline specificity of the purified antibodies (A). In the 
elution step the two columns were disconnected and the antibodies were eluted off sepa-
rately. Start material (serum or synovial-fluid) (1), flow through (2), elution CCP2-arginine 
(3) and elution CCP2-citrulline (4) were measured for ACPA presence and total immuno-
globulin content. ACPA were effectively purified using HiTrap Streptavidin columns (B). 
Hardly any ACPA remained in the flow-through (FL). However, not all ACPA-activity could 
be recovered as in some patients only 20% of the ACPA-activity present in the start mate-
rial were present in the elution, indicating an underestimation of the amount of quantified 
ACPA. The elution of the arginin-column contained barely any ACPA. The percentage in the 
graph represents the amount of ACPA present in relation to the startmaterial. The different 
fractions were measured with an anti-CCP2 ELISA and the amount was measured in AU/ml. 
Quantification of ACPA immunoglobulins present in serum and synovi-
al-fluid
After affinity purification, ACPA-IgG levels of ACPA-positive patients were quan-
tified by measuring the amount of IgG present. In sera of ACPA-positive patients, 
we measured up to 60 μg/ml IgG-ACPA (mean: 28µg/ml). As hardly any IgG could 
be isolated and measured from sera of ACPA-negative RA patients (mean: 1.5 μg 
IgG/ml), we conclude that considerable amounts of ACPA are present in ACPA-pos-
itive sera (table 1). These levels were estimated to be on average almost 1 in 183 
IgG-antibodies. Within patients with high levels even up to 1 in 80 antibodies were 
ACPA (figure 2). IgA-ACPA is less abundant, only 4 patients displayed a level high-
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with a maximum of 0.36% of all IgA present in serum. IgM-ACPA was abundantly 
present in some subjects, in 2 patients around 10% of the serum IgM appeared to 
be ACPA. 
Next we compared ACPA levels in paired serum- and synovial-fluid samples. 
A trend towards higher levels of ACPA-IgG in synovial fluid as compared to se-
rum was observed, however this difference does not reach statistical significance 
(p=0.07). In contrast, a significant increase in IgM-ACPA was noted in synovial flu-
id as compared to serum (Fig 2a). To quantify these ACPA-levels we next purified 
ACPA from synovial-fluid to investigate the local presence of the ACPA isotypes in 
the joint. Surprisingly, IgM-ACPA was most abundantly present in synovial fluid, 
where up to 13% of IgM-antibodies were estimated to be ACPA (figure 2). These 
2 patients displayed high IgM ACPA levels in synovial-fluid (~5000 AU/ml). Up to 
101 μg/ml IgM-ACPA was present in synovial-fluid (range: 2.8-101 μg/ml).
Figure 2. ACPA immunoglobulins in serum and synovial fluid of RA patients. ACPA 
IgG in relation to total IgG (aU/mg total IgG) is not significantly higher in synovial fluid as 
compared to serum, only a trend was found (Wilcoxon signed-rank test p=0,09) (A). ACPA 
IgA (aU/mg total IgA) and ACPA IgM (aU/mg total IgM) are significantly enriched in syno-
vial fluid as compared to serum (Wilcoxon signed-rank test: IgA, p=0,002, IgM, p=0,0003) 
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(B-C). Percentage ACPA IgG, IgA and IgM of total IgG, IgA and IgM in serum are depicted 
for 10 ACPA positive RA patients, 2 ACPA negative RA patients and 2 healthy controls (D). 
Percentage ACPA IgG, IgA and IgM of total IgG, IgA and IgM in synovial fluid are depicted 
for 5 ACPA positive RA patients, 1 ACPA negative RA patient and 1 osteoarthritis patient (E).
IgG-ACPA was found in synovial fluid up to 103 μg/ml (table 1), based on the 
total amount of IgG present, this indicates that in synovial-fluid up to 2.3% of total 
IgG is ACPA. 
In line with the small amount IgA-ACPA in serum, also little IgA-ACPA was pres-
ent in synovial fluid. We included synovial fluid of one ACPA-negative patient with 
RA and one patient with osteoarthritis patient as controls. In these samples, no 
IgA-ACPA and IgG-ACPA were detected. The purified sample of the ACPA-negative 
patient contained 0.5µg/ml IgM.
DISCUSSION
In this study, we quantified the abundance of different ACPA-immunoglobulins 
in serum and synovial-fluid of RA patients. IgG-ACPA is present in relatively high 
concentrations in serum and synovial-fluid as up to 1 out of 80 IgG-antibodies can 
be ACPA. These findings extend a previous observation describing the estimation 
of IgG-ACPA amounts using 3 RA sera.18 Furthermore, we now report that IgM-AC-
PA can be abundantly present in synovial-fluid (up to 13% of total IgM). Next to 
IgM-ACPA, also IgG-ACPA was found in relatively high concentrations in synovi-
al-fluid (up to 2.3% of total IgG). The estimations presented are conceivably an 
underestimation of the true quantity as not all ACPA-activity could be recovered 
after purification possibly as a result from the isolation procedure. Nonetheless, we 
feel that the estimations presented provide a good reflection of total Ig ACPA levels 
as also evidenced by the good correlation between ACPA-IgG levels in serum and 
purified ACPA-IgG concentrations (Spearman’s rank correlation coefficient: 0.931. 
p<0.01).
The amounts of IgG-ACPA (mean: 28 μg/ml) present in the sera are remark-
ably in line with the peak levels of IgG directed against tetanus following repeti-
tive vaccinations (20-28 μg/ml).19 Protective antibody titers after vaccination have 
been described as titers above 1 μg/ml against for example Haemophilusinfluenza 
type-b and group-B streptococci.19-22 Surprisingly, the ACPA-concentrations found 
exceed these protective antibody titers and are in the same range as the amount 
of antibody present shortly after vaccination. The relatively high ACPA antibody 
levels might be related to the continuous presence of citrullinated antigens in the 
joint, which could activate ACPA producing B cells. 
Furthermore, the results indicate the abundant presence of IgM-ACPA in synovial 
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fluid, as up to 1 in 8 IgM antibodies can be ACPA in patients with high ACPA-levels. 
IgM responses against T cell dependent antigens are, in general, not continuously 
present. In the setting of vaccination, for example, levels of antigen specific IgM 
decrease within weeks after immunization against rabies.23 Therefore the high con-
centrations of IgM-ACPA in sustained disease is intriguing and suggest the contin-
uous local production and conceivably persistence of autoreactive B cell clones at 
the site of the inflamed joint. Previously, we reported that some IgG-ACPA positive 
patients harbour IgM-ACPA 7 years after the initial presence of IgG-ACPA.10 Since 
IgM-antibodies have a half-life of days and long-lived plasma cells producing IgM 
against protein antigen have not been described in humans, the continuous pres-
ence of IgM against T cell dependent antigens, indicate the continuous triggering 
of newly generated B cells. This suggests also that novel IgM producing B-cells are 
continuously recruited into the ACPA-response, indicating that the ACPA-response 
is continuously reactivated during the course of arthritis.10 
Nonetheless we feel that the data presented on IgM-ACPA levels should be 
taken with caution as we can formally not exclude that the measured IgM-ACPA 
levels are influenced by IgM-rheumatoid factor (RF) bound to ACPA. However, 
previously reported data by our group showed that the depletion of IgM-RF did 
not result in reduction of IgM-ACPA levels. Furthermore mixing sera of RF-positive 
with IgM-ACPA-negative patients did not change the reactivity.10 Likewise, not all 
IgM-ACPA positive patients included in this manuscript were IgM-RF-positive, ex-
cluding a contribution of IgM-RF, at least in these patients. 
In conclusion, high concentrations of ACPA are present in serum and synovial 
fluid of ACPA-positive RA patients, exceeding protective antibody levels against re-
call-antigens. Furthermore, the abundance of IgM-ACPA in synovial-fluid indicates 
ongoing recruitment of new B cells into the ACPA response, reflecting a continuous 
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Recently, a novel family of autoantibodies in rheumatoid arthritis (RA) patients 
was described: anti-carbamylated protein (Anti-CarP) antibodies, which target 
carbamylated (homocitrulline-containing) epitopes.1, 2 Since citrulline and homoc-
itrulline have a similar structure, we wished to determine to what extent human 
autoantibodies can differentiate between them. Unlike human antibodies, the an-
ti-modified citrulline (AMC) antibody developed by Dr Senshu3-7 is able to recog-
nise citrullinated epitopes irrespective of the neighbouring amino acids. Thus, we 
also aimed to verify whether the AMC assay could distinguish between these two 
amino acids.
Figure 1 The ‘Anti-Modified Citrulline (AMC)-Senshu’ method does not discrim-
inate citrullinated and carbamylated antigens, while human autoantibodies do. 
(A) Coomassie blue staining showed equal loading of foetal calf’s serum (FCS), Ci-FCS, 
Ca-FCS, fibrinogen (Fib), Ci-Fib and Ca-Fib. (B) The ‘AMC-Senshu’ antibody used according 
to the protocol of the manufacturer, did not recognise FCS and Fib, but strongly recognised
Ci-FCS, Ca-FCS, Ci-Fib and Ca-Fib. (C) Three selected rheumatoid arthritis sera can recog-
nise both Ci-Fib and Ca-Fib, or only one of the modifications specifically. 
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To address this, we loaded gels with citrullinated, carbamylated and non-modified 
forms of foetal calf’s serum (FCS) and human fibrinogen (Fib). Gels loaded with 
equal amounts of these protein preparations (figure 1A) were used for western 
blotting and staining with the ‘AMC-Senshu’ method. Both the citrullinated and the 
carbamylated forms of the proteins tested were strongly recognised, whereas, the 
non-modified form did not reveal any staining (figure 1B). Staining similar western 
blots with selected human sera2 revealed that sera-positive for anti-citrullinated 
protein antibodies (ACPA) and anti-CarP stained both citrullinated (Ci) and car-
bamylated (Ca) forms of Fib, whereas, single positive sera stained only one form 
of modified Fib (figure 1C). These data indicate that although the ‘AMC-Senshu’ 
method does not discriminate between these two modifications, human sera of RA 
patients are able to.
In the double positive sera, the antibody response may either be cross-reactive, 
or harbour two separate reactivities. Four double positive sera were tested in in-
hibition assays in which the sera were incubated with Fib, Ci-Fib or Ca-Fib at 4°C 
overnight before detecting binding to Ci/Ca-Fib. Fib did not inhibit sera binding to 
Ci/Ca-Fib (figure 2A,B). In the sera analysed, binding to Ca-Fib can be inhibited 
by Ci-Fib to various degrees, whereas, binding to Ci-Fib could be inhibited by Ca-
Fib to approximately 30% (figure 2A,B). These data indicate that part, but not all 
ACPA and anti-CarP antibodies are cross-reactive.
In addition, we performed ACPA depletion studies in which double positive sera 
were depleted of ACPA. Biotinlylated CCP2 peptide and its arginine control were 
loaded separately onto HiTrap Streptavidin HP Columns. ACPA/anti-CarP double 
positive sera were applied to one CCP2 arginine-loaded column connected to one 
CCP2 citrulline-loaded column. The starting material and flow-through were tested 
on anti-CarP FCS and CCP2 ELISAs. After ACPA depletion, more than 98% of ACPA 
in the sera was depleted (figure 2C), while more than half the anti-CarP antibodies 
remained in the flow-through in five out of seven samples (figure 2C), confirming 
the data presented in figure 2A,B by showing that part, but not all anti-CarP anti-
bodies are cross-reactive to citrullinated epitopes.
As suggested before, we found the ‘AMC-Senshu’ method cannot differentiate 
citrullination and carbamylation.8, 9 Interestingly, part of the human sera can make 
this distinction. Anti-CarP antibodies and ACPA are often detected together, and here 
we show that double positive samples harbour anti-citrullinated epitope-specific 
antibodies, anti-carbamylated epitopes specific antibodies and cross-reactive an-
tibodies. The finding that the ‘AMC-Senshu’ method recognises both citrullinated 
and carbamylated proteins does not argue against the notion that citrullinated pro-
teins are present in synovial fluid and tissues, since a number of studies confirmed 
the presence of citrullinated proteins by mass spectrometry fingerprinting.3-5, 7 
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However, our study suggests that the extent and nature of citrullination and 
carbamylation in the joint should be re-evaluated especially in light of our recently 
described anti-CarP response that is, at least in part, not cross-reactive with ci-
trullinated proteins. 
Figure 2 Anti-carbamylated protein (Anti-CarP) antibodies and ACPA represent two 
families of autoantibodies. (A) Inhibition studies on sera double positive for ACPA and 
anti-CarP antibodies. Fibrinogen (Fib) does not inhibit sera binding to Ca-Fib. Ci-Fib can par-
tially inhibit sera binding to Ca-Fib, whereas, Ca-Fib can completely inhibit binding to itself. 
(B) Fib does not inhibit sera binding to Ci-Fib, whereas, Ci-Fib can inhibit more than 97% 
of binding to itself. Ca-Fib can only inhibit less than 30% of sera binding to Ci-Fib. (C) After 
ACPA depletion using CCP2 loaded columns, more than 98% of ACPA was depleted from the 
sera, while more than 50% of anti-CarP antibodies remained in five out of seven samples.
11
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Rheumatoid arthritis (RA) is a common chronic auto-immune disorder, of which 
persistent synovitis, bone erosions and auto-antibody formation are characteristic 
features.1 Although it poses a considerable health problem, relatively little remains 
known about the disease pathogenesis and etiology. In the past decade anti-citrul-
linated protein antibodies (ACPA) have emerged as suspects in the development 
and/or progression of RA.2-4 Citrullinated proteins-containing the amino acid ci-
trulline, generated post-translationally from arginine-are found in the joints of pa-
tients with RA, but are not specific for the disease.5, 6 This situation contrasts with 
the presence of ACPA, which are mostly found in individuals with RA. Intriquingly, 
ACPA can also be found in individuals before symptom onset.7, 8 In these instances 
the ACPA response seems to be in its infancy, recognizing only a few citrullinated 
antigens and not using the full isotype repertoire. The characteristics of the ACPA 
response mature before clinical disease precipitates.9, 10 Evidence is emerging that 
ACPA status can further characterize the heterogeneous RA phenotype, not only 
with respect to outcome, but perhaps also with respect to intervention. 
In this thesis, we studied potential roles of ACPA in RA pathogenesis, the mech-
anisms that underlie the occurrence, and evolution of the ACPA response, as well 
as the relationship of these autoantibodies with clinical phenotypes and disease 
outcome.
The prevalence of the ACPA response in Caucasians is estimated to be 1-2% of 
the population; therefore little information about ACPA in unaffected individuals is 
present in the literature. In chapter 2 we investigated the presence and charac-
teristics of ACPA in healthy individuals and RA patients. A North American native 
population in Central Canada is known to have a high predisposition to RA. Healthy 
family members from this population had a high prevalence of ACPA. However, the 
ACPA response in these healthy individuals was less mature as compared to the 
ACPA response of patients with RA, with a much lower isotype usage and less epi-
tope recognition. More strikingly, the ACPA and rheumatoid factor (RF) responses 
were associated in patients with RA, but were discordant in their healthy relatives. 
Our data indicate the presence of an interaction between these risk factors, with 
high odds for having RA when both antibodies are present. Furthermore the pres-
ence of ACPA was associated with RA irrespective of RF status, while the associa-
tion of RF with disease relied on its interaction with ACPA. 
We choose to investigate characteristics of ACPA in individuals from this cohort 
because North American Natives have previously been reported to have a young-
er age at disease onset and an increased prevalence and severity of RA. Genetic 
studies have also revealed a higher prevalence of HLA shared epitope (SE) alleles 
in North American Natives and increased frequency of RF positivity in patients with 
RA in several North American native populations.11 The data so far present about 
ACPA in healthy individuals originates from retrospective studies, collecting serum 
samples from blood donors with RA before disease onset.7, 8 These studies, how-
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ever did not investigate the characteristics of the ACPA response in health versus 
disease. The most striking finding in our study, the interaction between RF and 
ACPA, implies that these autoimmune responses may converge to precipitate dis-
ease. Although the biological mechanism underlying this observation is unknown, 
this association could be explained by a model proposed in a study from Wipke et 
al, suggesting that that autoantibody-mediated articular inflammation in mice may 
be facilitated by soluble immune complexes that enable the access of pathogenic 
antibodies into the joint.12 Because RF antibodies recognize IgG molecules, they 
can form soluble immune complexes, which could facilitate access of ACPA joints. 
An alternative explanation is that RF could amplify the effector mechanisms in-
duced by ACPA in the joint, thereby exacerbating joint inflammation.
Although we detected a relatively high prevalence of ACPA in the population of 
healthy relatives, our data indicate that the mere presence of ACPA is not enough 
to induce disease. The limited ACPA isotype usage in the healthy relatives is con-
sistent with a relatively immature autoantibody response. In patients with RA, 
chronic exposure to citrullinated antigens in the joint conceivably results in con-
tinuous (re)activation of antigen-specific B cells and favors isotype switching. This 
hypothesis is also supported by a low frequency of IgM ACPA in healthy relatives 
as IgM is indicative of ongoing immune responses. The fine specificity data in-
dicate that ACPA recognize at least partially different antigens in patients with 
RA and their healthy relatives, with responses against citrullinated fibrinogen and 
citrullinated vimentin being present in more than half of the patients while being 
virtually undetectable in their healthy relatives. These citrullinated antigens are 
present in the inflamed joint and may serve as an important source of continuous 
antigen stimulation in RA synovium.13, 14 In contrast, the antigens that stimulate 
the ACPA response in healthy individuals and are responsible for the initial loss of 
immune tolerance are currently not known. Considering that the unaffected rela-
tives are, on average, younger than patients with RA, it is conceivable that disease 
will develop in the future in at least some of the ACPA positive relatives. Therefore, 
we speculate that the relatively limited ACPA response in healthy individuals will 
change over time, leading to disease manifestations. These changes likely involve 
broader isotype usage and/or epitope spreading and could be facilitated by RF an-
tibodies that may allow access of ACPA into the joint or amplify their effects. Un-
derstanding the pathways responsible for the diversification of the ACPA response 
in RA is important, because such an understanding could provide new treatment 
possibilities for targeting the pathological autoimmune response before disease 
becomes manifest.
 
As described above, the transition from asymptomatic autoimmunity to clini-
cally detectable arthritis is not well understood. In chaper 3 we therefore studied 
an individual patient from a multi-case RA family from a North American Native 
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population. This young female had initially asymptomatic autoimmunity and sub-
sequently developed clinical features suggestive of early RA. These data suggest 
that onset of clinical synovitis was heralded by an expansion in ACPA isotype us-
age, along with epitope spreading to citrullinated fibrinogen-associated antigens. 
Interestingly, the autoantibody levels continued to rise despite disappearance of 
the clinical symptoms with pregnancy. This observation implies that the clinical 
improvement typically seen during RA pregnancy may not necessarily reflect an 
attenuation of the underlying autoimmune mechanisms, at least at this early stage 
of the process. At the time of the study, it was not possible to determine with 
certainty whether this patient’s synovitis represents the earliest clinical evidence 
of RA, since she had yet to meet the American College of Rheumatology criteria 
set. On the other hand, it is possible that the very early use of antimalarials may 
indeed serve to prevent the full expression of the clinical RA syndrome. This has 
been shown with the use of methotrexate in anti-cyclic citrullinated peptide-posi-
tive patients with undifferentiated arthritis.15 The serological evolution and synovi-
al features are consistent with the hypothesis that isotype expansion and epitope 
spreading of ACPA responses to synovial autoantigens are associated with the 
onset of synovitis in an individual who is genetically susceptible to RA.
ACPA positive and ACPA negative disease have been shown to be associated 
with different genetic and environmental risk factors, fuelling the hypothesis that 
different pathways mechanisms underlie these two separate disease subsets.16-18 
For example, ACPA negative RA associated with HLA-DR319, 20, whereas the HLA SE 
alleles predispose to ACPA positive disease.21 Likewise, the contribution of smoking 
to disease risk is mainly confined to the ACPA positive HLA SE positive group.18 
The HLA SE alleles are also involved in shaping the fine specificity response, as 
these alleles predispose to the development of antibodies against citrullinated vi-
mentin but not aginast citrullinated fibrinogen.22 This would indicate that HLA SE 
alleles influence the magnitude and the specificity of the ACPA response. It has 
even been suggested that a specific interaction between environment (that is, 
smoking) and genetic background (HLA expression profile) might explain the re-
activity against a specific citrullinated antigen.23 Since specific interaction between 
these two risk factors had been postulated in association with autoimmunity to 
citrullinated a-enolase peptide (CEP-1)23, it has been investigated whether the 
interaction was truly specific for this antigen or if it might also exist for other pep-
tides. Indeed, a more recent paper from our group revealed that this interaction 
was not specific for CEP-1, but rather extended to other citrullinated antigens as 
well, for example with antibodies directed against citrullinated vimentin.24 These 
data indicated that the interaction between HLA SE alleles and smoking extended 
to several citrullinated autoantigens, which might even be explained by a general 
predisposition to ACPA development. 
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In chapter 4 we wished to explore whether this effect of interaction would still 
be present in ACPA positive patients. These findings could be of relevance, since 
interactions between genotype, smoking, and autoimmunity to certain citrullinated 
antigens could further expand our understanding of RA pathogenesis. However, 
no stratification for ACPA status was performed in previous studies, allowing the 
possibility that the interaction effects were not explained by their influence on 
the formation of autoimmune reactions against specific citrullinated antigens, but 
rather by their influence on the formation of ACPA. Therefore, we reasoned that if 
such interaction effects only shaped the response to certain specific epitopes and 
not to other citrullinated epitopes, these effects should still be observed among 
the subset of ACPA-positive patients. However, after stratification for ACPA, there 
was no gene-environment interaction present in the shaping the reactivity against 
specific citrullinated antigens. This indicates that the association found is caused 
by the presence of ACPA rather than by the presence of an autoimmune reaction 
to specific citrullinated epitopes. 
Taken together, these data indicate that the gene–environment interaction be-
tween tobacco exposure and HLA shared epitope alleles does not influence the 
reactivity of the ACPA response. Rather, the presence of HLA shared epitope alleles 
seems to be the main factor in shaping the antigen recognition of the ACPA re-
sponse. This is evidenced by the fact that the association between HLA shared epi-
tope alleles and certain fine specificities, such as citrullinated vimentin 59–74 and 
citrullinated α-enolase, remained after stratification for ACPA status, as has been 
demonstrated previously.22 Thus, these results suggest that ACPA fine specificity 
recognition is mainly dependent on HLA shared epitope status and that tobacco 
exposure and the interaction between HLA shared epitope alleles and tobacco ex-
posure contribute little. 
As discussed above, citrullinated proteins are found at inflamed sites in healthy 
individuals as well as in patients.5, 6 However, antibodies directed against citrulli-
nated proteins are very specific for RA. One of the most abundant proteins in the 
joint is fibronectin. In chapter 5 we characterized the citrullination of fibronectin 
in the joint of patients with RA. Furthermore, we studied the prevalence, fine spec-
ificity en HLA association of autoantibodies direct against citrullinated fibronectin 
in patients with RA. Our study revealed that fibronectin can be citrullinated at least 
at five positions. Together with the flanking amino acids, three of these citrullinat-
ed residues comprise two eptiopes recognized by RA Autoantibodies. An epitope 
containing two adjacent citrullines at positions corresponding to residues 1035 and 
1036 appeared to be most frequently recognized by RA sera. The data presented 
in chapter 5 not only showed that antibodies against citrullinated FN are present in 
RA patients,  but  also demonstrated that  the anti-FN  antibodies  represent a sub-
group of anti-CCP2 antibodies and that they can already be detected  very early in 
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the disease. Anti-citrullinated fibronectin antibodies recognizing anti-FN-Cit1035,1036 
were associated with HLA SE alleles, however not with clinical features of RA. 
The fact that RA sera were only reactive with two of the found peptides is con-
sistent with the results of other studies showing that the amino acids flanking the 
citrulline residue contribute to the formation of auto-epitopes.6 Several studies 
with synthetic citrullinated peptides (derived from vimentin, fibrinogen and α-eno-
lase) showed that not all peptides containing citrullinated residues are recognized 
by patient sera, indicating that not only the citrulline is important, but also the 
amino acids surrounding the citrullinated residue.25-27 A large overlap of anti-FN-
Cit1035,1036 with reactivities to other fine specificity peptides was observed, as might 
be expected  from previous  data.28, 29 These data display the large heterogeneity 
of the ACPA response in RA and indicate that the anti-FN-Cit1035,1036 antibodies are 
an abundant ACPA subclass that can be detected with synthetic  peptides derived 
from citrullinated synovial proteins. The association of the recognition of anti-FN-
Cit1035,1036 with HLA SE alleles as such is not surprising as it was show before that 
HLA SE alleles are associated with not only the magnitude but also with the fine 
specificity of the ACPA response.22 One could imagine that the selection of citrulli-
nated epitopes presented to T cells are restricted by the HLA-DRB1 SE alleles (or 
the HLA-DQ alleles that are genetically linked to the SE alleles).  
  As antibodies directed against some citrullinated peptides are associated 
with HLA SE alleles22, 30, one would expect that reactivity towards some epitopes 
plays a more relevant role than others in disease pathogenesis.22-24 Indeed, it has 
been described that ACPA eptitope spreading occurs over several years prior to the 
diagnosis of RA. The initial auto-immune response is mostly directed towards only 
one auto-antigen, but this is not always the same autoantigen.10 Furthermore, in 
patients with undifferentiated arthritis (UA), a more extended epitope recognition 
profile was found in individuals that develop RA over time.29 The relevance of epi-
tope spreading before disease onset raised the question as to whether a different 
epitope recognition pattern would be associated with different clinical phenotypes. 
Therefore, we wished to study the relation between the fine specificity profile of RA 
patients with clinical phenotype in chapter 6 and chapter 7. 
We first studied the association of the ACPA fine specificity and the rate of joint 
destruction over time, under the influence of HLA SE alleles in chapter 6. Further 
insights into which ACPA fine specificities might be associated with disease sever-
ity could therefore have prognostic value and contribute to our understanding of 
disease pathogenesis. In this study, however, we could not detect an association 
between ACPA fine specificities and radiographic joint damage. An anti-citrulline 
immune response to 3 out of 6 of the epitopes studied developed preferentially 
in patients harboring SE alleles, but this did not translate into more severe ra-
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diographic outcome. Also, the number of citrullinated epitopes recognized by an 
individual patient did not influence the degree of joint destruction. We addressed 
this issue by using SE alleles as a surrogate marker for those ACPA fine specifici-
ties that develop under the influence of SE alleles. After stratification for ACPA, SE 
alleles no longer contributed to joint damage. Based on this finding, we consider 
it unlikely that a SE associated ACPA fine specificity can be identified that predicts 
disease course in RA. If such a predictive recognition profile exists, antibodies rec-
ognizing this epitope are likely to be generated independent of SE alleles. 
These findings are relevant for strategies aimed at identifying patients that are 
at risk for rapidly progressive disease and provide evidence that the recognition 
profile of the ACPA response is unlikely to have a relevant impact on radiographic 
progression. HLA SE alleles are instrumental in shaping the ACPA repertoire. How-
ever, ACPA fine specificities formed under the influence of SE alleles do not seem 
to affect joint destruction.  
As we found no influence of the ACPA fine specificity repertoire on the rate of 
joint destruction over time, we extended our search towards other clinical char-
acteristics of RA in chapter 7. In this chapter we investigated whether specific 
subsets of RA patients could be distinguished on the basis of an autoimmune re-
sponse to specific citrullinated epitopes and investigated the effects of the ACPA 
fine specificity on clinical features of RA. The analyses were performed within the 
ACPA-positive stratum to exclude the influence of ACPA status on disease outcome, 
as published before.31 Our data showed that the ACPA response is highly diverse 
with respect to recognition of specific citrullinated epitopes. We found a strong as-
sociation between the number of ACPA fine specificities and the anti-CCP2 (cyclic 
citrullinated peptide-2) levels.  
Furthermore, the recognition of different citrullinated peptides at baseline 
correlated with similar clinical characteristics, irrespective of differences in pep-
tide-backbone structure, indicating that breaking of tolerance towards citrullinated 
proteins as such provides more information than the recognition of a particular 
peptide or set of peptides. As subgrouping patients based on their epitope recog-
nition profile could be potentially useful to get more homogenous patient groups, 
we analysed different recognition profiles in detail. These data suggested that the 
recognition profile of patients with RA displays a large heterogeneity and that pa-
tients are not characterised by a unique and specific epitope recognition pattern. 
The lack of association between ACPA fine specificities and clinical characteristics 
might not be surprising, given the observation that even the baseline differenc-
es between ACPA-positive and ACPA-negative patients with RA are rather small. 
Nonetheless, these latter subgroups differ considerably with respect to disease 
course as measured by radiological progression.31 We feel that it is unlikely that 
ACPA fine specificity within ACPA-positive disease will have a similar impact as 
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found for ACPA status within RA. This notion is supported by our observation that 
a similar rate of joint destruction is observed between ACPA positive patients with 
high- and low-baseline anti-CCP2 levels as proxy for the extent of epitope rec-
ognition. Likewise, the data presented in chapter 6 and a recent observations by 
Fisher et al analysing the possible connection between reactivity against a specific 
citrullinated epitope provided similar indications.32
Remarkably, these findings contrast observations made in early/predisease RA, 
as it has been shown that ACPA-positive subjects who are still healthy or have ear-
ly arthritis are more likely to develop arthritis when harbouring a more extended 
generalised citrullinated epitope recognition pattern.29 The reason why ‘matura-
tion’ of the ACPA response with respect to its epitope recognition profile is asso-
ciated with transition to disease but, once disease is established, not with disease 
outcome, is not known. However, it is tempting to speculate that once a certain 
threshold is reached, disease manifestations become apparent. In case ACPA would 
be involved in disease pathogenesis, it is conceivable that over this threshold, 
higher levels or a more extended recognition profile does not contribute further to 
disease progression, as the response is already maximally involved in creation of 
the harmful inflammatory milieu underlying the signs and symptoms associated 
with RA. Obviously this could lead to two phenotypically different subgroups. Alto-
gether, the data in chapter 7 indicate that the epitope recognition profile is highly 
diverse. The recognition of different citrullinated peptides at baseline correlated 
with similar clinical characteristics, irrespective of differences in peptide-backbone 
structure, indicating that the breaking of tolerance towards citrullinated proteins 
as such provides more information than the recognition of a particular peptide 
or set of peptides. Thus, although studies investigating ACPA characteristics in 
relation to clinical phenotypes have not yet resulted in further refinement of the 
ACPA-positive subgroup, it is clear that stratifying patients with RA on the basis of 
ACPA status has resulted in the identification of more homogenous patient groups, 
with respect to both disease course and response to treatment.
Although the ACPA fine specificity repertoire seems not to play a role in the rate 
of joint destruction in RA patients, the presence of ACPA does play an important 
role.31, 33-35 The observation that ACPA status is, to some extent, related to ther-
apeutic outcome in early disease is intriguing. For a number of diseases, such as 
diabetes mellitus, it has been suggested that a critical period exists in which inter-
ventions might reverse the disease process.36 For RA, such a ‘window of opportuni-
ty’ might also exist, because symptom duration >12 weeks at treatment initiation 
is a strong and independent risk factor for a persistent disease course with more 
joint destruction.37-40 Although this observation could be explained by the assump-
tion that acute-versus-insidious symptom onset characterizes the manifestation 
of different disease subsets, it could also be indicative of a window of opportunity. 
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The difference in outcome in relation to symptom duration raised the question of 
whether a difference in ACPA characteristics could be involved. However, in chap-
ter 8, we show that ACPA-positive patients with symptoms of RA for <12 weeks 
display no difference in the specificity and isotype repertoire of their ACPA re-
sponse compared with patients with longer symptom duration. These findings indi-
cate that the ACPA-characteristics analyzed do not have an impact on the putative 
window of opportunity and emphasize further that maturation of the autoantibody 
response occurs at an early stage, before the first signs and symptoms of disease 
appear.41 
In the previously mentioned studies we investigated to role of the IgG ACPA fine 
specificity repertoire. As IgM producing memory B cells have not been described, 
the presence of IgM ACPA suggests that activation of recently recruited naïve B 
cells recognize citrullinated antigens because the halflife of circulating IgM is short. 
Therefore, in chapter 9 we sought to find certain epitopes that shape the ACPA 
IgM response in RA. We observed that ACPA IgM responses are different from 
ACPA IgG responses, as they display a more restricted antigen recognition pattern. 
These data are intriguing, as they indicate that the regulation of the IgM ACPA re-
sponse differs from the regulation of B cells producing IgG-directed against citrulli-
nated antigens. Although the reason for this difference is not known, we think it is 
most conceivable that these findings are explained by a limited recruitment of new 
B cells into the ACPA response that is driven by some, but not other, citrullinated 
antigens. Given the short half-life of circulating IgM and the lack of memory B cells 
producing IgM against protein antigens, we think that the IgM ACPAs detected in 
this study are produced by new B cells that are recruited into the ACPA response 
against certain citrullinated antigens. Even in the case where ACPA IgM-producing 
memory B cells exist, it is still interesting that such cells are present only against 
certain citrullinated antigens. 
To exclude the possibility that our findings were influenced by IgM RF, we ana-
lyzed ACPA IgM specificities in relation to IgM RF. We observed that IgM RF-positive 
samples can be negative for IgM ACPA reactivities and that, in the absence of IgM 
RF, IgM ACPA reactivities can be detected readily. RF-positive samples that have 
IgG reactivity against all fine specificity epitopes may have IgM ACPA against only 
some antigens and not others, confirming that our assay did not merely detect IgM 
RF. Collectively, these observations support the notion that true IgM ACPA and not 
IgM RF bound to ACPA IgG were detected by the methods employed. Although it is 
tempting to speculate, these studies should not be taken as an argument for the 
involvement of the antigens analyzed here in the recruitment of new B cells into 
the ACPA response. Peptides are unlikely to reflect correctly the three-dimensional 
structure of citrullinated proteins that form the epitope for antibodies. 
Moreover, ACPA IgG is cross-reactive to multiple citrullinated antigens15,16, and 
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therefore recognition of a citrullinated antigen by ACPA IgG does not indicate that 
this antigen is necessarily involved in the induction of B-cell responses.
Nonetheless, our data do show that the IgM ACPA response is significantly more 
restricted than that of the IgG ACPA present in the same patient. How IgM can be 
formed in the presence of an active IgG response against the same antigen is not 
clear. In other situations, as exemplified by the prophylactic administration of an-
ti-Rhesus D antigen antibodies to pregnant women carrying a rheusus D-positive 
child, the presence of IgG against a certain antigen will precent the induction of 
a novel IgM response. The mechanism behind this protective measure is thought 
to be mediated by either the capture of clearance of circulating Rhesus D antigen 
and/or by IgG-Rhesus D immune complexes that inactivate new Rhesus D-reactive 
B celles trough FcγRIIB, the inhibitory FcγRIIB receptor.42 Clearly, IgG ACPAs do not 
inhibit the activation of IgM-positive, citrullinated antigen-reactive B cells. The rea-
son for this finding is not known but could possibly be explained by the low avidity 
of the ACPA18, conceivably resulting in “nonstable” immune complexes unable to 
trigger FcγRIIB. Collectively, the data in chapter 9 show that the immune response 
against one citrullinated antigen is different from the immune response against 
another citrullinated protein. Some responses are dominated by IgG, whereas both 
IgM and IgG responses were found for other ACPA antigens. Elucidation of the 
mechanism behind this observation could be of relevance to the identification of 
those citrullinated antigens that drive ACPA responses and could provide clues to 
how the continuous recruitment of new B cells can be halted.
Previously it has been shown that the levels of ACPA are higher in synovial-fluid 
than serum.5, 54, 55 However, very limited information on absolute levels of ACPA in 
either synovial fluid or serum is present as the levels are generally expressed as 
arbitrary units. Nonetheless, it is interesting to obtain information on the absolute 
concentration of ACPA as this would allow the comparison of the ACPA response 
to other antibody responses in quantitative terms. In order to quantitate ACPA 
levels it is required to isolate ACPA. In chapter 10, we quantified the abundance 
of different ACPA immunoglobulins in serum and synovial fluid of RA patients. We 
found that IgG ACPA is present in relatively high concentrations in serum and sy-
novial-fluid as up to 1 out of 100 IgG-antibodies can be ACPA. These findings ex-
ceed a previous observation describing the estimation of the amount of IgG ACPA 
using 3 RA sera, most likely due to the current, more efficient purification meth-
od.30 Furthermore, we now reported that IgM ACPA can be abundantly present in 
synovial-fluid (up to 3% of total-IgM). Next to IgM ACPA, also IgG ACPA was found 
in relatively high concentrations in synovial-fluid (up to 1% of total IgG). The esti-
mations presented are conceivably an underestimation of the true quantity as not 
all ACPA activity could be recovered after purification.
The amounts of IgG ACPA present in the sera are remarkably in line with the 
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peak levels of IgG directed against tetanus following repetitive vaccinations.56 Pro-
tective antibody titers after vaccination have been described as titers above 1 μg/
ml against for example Haemophilus influenza type b and group B streptococci.56-59 
Surprisingly, the ACPA concentrations found exceed these protective antibody ti-
ters and are in the same range as the amount of antibody present shortly after 
vaccination. The relatively high antibody levels of ACPA might be related to the 
continuous presence of citrullinated-antigens in the joint, which could activate 
ACPA producing B-cells. 
Furthermore, the results indicate the abundant presence of IgM ACPA in relation 
to total IgM in synovial fluid, as up to 1 in 33 IgM-antibodies can be ACPA in pa-
tients with high ACPA levels. IgM responses against T-cell dependent antigens are, 
in general, not continuously present. In the setting of vaccination, for example, 
levels of antigen specific IgM decrease during the weeks after immunization against 
rabies.60 Therefore the presence of IgM ACPA in high concentrations in sustained 
disease is intriguing. Previously published data by our group displayed that some 
IgG ACPA positive patients, still harbour IgM ACPA 7 years after the initial presence 
of IgG ACPA.61 As described above, the continuous presence of IgM against T-cell 
dependent antigens, indicate the continuous triggering of newly generated B-cells. 
This suggests also that novel IgM producing B cells are continuously recruited into 
the ACPA response, indicating that the ACPA response is continuously reactivated 
during the course of arthritis.61 
Nonetheless, in line with chapter 9, we feel that the data presented on IgM ACPA 
levels should be taken with some caution as we can formally not exclude that the 
measured IgM-ACPA levels are influenced by IgM RF bound to ACPA. However, 
previously reported data by our group showed that the depletion of IgM RF did not 
result in reduction of IgM ACPA levels. Furthermore mixing sera of RF-positive with 
IgM ACPA negative patients did not change the reactivity.61 Likewise, not all IgM 
ACPA positive patients included in this chapter were IgM RF positive, excluding a 
contribution of IgM RF, at least in these patients. Therefore, the increased pres-
ence of IgM-ACPA in synovial-fluid indicates ongoing recruitment of new B-cells 
into the ACPA-response, reflecting a continuous (re)activation of the RA-specific 
ACPA-response during the course of ACPA-positive arthritis. 
Besides antibody responses directed against citrullinated proteins, also antibod-
ies directed against carbamylated proteins (anti-CarP) have recently been shown 
to be present in RA.43 Interestingly, these anti-CarP antibodies are also present 
in around 20% of the ACPA negative RA patients and are associated with more 
severe joint damage in this group. ACPA recognize proteins only after the enzy-
matic conversion of the amino acid arginine by PAD enzymes to become the amino 
acid citrulline. Next to citrullination, also other post-translational modifications are 
known to occur. Therefore, it is likely that proteins that have undergone a differ-
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ent type of post-translational modification are also recognized by autoantibodies. 
One of these other post-translational processes is the process of carbamylation. In 
this chemical reaction, mediated by cyanate, the amino acid lysine is changed to 
become the amino acid homocitrulline. Cyanate, necessary for such carbamylation 
is naturally present in the body and in equilibrium with urea.44 In the healthy situ-
ation the concentration of urea is rather low. It is likely that under such conditions 
especially long lived proteins, such as matrix molecules, become carbamylated. 
Renail failure, a condition with increased urea concentrations, is known to be asso-
ciated with enhanced protein carbamylation.45 Also smoking, the most prominent 
environmental risk factor for RA, enhances carbamylation by increasing the cya-
nate concentration.46 Extensive carbamylation is especially thought to occur during 
(chronic) inflammation, when myeloperoxidase is released from neutrophils as this 
enzyme shifts the equilibrium of thiocyanate towards cyanate.46 As smoking and 
chronic inflammation are important in the context of RA, it is likely that in the in-
flamed synovium carbamylation is taking place. The post-translationally modified 
amino acids citrulline and homocitrulline are very similar structures (figure 1). 
Figure 1. Illustration of citrullination and carbamylation. Citrullination (A) and car-
bamylation (B) occur on different amino acids via different mechanisms, but yield similar 
end-products.  
In both cases a positively charged amino acid is replaced by a neutral one. The 
only structural difference is the difference in length; homocitrulline is one CH3 
group longer. As these structures are really similar, in chapter 11 we wished to 
determine to what extent human antibodies can differentiate between them. Un-
like human antibodies, the anti-modified citrulline (AMC) antibody developed by Dr 
Senshu47 is able to recognize citrullinated epitopes irrespective of the neighbouring 
aminoacids. Thus, we also aimed to verify whether the AMC assay could distin-
guish between those two amino acids. 
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Both the citrullinated and the carbamylated forms of the proteins tested were 
strongly recognized, whereas, the non-modified form did not reveal any staining. 
Staining similar western blots with selected human sera revealed that sera-posi-
tive for ACPA and anti-CarP stained both citrullinated and carbamylated forms of 
Fib, whereas, single positive sera stained only one form of modified Fib. These data 
indicate that although the ‘AMC-Senshu’ method does not discriminate between 
these two modifications, human sera of RA patients are able to. Furthermore, we 
also showed that part, but not all ACPA and anti-CarP antibodies are cross-reactive.
As suggested before, we found the ‘AMC-Senshu’ method cannot differentiate 
citrullination and carbamylation.48, 49 Interestingly, part of the human sera can 
make this distinction. Anti-CarP antibodies and ACPA are often detected together, 
and here we show that double positive samples harbour anti-citrullinated epitope 
specific antibodies, anti-carbamylated epitopes specific antibodies and cross-reac-
tive antibodies. The finding that the ‘AMC-Senshu’ method recognizes both citrul-
linated and carbamylated proteins does not argue against the notion that citrulli-
nated proteins are present in synovial fluid and tissues, since a number of studies 
confirmed the presence of citrullinated proteins by mass spectrometry fingerprint-
ing.50-53 However, our study suggests that the extent and nature of citrullination 
and carbamylation in the joint should be re-evaluated especially in light of our 
recently described anti-CarP response that is, at least in part, not cross-reactive 
with citrullinated proteins.
CONCLUSION
The identification of ACPA has been a major breakthrough in the understanding 
of pathogenesis in RA. It has become clear that this unique autoantibody response 
identifies more homogenous subsets of patients with RA than those character-
ized by levels of other autoantibodies, and that differing disease courses possibly 
reflect the involvement of ACPA in disease pathogenesis. The elucidation of the 
characteristics of the ACPA response have shown that ACPA are not pathogenic 
per se, as illustrated by the fact that most patients are ACPA-positive a while be-
fore they develop disease. Possibly, a more mature ACPA response—as illustrated 
by more extensive isotype switching, enhanced antigen-recognition profile and 
higher titers—might be required for these autoantibodies to contribute to disease 
pathogenesis. Once RA is established, the ACPA response does not seem to ma-
ture. Nonetheless, ACPA status is important for clinical decision making, as it is the 
factor that is most predictive of disease outcome and associates with the effective-
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Reumatoïde artritis (RA) is een veel voorkomende chronische auto-immuun 
ziekte, waarbij ontsteking van de gewrichten het belangrijkste kenmerk is. In de 
westerse wereld is ongeveer 0.5-1% van de volwassen bevolking aangedaan door 
de ziekte. Een aanzienlijke geografische variatie in het optreden van RA wordt 
beschreven, met een zeer hoge prevalentie in inheemse Amerikaanse populaties 
en een zeer lage prevalentie in de bevolking van Zuidoost Azië. De aandoening 
komt ongeveer drie keer vaker bij vrouwen dan bij mannen voor en de prevalen-
tie neemt toe met de leeftijd. Aangezien RA een systeem ziekte is, kunnen naast 
symptomen van vermoeidheid, gewichtsverlies en koorts ook ontstekingsreacties 
in de inwendige organen optreden zoals in het hart, de longen en de nieren. 
De ziekte presenteert zich vaak met gezwollen en pijnlijke gewrichten, waarbij 
voornamelijk de kleine gewrichten van de handen en voeten meedoen. Een lang-
durige aanwezigheid van synovitis kan leiden tot beschadiging van kraakbeen en 
subchondraal bot, uiteindelijk leidend tot misvormingen en invaliditeit. Indien geen 
of onvoldoende behandeling plaatsvindt, kan RA ertoe leiden dat patiënten steeds 
meer moeite hebben met  hun normale dagelijkse bezigheden en daarbij een ver-
minderde kwaliteit van leven veroorzaken. Voor de samenleving kan dit uiteindelij-
ke leiden tot enorme toename in de kosten van de gezondheidszorg en verlies van 
arbeidskrachten op de arbeidsmarkt. 
Voor patiënten met RA zijn de behandelmogelijkheden de laatste jaren sterk 
verbeterd. De steunpilaren van de behandeling zijn de ‘Disease Modifying Anti 
Rheumatic Drugs’ (DMARDs). Deze vormen een heterogene verzameling van the-
rapeutische middelen waarvan de werkingsmechanismen grotendeels onbekend 
zijn. Indien de artritis, ondanks het gebruik van DMARDs, onvoldoende onder con-
trole is of als er sprake is van bijwerkingen van deze medicatie, dan spelen de 
zogenoemde ‘biologicals’ zoals tumor necrosis factor (TNF) blokkers een belang-
rijke rol in het effectief onderdrukken van de ziekte. Hierdoor is het tegenwoordig 
mogelijk om bij een groot deel van de patiënten het ontstekingsproces te remmen 
en gewrichtsschade te voorkomen. 
ACPA
Hoewel RA een aanzienlijk gezondheidsprobleem vormt is relatief weinig bekend 
over de pathogenese en etiologie van de ziekte. In het afgelopen decennium zijn 
antilichamen tegen gecitrullineerde eiwitten (anti-citrullinated protein antibodies; 
ACPA) in beeld gekomen  als verdachten voor de ontwikkeling en/of progressie van 
RA. Gecitrullineerde eiwitten bevatten het aminozuur citrulline, dat onder invloed 
van het enzym peptidyl arginine deiminase (PAD) uit het aminozuur arginine ge-
vormd wordt. De rol van citrullinatie is nog onduidelijk. Wel is bekend dat gecitrul-
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lineerde eiwitten vaker gezien worden bij ontsteking. 
Gecitrullineerde eiwitten worden aangetroffen in de gewrichten van patiën-
ten met RA, maar zijn niet specifiek voor de ziekte, aangezien zij ook gevonden 
worden bij gezonde personen. De aanwezigheid van ACPA is echter wel ziekte 
specifiek, aangezien deze antilichamen bijna uitsluitend worden gezien bij perso-
nen met RA. Voor het meten van ACPA worden verschillende diagnostische testen 
gebruikt, waarbij gebruik gemaakt wordt van “cyclisch gecitrullineerde peptiden” 
(cyclic citrullinated peptides; CCP). Indien deze vergeleken worden met het klas-
sieke auto-antilichaam, waarvan al veel langer bekend is dat het geassocieerd is 
met RA (IgM reumafactor, IgM-RF) blijkt de anti-CCP test een grotere specificiteit 
te hebben. De sensitiviteit van IgM-RF en anti-CCP is bij patiënten met een gedi-
agnosticeerde RA ongeveer even groot. 
ACPA kunnen vele jaren voordat de ziekte zich presenteert gevonden worden 
bij de op dat moment nog gezonde personen. De ACPA reactie is in dat geval nog 
niet volledig ontwikkeld. De antilichamen herkennen slechts enkele gecitrullineer-
de antigenen en hebben daarbij nog niet het volledige isotype profiel. Deze twee 
eigenschappen van ACPA breiden zich uit alvorens de ziekte echt tot ontwikkeling 
komt. Verder zijn ACPA een belangrijke voorspeller van bijvoorbeeld gewrichts-
schade in RA. 
In dit proefschrift onderzochten we de potentiële rol van ACPA bij de pathoge-
nese van RA, de mechanismen die betrokken zijn bij de ontwikkeling van ACPA, en 
de relatie van ACPA met het klinische fenotype en ziekte uitkomsten. 
ACPA in de gezonde populatie
De prevalentie van ACPA wordt in de westerse populatie geschat op 1% van de 
bevolking. Tot op heden is weinig informatie bekend in de literatuur over ACPA in 
gezonde personen. In hoofdstuk 2 hebben we de aanwezigheid en kenmerken van 
ACPA in gezonde individuen en patiënten met RA onderzocht. Van een Noord-Ame-
rikaanse inheemse bevolking in centraal Canada is bekend dat RA relatief vaak 
voorkomt. Gezonde familieleden van de deze patiënten hadden een hoge preva-
lentie van ACPA. De ACPA van deze gezonde personen zijn minder “volgroeid” dan 
de antilichamen van de patiënten, aangezien ze veel minder epitopen herkennen 
en een lager isotype gebruik hebben. Alhoewel we een relatief hoge prevalentie 
van ACPA in de gezonde eerstegraads familieleden zagen, lieten onze data zien dat 
enkel de aanwezigheid van ACPA onvoldoende is om ziekte te veroorzaken. 
Opvallender was dat ACPA en RF bijna alleen samen gezien werden bij patiënten 
met RA. Bij gezonde familieleden was geen of slechts één van deze autoantilicha-
men aanwezig. Mogelijk geeft een interactie tussen deze twee risicofactoren een 
verhoogde hoge kans op RA. Daarnaast was de aanwezigheid van ACPA geassoci-
eerd met RA ongeacht de aanwezigheid van RF, terwijl andersom RF alleen geas-
socieerd was met RA in de aanwezigheid van ACPA. 
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De verwachting is dat de ACPA reactie zich in gezonde mensen in de loop van 
de tijd zal ontwikkelen en tot ziekte kan leiden. Om dit te onderzoeken hebben 
we in hoofdstuk 3 een individuele patiënte bestudeerd uit een familie uit de 
Noord-Amerikaanse inheemse bevolking waar veel familieleden belast waren met 
RA. Deze jonge vrouw had aanvankelijk asymptomatisch auto-immuniteit en ont-
wikkelde vervolgens klinische kenmerken die passen bij vroege RA. Bij deze pa-
tiënte zagen we dat het ontstaan van een synovitis voorafgegaan werd door de 
ontwikkeling van ACPA (toename isotype gebruik en meer epitopen die werden 
herkend). Gedurende het onderzoek voldeed de patiënte niet aan de American 
College of Rheumatology criteria voor RA, maar zij werd ook in een vroeg fase 
behandeld met DMARDs, wat wellicht verdere ziekte progressie heeft voorkomen. 
ACPA, genetische risicofactoren en omgevingsfactoren
Het is bekend dat ACPA positieve en ACPA negatieve RA geassocieerd zijn met 
verschillende genetische en omgevingsfactoren. Om die reden wordt gedacht dat 
een verschillende pathofysiologie ten grondslag ligt aan deze twee ziektebeelden. 
Iets meer dan de helft van de vroege RA patiënten zijn ACPA positief. ACPA posi-
tieve en ACPA negatieve RA zijn geassocieerd met verschillende genen die coderen 
voor de humane leukocyten antigenen (HLA). ACPA negatieve RA is bijvoorbeeld 
geassocieerd met HLA–DR3, terwijl de HLA ‘Shared Epitope’ (HLA SE) allelen ge-
associeerd zijn met ACPA positieve ziekte. De HLA SE allelen worden gekenmerkt 
door een vergelijkbare aminozuurvolgorde ter plaatste van positie 70-74 van het 
HLA-DRB1 molecuul. Deze positie is gelegen in de bindingsplaats van het HLA 
molecuul. De HLA SE allelen predisponeren niet zo zeer voor RA, maar voor ACPA 
positieve ziekte. 
Daarnaast wordt de bijdrage van het roken aan ziekterisico voornamelijk be-
perkt tot de ACPA positieve, HLA SE positieve groep. Het is eerder beschreven 
dat een interactie optreedt tussen roken en HLA SE allelen en de ontwikkeling van 
ACPA. Later werd gesuggereerd dat dit gold voor de vorming van de auto-immuun 
reactie gericht op specifieke gecitrullineerde antigenen. Deze bevinding is van be-
lang aangezien interacties tussen genotype, roken en auto-immuniteit gericht te-
gen bepaalde gecitrullineerde antigenen verder helpen in het begrijpen van de 
pathogenese van RA. In hoofdstuk 4 laten we echter zien dat deze gen-omgeving 
interactie niet de specificiteit van de ACPA reactie bepaalt, maar geassocieerd is 
met de aanwezigheid van ACPA onafhankelijk van welk antigen herkend wordt. 
Indien de groepen gestratificeerd werden voor de aanwezigheid van ACPA waren 
de eerder gevonden associaties niet langer aanwezig. 
Gecitrullineerde eiwitten worden gevonden op plaatsen waar inflammatie op-
treedt, zowel in patiënten als in gezonde individuen. Zoals reeds hierboven be-
schreven zijn antilichamen gericht tegen gecitrullineerde eiwitten zeer specifiek 
voor RA. Een van de meest voorkomende eiwitten in het gewricht is fibronectine. 
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In hoofdstuk 5 beschrijven we de karakteristieken van gecitrullineerd fibronecti-
ne in het gewricht van patiënten met RA. Het eiwit fibronectine kan op 5 verschil-
lende posities gecitrullineerd worden. Twee van deze epitopen van gecitrullineerd 
fibronectine werden herkend door patiënten. De aanwezigheid van deze anti-geci-
trullineerde fibronectine antilichamen zijn geassocieerd met HLA SE allelen, maar 
niet met klinisch kenmerken van RA. 
ACPA fijn specificiteit en klinisch fenotype
Aangezien de aanwezigheid van antilichamen tegen bepaalde gecitrullineerde 
eiwitten geassocieerd is met HLA SE allelen, zou men verwachten dat de reactivi-
teit gericht op bepaalde epitopen relevanter zijn voor de pathogenese van RA dan 
andere. Eerder is inderdaad beschreven dat herkennen van meer epitopen enkele 
jaren voor de diagnose RA kan plaatsvinden. De oorspronkelijke respons is meest-
al gericht tegen één autoantigen, maar dit hoeft niet altijd dezelfde te zijn. Verder 
is eerder aangetoond dat patiënten met ongedifferentieerde artritis met een uitge-
breidere epitoop herkenning eerder RA zullen ontwikkelen dan patiënten met een 
meer beperkte herkenning. In hoofdstuk 6 en 7 hebben we daarom onderzocht 
of een verschil in epitoop herkenning (dus een andere fijn-specificiteit) samen zou 
gaan met een ander klinisch fenotype. 
In hoofdstuk 6 hebben we laten zien dat de fijn-specificiteit van de ACPA reac-
tie (het aantal of de herkenning van specifieke epitopen) niet geassocieerd is met 
meer gewrichtsschade gedurende follow up. 
 Aangezien we niet konden aantonen dat de ACPA fijn-specificiteit van in-
vloed was op gewrichtsschade over tijd, hebben we de analyse uitgebreid naar 
andere klinische karakteristieken van RA. In hoofdstuk 7 hebben we geprobeerd 
patiënten in te delen op basis van hun auto-immuunreactie gericht op specifieke 
gecitrullineerde antigenen en hun effect op klinische eigenschappen. Deze analyse 
werd uitgevoerd binnen de ACPA positieve groep om het effect van de ACPA status 
uit te sluiten zoals reeds hierboven beschreven. Zoals men ook zou verwachten 
waren de concentraties van anti-CCP2 (cyclic citrullinated peptide-2) sterk ge-
associeerd met het aantal ACPA fijn-specifiteiten aanwezig in serum. De ACPA 
concentraties, gebruikt als surrogaat marker voor de fijn-specificiteit, waren niet 
geassocieerd met gewrichtsschade. Herkenning van verschillende gecitrullineerde 
eiwitten bij binnenkomst van de patiënten ging samen met vergelijkbare klini-
sche karakteristieken onafhankelijk van welke peptiden we bestudeerden. In dit 
hoofdstuk laten we zien dat de ACPA reactie erg gevarieerd is, maar dat er geen 
duidelijk associatie aanwezig is tussen herkenning van bepaalde gecitrullineerde 
epitopen en fenotype van RA. 
Deze bevindingen suggereren dat individuen met een bredere ACPA reactie wel 
een verhoogd risico hebben om RA te ontwikkelen wanneer zij nog gezond zijn of 
vroege artritis hebben, maar dat wanneer de ziekte eenmaal echt aanwezig is de 
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verdere ontwikkeling van de antilichaam reactie van minder groot belang is. De 
reden hiervan is onbekend, mogelijk is een bepaalde grenswaarde aanwezig waar 
patiënten overheen moeten om ziek te worden. Indien ACPA betrokken zijn bij  de 
pathogenese van ACPA is het mogelijk dat wanneer de ziekte eenmaal volledig 
aanwezig is, een bredere reactiviteit niet meer extra schade geeft aangezien de 
schadelijke inflammatoire reactie al is aangezwengeld. 
ACPA en de ‘window of opportunity’ 
Het is interessant dat de aanwezigheid van ACPA gerelateerd is aan uitkomst 
van de ziekte (zoals gewrichtsschade). Voor een aantal ziektebeelden zoals diabe-
tes mellitus wordt gesuggereerd dat een tijdsframe bestaat waarin de ziekte rever-
sibel is. Voor RA wordt ook beschreven dat een dergelijke ‘window of opportunity’ 
mogelijk zou bestaan. Dit zou kunnen betekenen dat als je RA binnen de ‘window 
of opportunity’ zou behandelen je de ziekte zou kunnen voorkomen. Eerder is aan-
getoond voor RA dat gewrichtsklachten die langer dan 12 weken bestaan bij het 
begin van de behandeling een sterke en onafhankelijke voorspeller zijn voor een 
hardnekkige ziekte met meer gewrichtsschade. Dit zou verklaard kunnen worden 
door het verschil van een acuut versus sluipend begin van de ziekte, maar ook 
door de window of opportunity waar een vroege behandeling problemen kan voor-
komen. In hoofdstuk 8 hebben wij onderzocht of patiënten met een verschillende 
klachtenduur bij presentatie een verschil in ACPA karakteristieken lieten zien. In 
dit hoofdstuk tonen wij dat patiënten met symptomen passend bij RA < 12 weken, 
geen andere fijn-specificiteit of isotypen-gebruik van hun ACPA reactie laten zien 
in vergelijking met patiënten met een langere ziekte duur bij de start van de be-
handeling. Deze data zijn een indicatie dat de bestudeerde ACPA karakteristieken 
geen invloed hebben op de window of opportunity en benadrukken dat de ontwik-
keling van de antilichaam reactie mogelijk optreedt voor de eerste presentatie van 
de symptomen van RA. 
ACPA immunoglobulines
In de bovengenoemde studies hebben we de rol van de fijn-specificiteit van IgG 
ACPA bestudeerd. Aangezien IgM ACPA producerende memory B cellen niet eerder 
beschreven zijn, suggereert de aanwezigheid van IgM ACPA de recente activatie 
van naïeve B cellen, die gecitrullineerde antigenen herkennen, aangezien de half-
waarde tijd van circulerend IgM kort is. 
In hoofdstuk 9 hebben we verschillende epitopen onderzocht die de ACPA IgM 
reactie van RA kunnen vormen. Onze data laten zien dat de ACPA IgM reactie 
anders is dan de ACPA IgG respons. ACPA IgM laat een beperktere antigen her-
kenning zien. Dit zou kunnen betekenen dat niet alle gecitrullineerde antigenen 
in staat zijn om nieuwe B cellen te activeren. Het is interessant dat patiënten IgM 
ACPA kunnen vormen tegen een epitoop waar reeds IgG ACPA aanwezig is. 
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In zwangere vrouwen worden bijvoorbeeld profylactisch anti-Rhesus D antigen 
antilichamen (IgG)  toegediend om zo te voorkomen dat de moeder een nieuwe 
IgM respons ontwikkelt. Hierdoor wordt het circulerende Rhesus D antigen ge-
klaard of gevangen en worden geen nieuwe B cellen geactiveerd. IgG ACPA zorgt 
klaarblijkelijk niet voor inhibitie van de activatie van IgM positieve gecitrullineer-
de-antigen-reactieve B cellen. Het ontdekken van het mechanisme hierachter zou 
kunnen helpen bij het ontwikkelen van medicatie betrokken bij het remmen van 
nieuwe B cellen die betrokken worden in het proces. 
Eerdere studies hebben aangetoond dat ACPA concentraties in synovial vocht 
hoger zijn dan in serum. Er is echter weinig bekend over de absolute concentra-
ties van ACPA in zowel serum als synoviaal vocht, aangezien de levels meestal 
uitgedrukt worden in ‘arbitrary units’. Het is interessant om absolute concentraties 
te weten van ACPA om de antilichaam reactie kwantitatief te kunnen vergelijken 
met andere antilichaam reacties. In hoofdstuk 10 hebben we de kwantitatieve 
hoeveelheid van de verschillende ACPA immunoglobulines in serum en synoviaal 
vocht van RA patiënten onderzocht.  In serum en synoviaal vocht wordt IgG ACPA 
in relatief hoge concentraties gevonden, 1 van de 100 IgG antilichamen kan ACPA 
zijn. IgM ACPA kan overvloedig aanwezig zijn in synoviaal vocht (tot 3% van to-
taal IgM). Ook IgG ACPA was in relatief hoge concentraties aanwezig in synoviaal 
vocht (tot 1% van totaal IgG). Deze berekeningen werden gemaakt na zuivering 
van ACPA. Mogelijk werden niet alle ACPA gemeten na zuivering, dus het zou een 
onderschatting kunnen zijn. De hoeveelheid IgG ACPA komt opvallend overeen 
met de piek levels van IgG gericht tegen tetanus na een herhaaldelijke tetanus 
vaccinatie. De relatief hoge ACPA concentraties kunnen gerelateerd zijn aan de 
continue aanwezigheid van gecitrullineerde antilichamen in het gewricht, welke 
ACPA producerend B cellen kunnen activeren. 
ACPA en Anti-CarP antilichamen
Naast een antilichaam reactie gericht tegen gecitrullineerde eiwitten zijn recent 
ook antilichamen gericht tegen gecarbamyleerde eiwitten (anti-CarP) beschreven 
in RA. Deze anti-CarP antilichamen zijn aanwezig in 20% van de ACPA negatieve 
RA patiënten en zijn geassocieerd met meer gewrichtsschade in deze groep. ACPA 
herkennen eiwitten alleen na een enzym reactie waarbij het aminozuur arginine 
door PAD enzymen wordt omgezet in het aminozuur citrulline. Naast citrullinatie 
kunnen eiwitten ook andere post-translationele veranderingen ondergaan. Moge-
lijk worden deze veranderde eiwitten ook herkend door auto-antilichamen. Car-
bamylatie is een chemische reactie, gemedieerd door cyanaat. In deze chemische 
reactie wordt lysine veranderd in homocitrulline. Cyanaat is normaal gesproken 
aanwezig in het lichaam in een lage concentratie en in evenwicht met ureum. 
Roken kan de cyanaat concentratie verhogen en zorgen voor meer carbamylatie. 
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Chronische infl ammatie kan ook leiden tot meer carbamylatie. De combinatie van 
deze twee in RA maakt het waarschijnlijk dat in een ontstoken gewricht ten ge-
volge van infl ammatie meer carbamylatie plaats vindt. Homocitrulline en citrulline 
hebben erg veel overeenkomsten, homocitrulline is slechts één CH3 groep groter. 
Aangezien deze structuren zo overeen komen hebben we in hoofdstuk 11 be-
studeerd of menselijke antilichamen deze twee antigenen kunnen onderscheiden. 
Een anti-modifi ed citrulline (AMC) antilichaam ontwikkeld door Dr Senshu is in staat 
om gecitrullineerde epitopen te herkennen ongeacht de omliggende aminozuren. 
We hebben ook gekeken of deze AMC assay kan differentiëren tussen citrulline en 
homocitrulline. Zowel de gecitrullineerde als de gecarbamyleerde eiwitten werden 
sterk herkend door de ‘AMC-Senshu’ methode en kon dus geen onderscheid ma-
ken. De antilichamen uit serum van RA patiënten konden dit echter wel. Anti-CarP 
antilichamen en ACPA worden vaak samen gezien, maar kunnen ook onafhankelijk 
van elkaar voorkomen. 
Aangezien de ‘AMC-Senshu’ methode geen onderscheid kan maken tussen cit-
rulline en homocitrulline en deze methode in het verleden gebruikt werd om ge-
citrullineerde antigenen aan te tonen, zal dit opnieuw evalueerd moeten worden. 
Met massa spectrometrie is echter wel aangetoond dat gecitrullineerde eiwitten 
voorkomen in het gewricht.
CONCLUSIE
De identifi catie van ACPA is een belangrijke ontwikkeling geweest in het be-
grijpen van de pathogenese van RA. Het is duidelijk geworden dat deze unieke 
antilichaam reactie meer homogene groepen kan vormen bij patiënten met RA 
met betrekking tot klinische presentatie en uitkomst dan eerder het geval was met 
andere auto-antilichamen. Verder kan mogelijk een verschil in het beloop van de 
ziekte veroorzaakt worden door de betrokkenheid van ACPA in de pathogenese van 
de ziekte.  
Het ophelderen van de karakteristieken van de ACPA reactie heeft laten zien 
dat ACPA niet per se pathogeen hoeven te zijn, aangezien ook gezonde individuen 
ACPA bij zich kunnen dragen. Mogelijkerwijs is een meer ontwikkelde ACPA reactie 
(door bijvoorbeeld een breed isotype gebruik, toegenomen antigen-herkenning 
en hogere concentraties) nodig voordat de antilichamen kunnen bijdragen aan 
het klinisch manifest worden van de ziekte. Wanneer de ziekte eenmaal tot bloei 
gekomen is, lijkt de ACPA reactie zich niet verder te ontwikkelen. De ACPA status 
blijft echter wel belangrijk voor het maken van klinisch beslissingen, aangezien 
het de belangrijkste voorspeller is van ziekte uitkomst en geassocieerd is met de 
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